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Lung health across the life course in Malawi: Dr. Sarah Rylance 
Background: Chronic respiratory symptoms are common in Malawian adults and might be 
determined by lung development, growth and exposures in earlier life: alternative cooking 
methods, such as cleaner-burning cookstoves, have been proposed as a way to reduce biomass-
fuel smoke exposure and improve lung health. Tailored strategies for resource-limited settings 
are needed to improve the management of common childhood respiratory conditions. 
Aims: 1. To explore the prevalence of non-communicable lung disease and air pollution 
associated determinants in children and adults in rural Malawi 2. Evaluate a novel task shifting 
approach to asthma management for children. 
Methods: Within the same rural Chikhwawa communities, we conducted a prospective cohort 
study of adults, collecting respiratory questionnaire data, spirometry and personal air pollution 
exposure measurements at three timepoints over 3-years, and a cross-sectional study, 
collecting similar data from children aged 6-8 years at one timepoint.  
We also conducted a randomised-controlled trial and qualitative sub-study to evaluate the 
feasibility and effectiveness of a task shifting intervention, using non-medically trained asthma 
educators, on asthma outcomes. The intervention comprised detailed clinical assessment, 
optimisation of inhaled treatment, and asthma education delivered by lay educators. Asthma 
symptoms and exacerbations, spirometry and exhaled nitric oxide were assessed at 3-months. 
Results: We recruited 1481 adults, mean (SD) age 43.8 (17.8) years, (654 with acceptable 
spirometry at ≥2 timepoints) and 804 children, mean (SD) age 7.1 (0.8) years, (522 with 
acceptable spirometry) in Chikhwawa. Forced expiratory volume in 1 second (FEV1) and Forced 
Vital Capacity (FVC) decline were 30.9 ml/year (95% confidence interval (CI): 21.6-40.1) and 
38.3ml/year (95% CI: 28.5-48.1), respectively: comparable to natural age-related decline seen in 
healthy non-smokers in high-income settings. Lung function z-scores, referencing Global Lung 
Initiative African-American predicted values, were similar in children and adults and we found 
no evidence of an association between personal air pollution exposure and lung function or 
respiratory symptoms. Secondary analysis of a sub-group of children from households 
previously enrolled in a cookstove trial suggested a potential benefit: children from intervention 
households had a lower carboxyhaemoglobin level and higher FVC z-scores compared to 
controls. 
We recruited 120 asthmatic children at a tertiary hospital in urban Blantyre; 59 received the 
intervention, 61 continued with standard care in the outpatient clinic. At 3-months, we found a 
clinically and statistically significant improvement in the primary outcome: asthma control in 
intervention vs standard care group (increase in mean (SD) cACT score of 2.7 (2.8) vs 0.6 (2.8), 
p<0.001). In addition, fewer children receiving the intervention required emergency health care 
(7.3% vs 23.7%, p=0.03) or missed school (20.0% vs 61.0%, p<0.001) due to exacerbations. 
Children and carers described the positive impact of asthma education on their knowledge 
levels and increased confidence to self-manage symptoms. 
Implications: Our findings from Chikhwawa suggest that lung function deficits seen in adults are 
present in childhood, and that early life influences are likely an important contributor to adult 
lung health. Future research should consider public health interventions addressing multiple 
adverse risk factors encountered in utero and early childhood.  
Task shifting asthma education roles resulted in improved asthma outcomes and high levels of 
patient satisfaction, suggesting this could be an effective strategy in resource-limited settings. 
Further research is needed to assess the wider application of this approach across all levels of 
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1 General introduction 
This thesis explores “Lung health across the life-course in Malawi”, including 
novel research relating to non-communicable lung disease in Malawian 
children and adults. This chapter provides broad context for those which 
follow, introducing 1. the subject of non-communicable diseases (NCDs), in 
sub-Saharan Africa and Malawi more specifically, 2. the rationale for taking a 
life-course approach to lung health, and 3. the challenges of managing NCDs 
in a resource-poor setting. 
 
1.1 Non-communicable diseases: an emerging global problem 
NCDs present an increasing challenge for health care systems as the global 
burden of infectious diseases falls, due to improvements in disease 
prevention and treatment.1 The most prevalent NCDs include cardiovascular 
diseases, cancers, chronic respiratory diseases and diabetes: conditions which 
require long-term management to minimise symptoms, improve quality of life 
and reduce risk of future adverse events.2  
The World Health Organization (WHO) has identified the prevention and 
management of NCDs as a priority, emphasizing the importance of a life-
course approach, with multi-stakeholder engagement and empowerment of 
people and communities.3 The majority (approximately 80%) of global deaths 
from NCDs occur in low- and middle-income countries (LMICs).3  Poverty and 
NCDs are intertwined; health systems in low-income countries are ill-
equipped to detect and manage chronic conditions, and there are high 
household costs associated with long-term treatment. The 2030 Agenda for 
Sustainable Development recognises NCDs as a major threat and includes a 
target (Sustainable Development Goal 3.4) of reducing premature deaths 
from NCDs by one-third by 2030.4 
Sub-Saharan Africa (sSA) is home to approximately one-third of the world’s 
poorest population.5 Historically, health care and research priorities have 
2 
 
focused on maternal-child health and infectious diseases. However, shifting 
demographic and lifestyle trends in the region, and a greater awareness of 
NCD risk factors has prompted increasing recognition of the importance of 
the dual burden of infectious diseases and NCDs, and the interaction between 
them.6 
Malawi is one of the poorest countries in the world: classified as a Low 
Income Country (LIC) by the World Bank, 70% of the population live on less 
than $1.90 per day and the life expectancy at birth is 63.7 years.7 The 
economy is heavily dependent on agriculture, and is particularly vulnerable to 
climatic shocks, Cyclone Idai (in March 2019) being a recent and devastating 
example. Malawi suffers from a shortage of trained clinical staff with 2 
physicians and 28 nurses per 100,000 population, well below the WHO 
“critical shortage” threshold of 2.5 health professionals (including doctors, 
nurses and midwives) per 1000 population.8,9 Currently, there are three 
tertiary level referral hospitals (Blantyre, Lilongwe and Zomba), 27 secondary 
level district hospitals, and 460 primary health care centres.10 Most patients 
with NCDs are managed in one of the tertiary care facilities, although there is 
growing interest in decentralising care, with management of common 
conditions at the primary health care level.11  
In Malawi, NCDs are associated with considerable direct and indirect costs, 
causing catastrophic household spending and exacerbating poverty.12 NCDs 
are estimated to account for 32% of all deaths, with 2% reported to be due to 
chronic respiratory diseases.13 Risk factors for NCDs are common in Malawi, 
with high blood pressure, sedentary lifestyle and raised body-mass-index 
(BMI) increasingly prevalent, particularly in urban areas.14,15 The National 
Health Research Agenda recognises the burden of NCDs as a significant public 
health problem, including cardiovascular disease, cancer, diabetes and 





Figure 1-1. Map of Malawi, highlighting location of study sites: Blantyre and 
Chikhwawa 
 
1.1.1 Non-communicable lung diseases 
Non-communicable lung diseases (NCD-L) includes chronic obstructive 
pulmonary disease (COPD) and asthma; respiratory conditions associated with 
considerable morbidity and mortality. It is estimated that asthma affects 358 
million people, and COPD 174 million people, worldwide.17 The Global Burden 
of Disease Study 2016 reported COPD in the top ten causes of both death and 
disability worldwide.2,18 Although a much rarer cause of death, asthma still 
accounts for 1000 deaths worldwide every day.19 Asthma is a major cause of 
morbidity in childhood, ranking in the top ten causes of disability-adjusted life 
years in both younger and older children.20  
There are limited data relating to NCD-L in sSA: the literature is reviewed in 
detail in Chapter 2. 
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Considering Malawi, there is no published research relating to NCD-L in 
children and the local prevalence of asthma is unknown. At Queen Elizabeth 
Central Hospital (QECH) both children and adults frequently attend the 
emergency department with acute wheeze, and severe cases are admitted to 
the wards. Adults with presumed COPD attend a weekly outpatient 
respiratory clinic, but limited access to spirometry prevents formal diagnosis. 
Malawi is one of the few sSA sites involved in the Burden of Obstructive Lung 
Disease (BOLD) Initiative. BOLD was developed to explore the global 
prevalence and risk factors associated with COPD in adults with data, 
including pre- and post-bronchodilator spirometry, collected from 12 initial 
sites in 2006.21 Data collected following this protocol in urban Blantyre (in 
2013-2014), found chronic respiratory symptoms in 11.8% of adults, with low 
rates of spirometric obstruction (3.6%), and high rates of low Forced Vital 
Capacity (FVC) (38.6%), when compared to Caucasian spirometry reference 
ranges.21,22 
In light of these results, a corresponding study was conducted in rural 
Chikhwawa (in 2014-2015) with similar findings; 13.6% of adults reported 
chronic respiratory symptoms, with spirometric obstruction in 8.7% and 
decreased FVC in 34.8%.23 These findings raised concerns, as decreased FVC 
has been associated with increased mortality, prompting two further 
epidemiological studies which each form a chapter in this thesis; 24,25   
The Child Lung Health Study (CLHS): Chapter 3: is a cross-sectional study, 
investigating whether children show similar patterns of lung health to adults 
from the same communities. 
The Adult Lung Health Study (ALHS): Chapter 4: is a longitudinal cohort study, 
following the adults included in the initial rural BOLD study, to explore 
whether the decreased FVC previously observed in Malawian adults is a result 
of accelerated lung function decline. 
Both the CLHS and ALHS were conducted in Chikhwawa: this was also the site 
for the Cooking and Pneumonia Study (CAPS). CAPS was a community-level 
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cluster randomised controlled trial (RCT) to evaluate whether an intervention 
comprising two cleaner burning biomass-fuelled cookstoves and a solar 
charger would reduce the incidence of Integrated Management of Childhood 
Illness (IMCI)-defined pneumonia in children under the age of 5 years 
compared to continuation of traditional cooking methods.26 CAPS recruited 
households from village clusters in Chikhwawa between December 2013 and 
February 2016. The primary intention-to-treat analysis found no difference in 
pneumonia incidence the between the two trial arms. The overlap of study 
participants in CAPS, CLHS and ALHS facilitated exploratory sub-analyses to 
assess the effect of the cookstove intervention on air pollution exposure, 
respiratory symptoms and lung function in children and adults from these 
communities. 
 
1.2 The case for a life course approach to lung health 
Under ideal circumstances, lung function increases steadily through 
childhood, with a steep climb during adolescence, reaching a plateau in early 
adulthood and then declining gradually as part of normal ageing.27 Lung 
growth and development may be influenced by factors present across the life 






Figure 1-2. The impact of common risk factors encountered in sSA on lung function 
trajectories across the life course. 
Trajectories shown (not to scale) demonstrate possible impact of adverse factors 
acting in childhood (dotted), in utero and childhood (dot-dash), in early adulthood 
(long dash) and later adulthood (long dash-dot-dot), compared to optimal lung 
growth (solid line).   
ETS, environmental tobacco smoke; FEV1, Forced Expiratory Volume in 1s; HAP, household air 
pollution; LRTI, lower respiratory tract infection 
Longitudinal cohort studies have established that lung function deficits 
detected in early childhood, persist through adolescence and into adulthood, 
even in the absence of respiratory symptoms.28,29 Reaching adulthood 
without having achieved maximal lung function, is a risk factor for 
development of COPD, as age-related lung function decline starts from an 
already reduced level.30 Furthermore, wheezing and impaired lung function in 
early childhood are associated with persistent wheeze, relapsing wheeze and 
new-onset asthma in young adults.31,32 
Risk factors for asthma and COPD overlap; persistent asthma in childhood is a 
risk factor for obstructive lung disease in adulthood.33,34,35 This overlap has 
prompted a call to redefine airways disease; to move away from age-related 
categories, and to consider airway disease in the context of a developmental 
trajectory across the life course, from birth (or even before birth) to old age.36 
Factors which might adversely affect lung development and growth in-utero, 
during the perinatal and neonatal period, childhood and into adulthood are 
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commonly encountered in low-income settings such as Malawi, including low-
birth weight, prematurity, air pollution and respiratory infections.37,38,39,40,41 
 
1.3 Non-communicable disease management in low-income countries 
Health care systems in LIC have previously focused on the prevention and 
management of acute communicable diseases (such as malaria, 
gastroenteritis, and pneumonia) which accounted for high mortality rates, 
particularly in young children. Malawi has made great progress in tackling 
these diseases, meeting the Millennium Development Goal 4 target to reduce 
under-5 mortality by two-thirds between 1990 and 2015.42 Acute infectious 
illnesses are usually managed during a single visit to a pharmacy or health 
centre, with a short course of medication (antibiotics or antimalarial 
treatment).  
However, non-communicable respiratory diseases such as asthma and COPD 
are chronic conditions requiring treatment over many years to reduce 
symptoms and prevent exacerbations and associated morbidity. The need for 
long term medications and ongoing monitoring to manage chronic conditions, 
requires a paradigm shift in health care provision, with education of patients, 
health care providers and communities.  
Non-communicable airways disease processes, and challenges to diagnosis 
and long-term treatment are common to adult and paediatric clinical practice. 
Under-resourced health services, with lack of appropriately trained clinical 
staff, diagnostic capability, and an unreliable supply of treatment, impact 
greatly on the quality of chronic disease management in LIC.43 Patients and 
their families may lack the knowledge to understand their medical condition, 
and the importance of adherence to long-term medications. Financial barriers 
to accessing healthcare, and cultural beliefs and misconceptions may further 
contribute to poor compliance and inadequate disease control. 
Sub optimal management of respiratory conditions in earlier life may have 
long-term detrimental effects on adult lung health. It is therefore important 
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to optimise the management of common childhood respiratory conditions, 
with consideration given to the constraints of resource-poor settings. The 
randomised controlled trial and qualitative sub-study described in chapters 5 
and 6 evaluate a task shifting approach, appropriate for a LIC setting, to 
improve asthma outcomes in children.   
 
1.4 Rationale for this thesis 
This thesis will explore non-communicable airways diseases across the life 
course, in a low-income setting. The studies comprising this thesis have all 
been conducted in Malawi, in both urban (Blantyre) and rural (Chikhwawa) 
settings (Figure 1-1) and have relevance to other LIC, particularly in sSA.  
1.4.1 Broad aims 
1. To explore the prevalence of chronic respiratory symptoms and 
spirometric abnormalities, and air pollution associated determinants, in 
children and adults in rural Chikhwawa. 
• Do children show similar patterns of respiratory symptoms and 
lung function abnormalities as adults from the same communities? 
• Is decreased FVC previously reported in Malawian adults due to 
accelerated decline in lung function? 
• What is the impact of household air pollution on respiratory 
symptoms and lung function? 
2. To evaluate a novel task shifting approach to asthma management for 
children. 
• What is the burden of asthma symptoms among children attending 
outpatient clinic in urban Blantyre? 
• Can a task shifting intervention improve asthma outcomes for 
children? 
• Is task shifting asthma education to non-clinical staff feasible and 
acceptable?  
Specific objectives are listed within each chapter. 
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1.5 Outline of thesis 
Chapter 2. Non-communicable lung disease in sub-Saharan Africa: a review of 
the literature 
Chapter 3. Lung health and exposure to air pollution in Malawian children: a 
cross-sectional study (Child Lung Health Study: CLHS) 
Chapter 4. Non-communicable respiratory disease and air pollution exposure 
in Malawi: a prospective cohort study (Adult Lung Health Study: ALHS) 
Chapter 5. Task-shifting to improve asthma management in Malawi: a 
randomised controlled trial 
Chapter 6. Task-shifting to improve asthma education at a tertiary hospital in 
Malawi: a qualitative analysis 
Chapter 7. Summary of findings and implications   
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2 Non-communicable lung disease in sub-Saharan Africa: 
a review of the literature 
This chapter is a review of the literature on non-communicable lung disease 
(NCD-L) in sub-Saharan Africa (sSA). It is deliberately broad as it aims to 
provide a wide perspective on our current state of knowledge about NCD-L in 
low- and middle-income countries (LMIC) in sSA, to put the original research 
that comprises the body of this thesis in context. 
The epidemiological studies in chapters 3 and 4 describe NCD-L in rural 
Malawi and explore factors which might influence lung health, in both 
children and adults. The first half of this review will discuss the definitions of 
NCD-L, NCD-L epidemiology among children and adults in sSA, and factors 
which influence lung growth and development across the life course. 
2.1 Definition of non-communicable lung disease 
Understanding the way in which NCD-L are defined and diagnosed is an 
important precursor to interpreting the literature relating to the 
epidemiology of these conditions. Both asthma and chronic obstructive 
pulmonary disease (COPD) are frequently diagnosed solely on reported 
symptom patterns, particularly in low-income settings. However, 
characteristic spirometric abnormalities form part of the internationally 
recognised diagnostic gold-standards.44,45 
NCD-L can be subdivided broadly into obstructive and restrictive lung disease, 
based on lung volume measurements made using a spirometer: the volume 
than can be forcibly expired in one second (Forced Expiratory Volume in 1s or 
FEV1) and the overall expired volume (Forced Vital Capacity or FVC) following 
a maximal inspiration. Obstructive lung disease is defined by a reduced ratio 
of FEV1 to FVC, and restrictive lung disease by a low FVC. 
2.1.1 Asthma: disease definition – clinical setting 




According to Global Initiative for Asthma (GINA) clinical recommendations, 
asthma diagnosis should be based on characteristic symptoms; cough, 
wheeze, shortness of breath, chest tightness, and evidence of variable airflow 
limitation.44 Airflow variability may be demonstrated by diurnal or day-to-day 
variation in lung function, bronchodilator reversibility or a positive exercise 
challenge test or bronchial challenge test. All of these tests require a measure 
of expiratory airflow; in low-resource settings, the World Health Organization 
(WHO) recommends peak expiratory flow (PEF) meters, as a potential low-
cost alternative to spirometry.47 Asthma is often associated with airway 
hyperresponsiveness and airway inflammation, but these are not necessary to 
make the diagnosis.44 Once diagnosed, asthma symptoms are monitored 
using a variety of assessment tools, discussed further in section 2.4.1 
2.1.2 Asthma: disease definition – epidemiological setting 
The requirements of diagnostic tools used to screen large community 
populations in epidemiological surveys, are different to the more focused 
approach described above, required in a clinical setting. Community 
prevalence surveys commonly rely on a questionnaire-based definition of 
asthma to describe the burden of symptoms.48 This approach has limitations; 
understanding of words such as “wheeze” and “asthma” is not 
straightforward, and appropriate translation into local languages may be 
difficult.49 There is often a discrepancy between wheeze as assessed by 
parents, compared to clinicians.50 However, evidence supports the use of a 
symptom questionnaire alone as a highly valid method to identify asthma in 
epidemiological prevalence surveys.46  
The largest asthma prevalence survey in children to date is the International 
Study of Asthma and Allergy in Children (ISAAC) and the ISAAC questionnaires 
are widely used in asthma research. ISAAC used a broad question: “Have you 
had wheezing or whistling in the chest in the last 12 months?”, to assess 
asthma symptom prevalence (current wheeze). Severe asthma was defined as 
children with current wheeze and; ≥4 attacks of wheeze, or ≥1 night per week 
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sleep disturbance from wheeze, or wheeze affecting speech, in the past 12 
months (Figure 2-1). 51  
1. Have you ever had wheezing or whistling in the chest at any time in 
the past? If no, skip to question 6 
2. Have you had wheezing or whistling in the chest in the last 12 
months? If no, skip to question 6 
3. How many attacks of wheezing have you had in the last 12 months? 
4. In the last 12 months, how often, on average has your sleep been 
disturbed due to wheezing? 
5. In the last 12 months, has wheezing ever been severe enough to 
limit your speech to only one or two words at a time between 
breaths? 
6. Have you ever had asthma? 
7. In the last 12 months, has your chest sounded wheezy during or 
after exercise? 
8. In the last 12 months, have you had a dry cough at night, apart from 
a cough associated with a cold or chest infection? 
Figure 2-1. Core questionnaire wheezing module for 13-14-year olds. 
From ISAAC survey 52 
 
2.1.3 COPD: disease definition 
COPD diagnosis is also based on typical symptoms; difficulty breathing, 
chronic cough or sputum production, associated with airflow obstruction. The 
Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy states 
that spirometric assessment, with a post-bronchodilator FEV1/FVC <0.70 is an 
essential part of making a diagnosis of COPD.45 Furthermore, spirometry is 
used to classify the severity of airflow limitation in COPD (Table 2-1). 
Table 2-1. GOLD classification of COPD severity. 
In patients with FEV1/FVC <0.70: 
GOLD 1 Mild FEV1 ≥ 80% predicted 
GOLD 2 Moderate 50% ≤ FEV1 <80% predicted 
GOLD 3 Severe 30% ≤ FEV1 <50% predicted 




There is debate as to whether it is preferable to use the lower limit of normal 
(LLN), which defines the lowest 5% of the non-smoking, asymptomatic 
population, as a cut-off for diagnosis, rather than a fixed FEV1/FVC ratio of 
<0.70.53 The FEV1/FVC ratio falls with age, and so the use of a fixed value will 
incorrectly classify older adults, with normal age-associated changes, as 
abnormal. Use of a fixed ratio will also underestimate COPD prevalence in 
adults <45years – this is particularly important in LIC where younger people 
constitute a greater proportion of the overall population.54 
It is recognised that patients diagnosed with COPD, using a broad spirometry-
based criteria, will encompass heterogenous airways disease, including three 
major sub-phenotypes; small airways obstruction, emphysema and chronic 
bronchitis.55 Airway obstruction results from smooth muscle contraction, 
mucus hypersecretion, and alveolar-tissue breakdown, with loss of elastic 
recoil: this leads to a progressive deterioration in lung function in many 
patients.56  
2.1.4 Asthma-COPD overlap 
The categorisation of patients into distinct clinical groups is not always 
straightforward; asthma and COPD are heterogenous conditions, with 
overlapping symptoms. GINA recommend the term “asthma-COPD overlap”, 
to describe patients who have features consistent with both asthma and 
COPD. In asthma-COPD overlap there is persistent airflow limitation between 
symptoms, which is not reversible with bronchodilators. The research relating 
to asthma-COPD overlap is limited: careful clinical characterisation of patients 
in clinical trials is required to inform individual patient management.56 
2.1.5 Lung function testing in asthma and COPD 
Spirometry is the gold standard for measuring airflow limitation. FEV1 is 
reduced in airflow limitation – however this may be found in many other lung 
diseases and also with poor spirometric technique. A reduced FEV1/FVC ratio 
is a more accurate assessment of airway obstruction, and the values obtained 
should be compared to age-specific predicted values.57 Repeated 
measurement, 10-15 minutes after administration of a rapid acting 
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bronchodilator (e.g. 200-400 µg Salbutamol) is used to demonstrate 
“reversibility”: defined in children as an improvement in FEV1 of >12% 
predicted value, and in adults as an increase in FEV1 of >12% and >200ml from 
baseline value.44 
Spirometry should be performed by experienced technicians according to 
American Thoracic Society/European Respiratory Society (ATS/ERS) 
guidelines.58 Subjects are instructed to take a deep breath, blow out as hard 
and fast as they can, and keep blowing. The quality of spirometry traces is 
highly dependent on the skill of the technician - the use of simple instructions, 
emphasized with exaggerated body language, is important for all age 
groups.59 
The crucial role spirometry plays in the diagnostic work-up and monitoring of 
asthma and COPD is problematic in resource poor settings, where there is 
limited access to spirometry or even peak flow monitoring. Estimates of 
disease prevalence are commonly extrapolated from research projects, rather 
than population-level surveillance data.60 
2.1.6 Reference ranges for normal lung function 
There are a number of reference ranges, against which measured lung 
function can be compared. The National Health and Nutrition Examination  
Survey (NHANES) III has been used extensively to calculate predicted lung 
function values, by studies including the Burden of Obstructive Lung Disease 
(BOLD) Initiative: this survey included white individuals, African Americans 
and Mexican Americans living in the USA.61 The Global Lung Initiative (GLI) 
2012 equations are preferred for younger (<8 years) and older (>65 years) 
patients and may be a better comparator for patient populations outside of 
the USA. 57,62 The GLI reference equations were derived using lung function 
data from healthy individuals, aged 3-95 years, from a variety of ethnic 
groups; Caucasians (n=57395), African-Americans (n=3545), North-East Asians 
(n=4992) and South-East Asians (n=8255). The dataset included 33 countries, 
however sSA was under-represented, with only South Africa included.57 
15 
 
Hence the African-American reference ranges are largely derived from 
individuals living outside of the African continent. 
The Prospective Urban and Rural Epidemiological (PURE) study analysed pre-
bronchodilator spirometry from healthy people aged 34-80 years, with <5 
pack-year smoking histories from 17 countries.63 Participants living in sSA 
(from South Africa and Zimbabwe) had lower age-, height- and sex-adjusted 
FEV1 and FVC values; by 20.9% (95% CI 19.9-22.0) and 24.3% (95% CI 23.3-
25.4) respectively, than those living in North America or Europe. Those from 
sSA (n=799) included 99.6% black Africans, 54.9% from urban communities, 
and 71.1% females. Absolute lung function measurements were; mean (SD) 
FEV1: 1.98L (0.50) for women, 2.65L (0.72) for men; mean (SD) FVC: 2.33L 
(0.58) for women, 3.16L (0.84) for men. The mean (SD) body mass index (BMI) 
for the sSA women was 30.1 (7.9) kg/m2 indicating considerable 
overnutrition, which would be unexpected in many communities from LIC in 
sSA and hence limits the generalisability of the data. Studies of urban and 
rural populations in Malawi reported rates of obesity (BMI>30) of 13% and 
3%, respectively.22,23  
Some authors have derived local reference ranges from symptom-free non-
smoking study participants.22,64,65 However, this normalises the impact of local 
environmental factors, such as nutrition, infections and pollutants, which may 
determine lung function. A local reference range is therefore unlikely to 
represent the best possible lung function attainable for an individual, had 
they experienced ideal conditions for lung growth and development.66 
 
2.2 Prevalence of non-communicable lung disease in sSA 
2.2.1 Children 
Among children, asthma is the most common chronic disease and is an 
emerging public health problem in Africa, where children account for a high 
proportion of the total population.20,67 The majority of data relating to global 
asthma prevalence is from the International Study of Asthma and Allergies in 
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Children (ISAAC) - the most comprehensive, international survey of childhood 
asthma prevalence to date. Phase 1 (1992-1996) used core questionnaires to 
assess the prevalence and severity of asthma and allergic disease and this was 
repeated in phase 3 (2000-2003) to assess prevalence trends.52,68  
During Phase 3, 22 centres were enrolled from 16 African countries, including; 
Morocco, Tunisia, Democratic Republic of Congo, Togo, Sudan, Cameroon, 
Gabon, Reunion Island, South Africa, Algeria, Kenya, Ethiopia, Ivory Coast, 
Nigeria, Congo, and Sudan.67  The prevalence of “current wheeze” among 13-
14 year old children from these countries is shown in Figure 2-2.   
 
Figure 2-2. Prevalence of symptoms of wheeze in the past 12 months, 13-14-year age 
group.  
From ISAAC Phase 3: Ait-Khaled et al.67 
Four urban sites from southern Africa; Eldoret and Nairobi (in Kenya) and 
Cape Town and Polokwane (in South Africa), reported the prevalence of 
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“current wheeze” as 14-20%, with severe asthma symptoms in 4-7% of 
children aged 13-14 years.67  
Only two sub-Saharan African sites included children aged 6-7 years, with 
reported “current wheeze” in 6% in Ibadan, Nigeria, and 13% in Polokwane, 
South Africa. Subsequent studies, adopting ISAAC methodology to explore 
prevalence in the younger age group, reported rates of current wheeze of; 
16% in Gaborone, Botswana; 5% in Lusaka, Zambia and 13% in Maputo, 
Mozambique: all urban sites.69-71 Only one study has reported asthma 
prevalence in younger children from a rural African setting; in Niakhar, 
Senegal, 9% had current wheeze, and 5% severe wheeze.72  
Table 2-2 details studies from sSA, published from 2000 onwards, reporting 
either asthma or exercise-induced bronchoconstriction (EIB) prevalence rates 
among school-aged children. One of the challenges in comparing these data is 




 Table 2-2 Studies from sub-Saharan Africa reporting prevalence of asthma or exercise induced bronchospasm in school-aged children from 2000 onwards 
Author and 
publication date 
Country and rural/urban location Number of 
subjects 
Age (years) Method of 
assessment  
Prevalence of asthma 
indicator 
Perzanowski, 200273 Thika town / Kabati village, Kenya 
Urban / Rural 
265 8-15 Questionnaire, 6-min 
exercise test (15% fall 
in FEV1) 
EIB: 12% urban, 11% rural 
Asthma history: 10% urban, 
4% rural 
Steinman, 2003 74 Cape Town/Transkei, South Africa 
Urban/peri urban/rural 
1457 10-14 Histamine challenge, 
skin prick test, 
questionnaire 
BHR: 17% rural Xhosa, 34% 
urban Xhosa, 33% urban 
white 
Hailu, 2003 75 Gondar town, NW Ethiopia 
Urban 










ISAAC Current wheeze: 13.3% in 
both age groups 
Davey, 2005 77 Butajira, Ethiopia 







Current wheeze: 8-9%, both 
age groups 
Mashalane, 200678 Thokoza, South Africa 
Urban Poor 
495 9-10 Questionnaire, 6-min 
exercise test (15% fall 
in PEFR) 
EIB: 7.3% 
Addo-Yobo, 2007 79 Kumasi, Ghana 
Urban rich, urban poor, rural 
1848 9-16 Exercise challenge 
(12.5% fall PEFR), skin 
prick test 
EIB: 8.3% urban rich, 3.0% 
urban poor, 3.9% rural 
 
BHR, bronchial hyperreactivity; EIB, exercise induced bronchoconstriction; FEV1, forced expiratory volume in 1 second; ISAAC, International Study of Asthma and Allergies 




Table 2.2 continued 
Author and 
publication date 
Country and rural/urban location Number of 
subjects 
Age (years) Method of 
assessment  
Prevalence of asthma 
indicator 
Berntsen, 2009 80 Manyara region, Tanzania 
Rural 
172 9-10 ISAAC - video Current wheeze 12%, severe 
5% 
Calvert, 201081 Khayelitsha settlement and 
Kentani district, South Africa 
Urban / Rural 
3322 8-12 6-min exercise test 
(15% fall in FEV1), skin 
prick test, IgE 
EIB: 14.9% urban, 8.7% rural 
Hooper, 201272 Niakhar, Senegal 
Rural 




Warri and environs, South Nigeria 
Rural/urban 
1397 7-14 ISAAC - written Current wheeze 5.7% urban, 
4.1% rural 
Oluwole, 201383 Ibadan / Abanla; Eruwa; Igbo-
Ora, Nigeria 
Urban / Rural 
1736 13-14 ISAAC questionnaire, 
skin prick test, serum 
eosinophils, IgE 
“Asthma” 7.5% rural, 8.0% 
urban 
Shimwela, 201484 Ilala / Bagamoyo districts, 
Tanzania 
Urban / Rural 
1229 Mean (SD) 
16.8 (1.8) y 
ISAAC questionnaire Current wheeze: 23.1% 
urban, 12.1% rural 






ISAAC - written Current wheeze: 5% age 7-8, 
8% age 13-14 






ISAAC - written Current wheeze: ~16% both 
ages, severe ~5% 
 
BHR, bronchial hyperreactivity; EIB, exercise induced bronchoconstriction; FEV1, forced expiratory volume in 1 second; ISAAC, International Study of Asthma and Allergies 
in Childhood; PEFR, peak expiratory flow rate 
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Authors have proposed that EIB provides a more objective measure of asthma 
than questionnaire data, particularly in settings where questionnaire 
responses may be unreliable due to cultural and linguistic reasons.79 
However, studies which have reported both EIB and asthma symptom 
prevalence demonstrate that using EIB as a proxy for asthma will 
overestimate the true burden of asthma symptoms.73,85 A study of Kenyan 
school children reported EIB rates of 11% and 12% in rural-dwelling and 
urban-dwelling children, respectively.73 Of these 30 children with EIB, only six 
(20%) reported a history of symptoms or medication use consistent with a 
diagnosis of asthma. 
 A study in Cape Town, South Africa, reported overall EIB rates of 5% among 
randomly selected school children.85 Questionnaire data was also used to 
identify children with asthma, based on previous episodes of airflow 
obstruction with a positive response to bronchodilator treatment. Using this 
definition of asthma, EIB had a sensitivity of 0.31, and specificity of 0.97. The 
use of EIB as a community screening tool for asthma is likely to identify many 
children who do not have symptomatic asthma. However, it may be a useful 
test to support diagnosis in those who have presented with symptoms.  
Among children worldwide with current wheeze, those from Africa showed 
the highest prevalence (51%) of severe symptoms, defined as; ≥4 attacks, or 
wheeze disturbing sleep at least once weekly, or speech-limiting wheeze, in 
the past 12-months.51 The clinical significance of “current wheeze” is 
debatable, particularly given the frequency of episodic wheeze induced by 
viral infections in children. However, sleep-disturbing or speech-limiting 
attacks are clinically important and are highly specific for airway hyper-
responsiveness assessed by methacholine challenge.49 
2.2.2 Adults 
Data regarding asthma in Africa is limited, with most research focusing on a 
few countries (particularly South Africa and Nigeria).86 However, increasing 
prevalence has been reported over the past twenty years, with an estimated 
119.3 million cases (12.8% prevalence) of asthma in Africa in 2010.87  
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Estimates of global asthma prevalence in adults have been derived from the 
WHO World Health Survey, the only standardised global data on asthma 
symptoms and diagnosis in adults, conducted between 2002-2003. 88,89 In 
Africa, the prevalence of self-reported wheeze in the past year ranged from 
4.8% (in Mali) to 15.4% (in Swaziland), with an average of 7.7%. The 
prevalence of doctor-diagnosed asthma was lower: 3.9% on average. The 
prevalence of wheezing in the past year and doctor-diagnosed asthma in 
Malawi were 7.8% and 4.6%, respectively.89 
A systematic review of COPD-related data from sSA published before 2011 
reported COPD prevalence varying between 4-25%.60 However, of the nine 
studies included, only two (relating to the same dataset from South Africa) 
used robust population sampling and diagnostic methods.60,90  
The Burden of Obstructive Lung Disease (BOLD) Initiative, using standardised 
post-bronchodilator spirometry with quality control, has conducted studies in 
South Africa, Nigeria, Malawi and Tanzania.22,23,90-92 
Table 2-3 presents these BOLD studies, and others from sSA that have 
described obstructive and restrictive spirometric patterns, using post-
bronchodilator spirometry, with representative population sampling.  
A high prevalence of moderate to severe obstruction in adults aged >40 years 
has been reported in Cape Town, South Africa (19.1%) compared to 7.0% in 
Blantyre, Malawi, and 7.7% in Ife-Ife, Nigeria.22,90,91 High rates of cigarette 
smoking were reported in South Africa (83% men and 59% women “ever 
smokers”), compared to 10% in Malawi and 11% in Nigeria which may explain 
the observed differences in obstruction. A more recent BOLD study from 
Tanzania reported an overall COPD prevalence rate of 17.5%, with moderate-
severe obstruction in 10.9%: 25.2% of participants reported “ever-smoking”, 
including 5.4% “current smokers”.92  
The FRESH-AIR study in Masindi district, rural Uganda, reported a prevalence 
of COPD of 16.2%, defined as an FEV1/FVC <LLN (using European Community 
for Steel and Coal/European Respiratory Society reference ranges93), or 12.4% 
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based on the fixed GOLD criteria.94 However, this COPD prevalence includes 
GOLD stage 1; 3.6% of participants were categorised as having GOLD stage 2 
or greater, which is in keeping with subsequent studies in Uganda reporting 
prevalence ranging from; 1.7% in urban Kampala, 7.4% in rural Nakaseka and 
3.3% in rural Mbarara.95,96  
The comparison of global COPD literature is challenging due to differences in 
diagnostic criteria (FEV1/FVC <LLN threshold or fixed ratio), reference ranges 
used (NHANES, GLI, local) and age ranges of participants.54 To summarise the 
data presented in Table 2-3, the prevalence of moderate to severe airway 
obstruction in sSA countries is relatively low, ranging from 3.3 - 10.9%, with 
the exception of South Africa. A systematic review and meta-analysis of global 
COPD prevalence in 2010 reported rates of 15.2% in the Americas, 13.2% in 
the Eastern Mediterranean region and 12.0% in Europe.97 Within this review, 
of 140 study sites, there were only six studies from Africa, and only 2 studies 
which performed post-bronchodilator spirometry.97,98  
A strong positive association between airflow obstruction and pack-years 
smoked, has been demonstrated across all the BOLD sites.24 However, high 
mortality rates are associated with spirometric restriction (reduced FVC), 
rather than obstruction, and this is seen in poorer countries, where smoking is 
far less prevalent.24  
The prevalence of spirometric restriction reported in studies, is highly 
influenced by the chosen population reference range.66 The third US National 
Health and Nutrition Examination Survey (NHANES III) Caucasian range, has 
been used across the BOLD research centres, for consistency, and to permit 
comparison of study sites.61 Using this reference population, reported rates of 
restrictive spirometry are; 39% and 35% in urban and rural Malawi, 
respectively; 70% in Ife-Ife, Nigeria; 46% in Cape Town, South Africa.22,24,64 
However, when locally derived reference comparisons are made, the rates of 




Table 2-3 Studies from sub-Saharan Africa assessing post-bronchodilator lung function in adults 




Age ≥40y, random sample 
from population (BOLD)  





Aged ≥15y, systematic 





Local reference ranges*  14% FEV1/FVC<LLN, post bronchodilator: 




Aged ≥19y, random 
population sampling 




Reference range derived by 
Musafiri for Rwandan 
population65 
FEV1/FVC<LLN 3.8%, post bronchodilator 
FEV1/FVC<LLN 2.4% 
Van Gemert, 201694 
Uganda (rural) 
Aged >30y, random sampling 




African and Indian estimates 
from ECSC/ERS 199393 





Aged ≥18y, age- and sex-
stratified random sample 




NHANES III (Caucasian), local 
reference ranges* 
Restriction (FEV1/FVC>0.7 and FVC<80% 
predicted): 38.6% NHANES, 9.0% local 




Aged ≥40y, random sample 




GLI 2012 (African Americans)57, 
NHANES III (Caucasian), local 
reference ranges* 
Post BD FEV1/FVC<LLN 7.7% (GLI), 6.9% 
(NHANES), 3.5% (local) 
Obaseki, 201764 
Nigeria (suburban) 
As above As above As above Restriction (FVC<LLN); NHANES 70.4% 
M, 72.8% F; GLI 15.5% M, 20.5% F; local 




Author, date, country Study population Sample size Spirometry reference range Results 
Magitta, 201892 
Tanzania (rural) 
Aged ≥35y, random 




Unclear from methods COPD 17.5% overall (post BD FEV1/FVC 




Aged >18y, age and sex 
stratified random sample 




NHANES III (Caucasian) Obstruction (FEV1/FVC<LLN) 8.7%, 
restriction (FEV1/FVC>0.7 or LLN and FVC 
<80% predicted) 34.8% 
North, 201995 
Uganda (rural) 
Aged ≥18y, from enumerated 





NHANES III (African American) COPD (post BD FEV1/FVC<LLN) 2.3% 
overall, 3.3% in ≥40y 
*Local reference ranges generated from subset of asymptomatic, non-smoking study participants 
BD: bronchodilator; BOLD: Burden of Obstructive Lung Disease study; COPD: Chronic Obstructive Pulmonary Disease; ECSC/ERS: European Community for 
Steel and Coal/European Respiratory Society; FEV1: Forced Expiratory Volume in 1s; FVC: Forced Vital Capacity; GLI: Global Lung function Initiative; LLN: 




2.2.3 Urban-rural differences 
In the last twenty years, Africa has experienced a rapid rate of urban growth. 
By 2025, it is estimated that more than half of the population of Africa will 
live and work in urban centres.100 Asthma is more prevalent in urban than 
rural populations: a recent meta-analysis of studies from LMICs reported a 
higher prevalence of asthma in urban settings, regardless of the way in which 
asthma was defined.101  
As a growing proportion of the African population is exposed to urban 
environments, so the prevalence of asthma is expected to rise.87 Surveys in 
Ghana, conducted in 1993 and 2003, assessed exercise-induced 
bronchoconstriction (EIB) in children aged 9-16 years from urban rich, urban 
poor and rural schools.79 Over ten years, EIB doubled across all sites, with an 
overall increase from 3.1% (95% Confidence Interval (CI): 2.2-4.3%) to 5.2% 
(95% CI: 4.3-6.3%). Sensitisation, particularly to cat and dog, also increased 
significantly (from 7.6% (95% CI: 6.1-9.5%) to 13.6% (95% CI: 12.1-15.3%) with 
EIB and sensitisation more common in those children from urban rich schools. 
Table 2-2 includes some studies where an urban-rural comparison has been 
made. These data show an increased rate of asthma symptoms or EIB in 
urban-dwelling children in Ghana, Kenya, Tanzania and South Africa.73,79,81,84 
However, studies from Nigeria and Mozambique did not detect such 
differences.76,82,83  
Urbanisation is clearly an important determinant of asthma prevalence, but 
the simple urban-rural categorisation does not permit a deeper 
understanding of the lifestyle or socioeconomic factors which might cause 
this.101 Furthermore, there is no agreed operational definition of “urban” or 
“urbanisation” to facilitate meaningful comparison or pooling of data. 
It has been proposed that childhood infections are less frequent in urban 
settings due to improved personal and public hygiene, and increased access 
to health care and use of antibiotics. However, in rapidly growing cities, living 
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conditions in some areas may be inferior to that in rural areas, with 
widespread poverty, inadequate housing, infrastructure, and poor access to 
services.102 
Urbanisation is also associated with increased environmental pollution, a 
more sedentary lifestyle, unhealthy “processed” diets and obesity; these 
factors are all linked to increased risk of asthma.103,104  Studies from high-
income countries (HIC) have demonstrated decreased prevalence of asthma 
and atopy among children raised in rural, farming environments.105 Early 
exposure to animals, consumption of unpasteurised farm milk, and high levels 
of endotoxin (a proxy for microbial exposure) have been associated with 
decreased asthma and atopic diseases. Studies of children from Amish 
traditional farming communities reveal extremely low rates of asthma, high 
levels of endotoxin exposure and differences in innate immune profiles, when 
compared to children from alternative farming communities in the USA.106 
Strachan’s original “Hygiene Hypothesis” proposed that early life infections 
might contribute to the development of the immune system and protect 
against allergic disease.107 However, the complex balance between microbe-
driven proinflammatory, type-1 T-helper cell innate immune responses and 
allergen-driven proallergic, type-2 T-helper cell adaptive immune responses 
are yet to be fully understood.108,109 
 
2.3 Non-communicable lung disease across the life course 
2.3.1 Lung development: airway and alveolar growth 
Human fetal lung development occurs in five phases (Table 2-4) with 
formation of the conducting airways and alveoli, essential components for 




Table 2-4. Phases of in-utero lung development 
Synthesized from Copland 2004, and Stocks 2013110, 111 
Embryonic phase 
4-7 weeks’ gestation 
Lung buds develop 
Pseudoglandular phase 
7-16 weeks’ gestation 
Conductive airway pattern develops 
Early airway epithelium differentiation 
Canalicular phase 
17-26 weeks’ gestation 
Completion of airway branching 
Development of gas-exchange region 
Saccular phase 
27-36 weeks’ gestation 
Growth and maturation of peripheral airways, 
differentiation of alveolar epithelial cells and 
maturation of surfactant system 
Alveolar phase 
34 weeks’ gestation to 
adolescence 
Increase in alveolar number and subsequent 
increase in gas exchange area 
Timings are approximate and there is overlap between developmental phases 
 
By the start of the third trimester of pregnancy (27-weeks’ gestation), airway 
branching is completed, the gas-exchange region is developing, and 
surfactant production has begun. Subsequently, there is further growth of the 
pulmonary parenchyma and maturation of the surfactant system. From 
approximately 32-weeks’ gestation, there is rapid expansion of alveolar 
numbers and resulting lung growth, which continues postnatally during the 
first 2 years of life. Stereological assessment of lungs from human autopsies 
and studies using helium-3 magnetic resonance to assess alveolar size, 
suggest that neoalveolarization continues throughout childhood and 
adolescence.112,113 After this point, alveolar size continues to increase with 
somatic growth but alveolar numbers remain constant, at around 300-600 
million.114 There is some evidence that lung growth is possible in adulthood, 
through expansion of alveolar numbers, under specific circumstances (post-
pneumonectomy).115 
In comparison to alveolar development, which is predominantly a postnatal 
process, airway development in largely completed by birth. Airway branching 
is completed by 17 weeks’ gestation, following which there is increasing 
vascularisation, and enlargement of the airway lumen, with reduction of 
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connective tissue (the canalicular phase).116 Airway growth, with increasing 
airway diameter and length, continues to a plateau at 20-25 years of age, with 
gradual decline thereafter.57  
Insults to the lungs at any point across the life course have the potential to 
disrupt the normal stages of growth and development. Repair of damaged 
airways, known as pathological remodelling, can affect various airway 
elements, including the epithelium, smooth muscle cells, extracellular matrix, 
nerve tissue and vasculature.117 In asthma, the changes typically involve 
thickening of the reticular basement membrane, increased airway smooth 
muscle mass, angiogenesis and goblet cell hyperplasia.118 COPD is associated 
with a thickened airway smooth muscle layer, with disproportionate increase 
in extracellular matrix, enlargement of submucosal mucous glands with 
hypersecretion, and destruction of the peripheral airways.119 
Pathological remodelling can develop during early childhood. Bronchial 
reticular basement membrane thickening and eosinophilic inflammation are 
absent in wheezy infants with reversible airflow obstruction: however, these 
abnormalities were identified in a group of children (median age 29-months) 
with severe pre-school wheeze.120,121  
The early life origins of lung function and respiratory disease have been 
established in several longitudinal cohort studies, all conducted in HIC.111  
Meta-analysis of 25,000 children from 24 birth cohorts, reported that 
prematurity, low birth weight and greater infant weight gain were associated 
with an increased risk of childhood asthma.122 The Tucson Children’s 
Respiratory Study described symptom patterns in early childhood; transient 
early wheeze (present before age 3 years, but not at 6 years), persistent 
wheeze (present before age 3 years and at age 6 years) and late-onset 
wheeze (no wheeze before age 3 years, but present at 6 years). Children with 
persistent wheeze show substantially lower FEV1 at age 6 years, compared to 
transient early wheezers.123 Follow-up of this cohort found that wheezing at 
age 6 years (whether persistent or late-onset), was associated with continuing 
symptoms at age 16 years, and that deficits in lung function are present by 
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age 6 years, with little change thereafter.29 Furthermore, children with 
wheeze before the age of 3 years demonstrate decreased lung function in 
early childhood, which persists throughout adolescence, even in the absence 
of continued wheezing symptoms.29  
Late-onset or persistent wheeze, or bronchial hyperreactivity in the absence 
of symptoms at age 6 are strong predictors for both chronic and new-onset 
asthma in adults.32  
Cohort studies from Dunedin, New Zealand and Melbourne, Australia, also 
reported tracking of lung function, with lung function following centiles set in 
early childhood throughout later childhood and adulthood, regardless of 
asthma severity.31,34  
The Copenhagen Prospective Studies on Asthma in Childhood (COPSAC) 
followed “at-risk” infants of asthmatic mothers, and reported that children 
who developed asthma symptoms by age 7-years had significant airflow 
deficits and bronchial hyperresponsiveness as neonates.124 
The Drakenstein Child Health Study (DCHS) in South Africa, will provide data 
of greater relevance to populations in sSA, as their cohort ages. This is 
particularly important as potential risk factors for adverse lung health 
outcomes vary between high- and low-income settings, with determinants 
such as prematurity and low birth weight, in-utero HIV-exposure, early life 
LRTI and exposure to indoor air pollution more common in LIC.125-128 
2.3.2 Determinants of respiratory health 
Factors affecting the lungs during critical periods of growth and development, 
both before and after birth, may have a long term impact on lung health in 
adulthood.114 In a low-income setting such as Malawi, prenatal risk factors 
such as poor maternal nutrition and in-utero exposure to particulate matter 
are commonly encountered. Low birth weight (LBW), due to premature 
delivery, suboptimal intrauterine growth, or a combination of the two, is 
associated with worse adult lung function.129 Postnatally, poor nutrition, 
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exposure to air pollutants, and respiratory infections, including tuberculosis 
(TB) and HIV-related infections, are of particular concern. 
2.3.2.1 Maternal exposure to inhaled pollutants during pregnancy: tobacco 
smoke, household and ambient air pollution  
There is strong evidence from HIC that in utero exposure to tobacco smoke is 
associated with reduced respiratory function in the early neonatal period, and 
increased prevalence of respiratory infections and asthma.130,131 The South 
African DCHS reported altered lung function at age 6-10 weeks in infants of 
maternal smokers, and increased wheeze and lower respiratory tract 
infection (LRTI) at age 1-year.125,127 Tobacco smoke contains thousands of 
chemicals, of which nicotine is thought to be a key mediator of altered 
pulmonary function. Nicotine exposure is unlikely to be a major problem in 
Malawi, where rates of maternal smoking are low, but impaired lung 
development may also result from hypoxaemia, secondary to carbon 
monoxide (CO). High levels of carbon monoxide are found in cigarette 
smokers and are also seen in those using biomass fuels to cook in low-income 
settings.23 The effect of in utero household air pollution, from incomplete 
combustion of biomass fuels, on fetal lung development is largely unknown. 
Recent work from Ghana described an association between in utero 
household air pollution exposure and impaired infant lung function, at 30 
days of age.40 In South Africa, antenatal exposure to the volatile organic 
compound toluene was associated with severe LRTI in infants; further 
research on this kind of exposure in early life is needed.127 
A few studies from high-income settings have explored the impact of air 
pollution exposure during pregnancy and postnatal lung function.132 One 
study measured lung function at 5 weeks of age and found altered lung 
function associated with higher maternal exposure to particulate matter 
≤10µm (PM10), particularly during the last trimester of pregnancy.133 Clinically 
significant lung function impairment at preschool age has been associated 
with higher levels of maternal exposure to outdoor air pollution (benzene, 
nitrogen dioxide (NO2) and fine particulate matter ≤2.5µm (PM2.5)) during 
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pregnancy.134,135 A population based nested case-control study reported an 
increased risk of asthma diagnosis with increased exposure to pollutants (CO, 
nitrogen oxides, PM10 and sulphur dioxide (SO2)) in utero and during the first 
year of life, with the strongest effects noted for traffic-related pollutants.136 
2.3.2.2 Maternal nutrition during pregnancy 
Modification of maternal nutrition has been suggested as a potential strategy 
in the primary prevention of asthma, with particular interest in maternal 
intake of vitamins D, E and omega-3 polyunsaturated fatty acids (PUFAs) 
during pregnancy.137,138 
Vitamin D is reported to have antimicrobial, antiviral and anti-inflammatory 
activity; vitamin D supplementation of known asthmatic patients has been 
found to decrease the rate of exacerbations requiring oral 
corticosteroids.139,140 
Observational studies exploring the role of maternal nutrition on childhood 
respiratory outcomes have suggested that higher intake of vitamins D, E and 
zinc during pregnancy is associated with a decreased risk of wheezing during 
the first 5 years of life.141,142 A large UK-based birth cohort study (n=8915) 
reported a beneficial effect of maternal zinc intake during pregnancy on lung 
function at age 7-9 years but no effect on asthma diagnosis, and found no 
association between other antioxidants, including vitamin E, and asthma or 
lung function.143 Although randomised-controlled trials (RCTs) from Denmark 
(Copenhagen Prospective Studies on Asthma in Childhood: COPSAC) and USA 
(Vitamin D Antenatal Asthma Reduction Trial: VDAART) suggested that high 
dose vitamin D3 supplementation during the second and third trimester of 
pregnancy might protect against wheeze at age 3 years, neither trial found an 
effect on asthma diagnosis at age 6 years. 144-146 
The COPSAC group also conducted an RCT (n=736) of n-3 long-chain PUFA 
supplementation during the third trimester of pregnancy. A 31% risk 
reduction for persistent wheeze at age 3-5 years was seen in children of 
32 
 
mothers receiving supplementation, with the greatest effect seen in mothers 
with the lowest blood levels of long-chain PUFAs at randomisation.147 
There has been no research to date on maternal micronutrient status and 
respiratory outcomes in LIC. However, a recent systematic review and meta-
analysis reported a high prevalence of vitamin D deficiency across the African 
continent, with women and newborns at particular risk.148 
Considering maternal nutritional intake more broadly, maternal 
undernutrition and subsequent fetal undernutrition leads to intrauterine 
growth restriction (IUGR).149 The effects on lung structure depend on the 
gestational timing and severity of IUGR; potential mechanisms include 
impaired alveolarization, thickening of inter-alveolar septa due to increased 
extracellular matrix deposition, and thickening of the alveolar blood-air 
barrier due to increased basement membrane thickness.150,151 IUGR, which 
may also result from non-nutritional factors, is discussed further in section 
2.3.2.3. 
2.3.2.3 Low birth weight and prematurity 
Low birth weight (LBW) – a birth weight of <2500g - may be due to IUGR, 
premature delivery (before 37-weeks’ gestation) or both. Premature delivery 
and IUGR are more common in LICs; in sSA approximately one in eight infants 
are born early and Malawi has the highest rate of premature birth (18.1%) in 
the world.152 Young maternal age and short inter-pregnancy intervals are 
common risk factors contributing to premature delivery and IUGR. Poor 
maternal nutrition, intrauterine and systemic infection (e.g. malaria and 
syphilis), and physical labour during pregnancy may precipitate early labour, 
while low maternal weight, hypertensive disorders of pregnancy, and 
congenital infections (e.g. cytomegalovirus, HIV, syphilis and malaria) are 
associated with IUGR.153,154,155 Meta-analysis of studies from HIC found a 
strong association between birth weight and adult FVC; with 60ml higher FVC 
in adulthood per kg increase in birth weight (95% CI: 43-76ml), but weaker 
evidence for airflow obstruction.156  
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A recent meta-analysis of 11 studies conducted in HIC, found that infants born 
<32 weeks’ gestation or with a birth weight <1500g had decreased airflow in 
late adolescence and early adulthood, with a mean difference in FEV1 z-score 
of -0.78 (95% CI: -0.96 - -0.61) compared to infants born at term or with 
normal birthweight.157 The infants included in these studies were born before 
the early 1990s, when surfactant therapy was not available, as is currently the 
case in Malawi. Babies with bronchopulmonary dysplasia were found to have 
worse lung function: however, bronchopulmonary dysplasia is usually seen in 
infants who have required invasive mechanical ventilation which is not 
available in low-income countries. Reduced lung function is also seen in 
infants born moderately to late preterm (i.e. at 32-36 weeks’ gestation); a 
Swedish birth cohort study found no evidence of catch-up lung growth for 
these children at the age of 16 years.158  
Due to the lack of intensive neonatal care, babies born very prematurely or 
with a birth weight of <1000g in Malawi are unlikely to survive.159 However, 
there is increasing availability and use of non-invasive continuous positive 
airways pressure (CPAP) in LMIC hospitals.160 Low-cost bubble CPAP machines 
were evaluated on the neonatal ward at Queen Elizabeth Central Hospital in 
Malawi in 2012; survival rates of infants weighing 1000-1500g were greater in 
those who received CPAP treatment: 65.5% (95% CI: 47–80%) in the CPAP 
group compared to 15.4% (95% CI: 4–45%) in the control group (p<0.001).161 
As advances in neonatal care in LMIC result in improved outcomes for LBW 
and premature infants, it is likely that increasing numbers of survivors will 
reach adulthood with sub-maximal lung volumes and airflow deficits. 
2.3.2.4 The effect of breastfeeding on lung health 
Human breast milk contains many immunological components, including 
antimicrobial, anti-inflammatory and immunomodulatory agents.162 It is 
widely accepted that breastfeeding reduces morbidity and mortality related 
to LRTIs.163,164,165 Meta-analysis of 18 studies estimated that breastfeeding 
reduces the risk of LRTI by 32% (pooled relative risk (RR) [95% CI] 0.68 [0.60-
0.77]), LRTI-related hospital admissions by 57% (pooled RR [95% CI] 0.43 
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[0.33-0.55]), and LRTI-related deaths by 70% (pooled RR [95% CI] 0.30 [0.16-
0.56]).166 
However, the effect of breastfeeding on the development of wheeze and 
asthma, is less clear. Results are conflicting, there is heterogeneity of 
methodology and definitions used, and the ethical problem of conducting 
RCTs with breastfeeding mothers limits the quality of evidence available. 
Human milk composition varies within and between mothers, which may also 
explain conflicting data, particularly relating to breastfeeding and the 
development of allergic sensitisation and allergic disease.167 Furthermore the 
research largely represents populations from HIC: a systematic review of 117 
studies included only one study from Africa, and no studies were from LIC.168 
The findings of this systematic review suggested that breastfeeding protects 
against the development of childhood asthma, with the strongest association 
seen in children aged 0-2 years old.168 Another meta-analysis reported 
decreased asthma at age 5-18 years in breastfed children, with a greater 
effect seen in LMIC (odds ratio (OR) (95% CI) 0.78 (0.70, 0.88)), however the 
quality of included studies were suboptimal.169 Phase 2 of ISAAC reported 
decreased nonatopic wheeze in children who had been breastfed, with a 
stronger effect in those from LMIC: adjusted OR (95% CI), 0.69 (0.53-0.90) vs 
0.87 (0.72-1.06) for LMIC and HIC, respectively.170 It seems likely that the 
major effect of breastfeeding is on respiratory infection induced wheeze 
rather than atopic wheeze.167 In addition, the reduction in early life 
respiratory infections associated with breastfeeding may reduce the 
subsequent development of asthma.169 The role of early life respiratory 
infections and subsequent lung health is discussed further in section 2.3.2.7. 
In Malawi, it is recommended that children are exclusively breastfed in the 
first 6-months of life. In practice however, the rate of exclusive breastfeeding 
declines with age, as other liquids and complimentary foods, most commonly 
porridge, are added to the diet. Overall 61% of infants aged below 6-months 
are exclusively breastfed: 80% at age 0-1 month, 69% at age 2-3 months and 
34% at age 4-5 months.10 
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2.3.2.5 Malnutrition during childhood 
The recent ChroSAM study from Malawi followed children who were 
admitted to hospital for severe acute malnutrition (SAM) during early 
childhood.171 Survivors of SAM had comparable lung function to two control 
groups (siblings and community controls) at 7-years post-treatment; however 
46% of the SAM cases had died before follow-up: these children are likely to 
have had more severe disease and possibly poorer lung function had they 
survived.172 Stunting of somatic growth, with preserved torso height and 
shorter legs, is seen in survivors of malnutrition and might suggest that lung 
function could also be preserved. 
A cross-sectional study of school-aged children from Angola, Democratic 
Republic of Congo and Madagascar found reduced FEV1 and FVC z-scores, but 
normal FEV1/FVC ratios, comparing undernourished (BMI z-score <-2) to 
normally grown children, suggesting decreased lung growth without evidence 
of airway obstruction.173 
2.3.2.6 Exposure to inhaled pollutants during childhood: tobacco smoke, 
household and ambient air pollution 
Over 90% of the world’s population breathe air that fails to meet WHO Air 
Quality Guidelines, with those from least developed countries worst 
affected.174 Inhaled pollutants come from various sources: exposure levels 
depend on many factors including social habits, domestic fuel use, 
urbanisation, traffic and transport, power plants and industry, policy and 
legislation.175   
There is strong evidence from across the globe, that children exposed to 
tobacco smoke, from either parent, have an increased risk of asthma.176 This 
risk is greatest for children exposed to maternal smoking in the first year of 
life, highlighting the importance of exposures during early childhood. 
Large cohort studies from high-income settings, following children in later 
childhood, have explored the impact of both regional air quality and local 
traffic exposure on lung development. Diminished lung function, most notably 
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FEV1, was found in children exposed to higher levels of air pollution 
(particularly NO2, PM2.5, acid vapour and elemental carbon).177-179 Conversely, 
long term improvements in air quality, with significantly decreased PM2.5 and 
NO2, have been associated with positive effects on lung function-growth in 
older children.180 
Although it is well established that outdoor air pollution contributes to 
exacerbations of pre-existing asthma, the association with new-onset asthma 
is less clear.104 There is accumulating evidence that ambient air pollution, 
particularly traffic-related, is associated with incident asthma in 
children.136,181-183 However, a meta-analysis of cross-sectional studies 
comparing communities with different air pollution levels, found no effect of 
long-term exposure to pollution on asthma diagnoses at community level.184 
Inhaled pollutants could contribute to the development of asthma through 
several proposed mechanisms; 1. oxidative stress and airway damage, 2. 
airway wall remodelling, 3. inflammatory pathways and immunological 
effects, 4. enhanced respiratory sensitisation to allergens.185  
Research has tended to focus on individual pollutants, reflecting air quality 
regulation methodology. However, the health effects of the pollutant mixture 
may be more relevant.104 Traffic-related air pollution is a complex pollution 
mixture containing particulate matter and primary gaseous emissions, 
including nitrogen oxides: these emissions in turn generate secondary 
pollutants such as ozone, nitrates and organic aerosols. The concentration of 
these pollutants decrease with distance from roadways: those living within 
300-500m of roadways are at greatest risk of adverse health effects.186 
Consideration of type of traffic, in addition to distance from traffic may also 
be important: ISAAC reported a positive association between self-reported 
exposure to truck traffic on the street of residence and asthma symptoms.187 
Exposure to household air pollution is a major concern in LMICs, where the 
use of inefficiently burned, highly polluting biomass fuel is common. Biomass 
is plant or animal material used for energy production, comprising five 
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primary components: cellulose, hemicellulose, lignin, extractives/volatiles and 
ash. In Malawi, over 95% of households depending on biomass (e.g. wood, 
charcoal, crop residues, animal dung) as their main source of fuel.188 
Incomplete combustion using traditional “open-fire” cooking methods 
produces high levels of pollutants such as CO and PM.189,190Exposure to solid 
fuel use assessed through questionnaires and interviews is associated with 
increased pneumonia risk in children aged under five years.191,192 However, 
the few studies that assessed exposure through objective measurements of 
CO and PM2.5 have not confirmed this association, raising the possibility that 
this association is at least partly explained by confounding by other poverty-
related exposures.193 Increased respiratory infections in early childhood may 
lead to long term defects in lung function, as discussed in section 2.3.2.7. 
The effect of household air pollution on wheezing and asthma is unclear. 
ISAAC reported an association between the use of open fires for cooking  and 
increased wheeze (OR 2.17 (95% CI) 1.64-2.87).194 However, a previously 
published meta-analysis of four small asthma studies in children exposed to 
biomass fuels was inconclusive, reporting a pooled OR of 0.5 (95% CI 0.12-
1.98).191 Young children are susceptible to high concentrations of particle 
deposition in lung tissue, due to physiological and anatomical factors.195 
Environmental exposures, including inhaled pollutants, during critical periods 
of lung growth and development may lead to irreversible long term deficits in 
adult lung function.55,178 
2.3.2.7 Respiratory infections in early life 
The importance of childhood respiratory infections on mortality in childhood 
and adult lung function is well recognised.129,196 Acute respiratory infections 
are the leading cause of death in children aged under five years worldwide, 
and may lead to long term sequelae in survivors, particularly in populations 
with significant comorbidity, such as HIV and malnutrition.197,198  
A meta-analysis evaluating long-term pneumonia outcomes in children under 
5-years, reported the risk of serious sequelae (restrictive lung disease, 
obstructive lung disease, bronchiectasis) as 13.6% and 5.5%, in hospitalised 
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and non-hospitalised children respectively, with the highest risk (15.7%) in 
children from Africa.199 Minor sequelae (including chronic bronchitis and 
asthma) were also reported in 6.7% of children overall. 
Wheezing illnesses in infancy due to respiratory syncytial virus (RSV) and 
rhinovirus are associated with increased risk of childhood asthma in later 
childhood.200 Adenovirus infection is associated with the highest rates of long-
term sequelae, including development of bronchiolitis obliterans in 
LMIC.199,201 
Globally, RSV is the commonest cause of childhood respiratory infection, with 
the highest incidence seen in LIC.202 Rhinovirus is the most frequent causative 
agent of upper and lower respiratory tract infections in infants and young 
children.203 Rhinovirus and RSV are both common in Malawi; RSV was 
detected in 12%, and rhinovirus in 20%, of severe acute respiratory illness 
cases seen in the paediatric department at Queen Elizabeth Central Hospital, 
Blantyre, between 2011-2014.204  
Children from a high-risk birth cohort (with parental allergy or asthma) 
showed an increased risk of asthma at age 6 years, following wheezing viral 
infections in the first 3-years of life: OR 2.6 with RSV, OR 9.8 with rhinovirus 
and OR 10.0 with RSV/rhinovirus co-infection.205 This increased asthma risk 
persisted at age 13-years following early life rhinovirus infection (OR 3.3 [95% 
CI: 1.5-7.1]) but not RSV infection.206 Spirometric assessment of children in 
this cohort at age 8-years demonstrated significantly decreased lung function; 
FEV1 (p=0.001) and Forced Expiratory Flow25-75 (p<0.001), in children with 
wheezing RV infection in the first 3-years of life.207 Aeroallergen sensitisation 
(measured by allergen-specific IgE) led to an increased risk of rhinovirus 
wheezing throughout the first 6-years of life (RR 2.3, 95% CI: 1.3-4.0).208 
The Tucson Children’s Respiratory Study Group reported an increased 
prevalence of wheeze (both frequent and infrequent) until age 11, following a 
relatively mild RSV LRTI (not requiring hospitalisation) during the first 3-years 
of life.209 However, by age 13-years this risk was no longer significant. In 
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contrast, a cohort of children with severe RSV LRTI in the first year of life 
demonstrated an increased prevalence of allergic asthma and decreased lung 
function, compared to controls, at age 18-years.210 
The question remains as to whether respiratory virus infection in early life is a 
causal factor in the development of asthma, or whether the association 
represents a vulnerability to viral infections in children with pre-existing 
airway abnormalities.203 The DCHS identified LRTI as an independent risk 
factor for reduced lung function at age 1-year, independent of baseline lung 
function.126 There are biologically plausible mechanisms for a causal 
relationship: inflammatory mediators induced by viral infection in early life 
may alter adaptive and innate immune responses and lead to remodelling of 
the developing alveoli and airways.211 HIV-infected children are at increased 
risk of infection from common childhood respiratory pathogens (viral and 
bacterial), and opportunistic pathogens such as Pneumocystis jirovecii, 
cytomegalovirus and Mycobacterium tuberculosis.198 Adolescents from sSA 
with perinatally acquired HIV infection have high rates of chronic respiratory 
symptoms, abnormal spirometry and chest radiographic abnormalities with 
increased burden among those with delayed diagnosis.212 HIV-exposed 
uninfected children show altered lung function in early life, with greatest risk 
for children of mothers with more severe disease.128 
Both immunocompetent and HIV-infected children are at risk of TB infection 
in a high prevalence country, such as Malawi. Late diagnosis or inadequate 
treatment, may lead to long term lung complications, including scarring and 
bronchiectasis.213  
2.3.2.8 Atopic sensitisation and asthma 
Atopic sensitisation and asthma are strongly associated, but it is unclear 
whether atopy is a causal risk factor for asthma.200,214 Atopy – the tendency to 
produce an exaggerated IgE immune response to an environmental exposure 
– is one of the main risk factors for asthma in high income settings. Allergens 
reported in African studies of atopy include cockroach, mango blossom and 
mouse, in addition to common allergens found in HIC; house dust mite, cat, 
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dog, grass and tree pollens. 74,83 Exposure levels are likely to differ between 
high- and low-income settings due to lifestyle differences: for example, pets 
in LMIC are predominantly kept outdoors.215  
ISAAC Phase 2 reported increased atopic sensitization and asthma symptoms 
in more affluent countries, and suggested that non-atopic asthma might be 
more prevalent in LMIC.214 Of note, only one country from sSA (Ghana) was 
included in the analysis. Atopic sensitization and allergic diseases are 
increasing in Africa, along with urbanisation and associated lifestyle 
changes.216 Rates of atopic sensitisation have doubled in Ghana over a 10-
year period, particularly among children from wealthier urban settings (from 
10.6% to 20.2%), with sensitisation to house dust mites (6.4%), cat (4.6%) and 
dog (3.1%).79 
Previously reported low rates of asthma in African studies were speculated to 
be due to intestinal helminth infection, with the hypothesis that parasite-
induced non-specific IgE might block receptor sites on mast cells and 
basophils, and prevent development of atopic disease. However, studies 
conducted in LMIC over recent decades have produced conflicting results: 
individual responses to parasite infections are likely to differ depending on 
the intensity and duration of infection, and helminth species.217 For example, 
hookworm infection has been associated with a reduction in asthma (OR 0.50, 
95% CI: 0.28-0.90, 9 studies), and Ascaris lumbricoides with an increased risk 
(OR 1.34, 95% CI: 1.05-1.71, 20 studies).218  
The development of atopy and allergic disorders, such as asthma, eczema and 
rhinitis, are influenced by a complex interaction of socioeconomic, 
environmental, dietary, and genetic factors.  
There is a strong genetic predisposition to atopy and allergic diseases, which 
often cluster within families. Genetic predisposition is an important but 
poorly understood risk factor for childhood asthma.200 While it is well 
recognised that a positive family history increases the likelihood of asthma 
developing in a child, inheritance does not follow a classic Mendelian pattern. 
41 
 
Many genetic loci across many chromosomes have been associated with 
asthma, with each gene contributing only a small fraction of disease risk, and 
heterogeneity of clinical phenotypes further confusing attempts to define the 
disease at a genetic level.219 To date, there is a lack of published data 
exploring genetic profiles of asthmatic individuals in sSA. 
2.3.2.9 Exposure to inhaled pollutants in adulthood: tobacco smoke, 
household air pollution and occupational exposures 
The detrimental effect of active tobacco smoking has been long established, 
with longitudinal studies documenting accelerated decline in FEV1 among 
smokers compared to non-smokers.220 Active smoking during adolescence 
impairs lung growth, meaning that lung function in young adults starts to 
decline from a lower peak FEV1.221 Once lung function decline begins, 
moderate to heavy smoking men have, on average, an annual decline in FEV1 
15ml greater than non-smokers, with a slightly lower effect reported among 
female smokers.220 
Accelerated FEV1 decline is one route by which patients may reach a lung 
function threshold in keeping with COPD.222 In those with mild-moderate 
COPD, smoking cessation has been reported to result in an improvement in 
FEV1 (47ml on average) in the year after quitting, and a subsequent reduction 
in the rate of decline: mean (standard deviation (SD)) 31 (±48) ml/year 
compared to 62 (±55) ml/year in continuing smokers.223 However, recent data 
from six US population based cohorts reported FEV1 decline at the median 
age (57 years) of 31.0 ml/year (95% CI: 30.7-31.4) in never smokers, 35.0 
ml/year (95% CI: 34.4-35.6) in former smokers and 39.9 ml/year (95% CI: 38.9-
40.9) in current smokers, suggesting that the ongoing process of progressive 
lung damage continues even after smoking cessation.224 Of particular 
relevance to sSA, active smokers are at increased risk of TB infection, with 
potential long-term respiratory sequelae.225 Compared to high-income 
settings, the incidence of lung cancer is relatively low in sSA, although data 
are unreliable due to challenges in diagnosis and reporting; tobacco smoking 
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is an important risk factor and explains the higher burden of lung cancer 
reported in men throughout the region.226 
The effects of household air pollution on adult lung health are likely to be 
most pronounced among women, due to greater involvement in domestic 
activities, including daily cooking.227 Studies have demonstrated increased 
respiratory symptoms (cough and sputum production), chronic bronchitis and 
obstructive airways disease among women who cook with biomass 
fuels.191,228,229  
The WHO identifies household air pollution, arising from solid fuel use for 
cooking, as a major risk factor for COPD worldwide.227 However, the studies 
informing this conclusion have largely included self-reported biomass fuel 
use, rather than objective measurement of pollution, and heterogeneous 
outcome variables, rarely including post-bronchodilator spirometry to 
diagnose COPD.230 Recent meta-analyses report conflicting results; a meta-
analysis of 25 BOLD study sites found no association between airflow 
obstruction and self-reported use of solid fuels for cooking or heating, in LMIC 
and HIC, while a pooled analysis from 13 LMIC sites reported increased COPD 
in those with self-reported household air pollution exposure (adjusted OR 
1.41 [95% CI: 1.18-1.68]).96,231 The challenges in relying on self-reported 
exposure data, which is subject to recall bias and misclassification, and 
inadequate adjustment for confounding factors are potential explanations for 
the conflicting results; furthermore all included data were from cross-
sectional surveys and therefore suboptimal for assessing a causal relationship. 
Intervention studies aiming to reduce household air pollution exposure and 
improve respiratory outcomes for adults have also yielded inconclusive 
results.232  
An RCT conducted in Mexico, comparing a Patsari chimney stove intervention 
with continued use of open fire for cooking, reported a significant reduction 
in respiratory symptoms and lung function decline among women who 
adhered to the intervention. Annual decline in FEV1 was 31ml among Patsari 
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users, compared to 61ml in those using open fires. However, only half of 
participants adhered to the intervention, and on intention-to-treat analysis of 
lung health indicators, no impact was observed.233   
The RESPIRE study in the Guatemalan highlands randomised women to 
receive a chimney woodstove (plancha) or continue cooking on a traditional 
indoor open fire. Women in the intervention arm reported reduced 
respiratory symptoms, especially wheeze, at follow-up but no significant 
effects on lung function were observed after 12-18 months.234 Further 
analysis reported an association between CO in exhaled breath levels (a proxy 
for household air pollution exposure), respiratory symptoms and decreased 
FEV1.235 However, lung function was not associated with average post-
intervention personal 48-hour CO exposure, measured by passive diffusion 
tubes at various timepoints.235 The inconsistent results from the two methods 
of CO measurement in this study cause more confusion than clarity and 
highlight the challenges in obtaining accurate measurement of personal 
exposure to household air pollution.236  
Although an uncommon diagnosis in Malawi, occupational lung disease is a 
considerable problem among miners (of gold, platinum and diamonds) in 
mineral-rich sSA countries.237 Inhalation of silica dust by South African gold 
miners causes inflammation and irreversible nodular fibrosis of the lungs 
known as silicosis with lung function decline proportional to the degree of 
pulmonary changes.238 Silica dust exposure and silicosis have additional 
negative impacts on lung health, as strong risk factors for pulmonary TB.239,240 
The majority of Malawians work in agriculture (59% women, 44% men), 
usually subsistence farming, or perform unskilled manual labour (20% 
women, 25% men).10 
2.3.2.10 HIV and TB in adulthood 
Despite advances in screening and access to treatment, sSA continues to face 
the greatest global burden of both HIV and TB infection.241,242 In sSA in 2017, 
an estimated 723,000 people were diagnosed with new HIV infection and 
712,000 people died from HIV.241  In 2015-16, the overall HIV prevalence 
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among those aged 15-49 years in Malawi was 10.4%, with higher rates among 
women (12.2%) compared to men (8.3%).10 Many HIV-infected people living 
in LMIC experience serious or fatal lung complications; impaired host 
defences increase the frequency and severity of bacterial, mycobacterial, 
fungal, viral and parasite infections. Additionally, non-infectious lung 
disorders; lung cancer, pulmonary arterial hypertension and COPD, are more 
common in HIV-infected individuals.243 Among those living with HIV/AIDS, TB 
is the major cause of mortality worldwide.243 However, although HIV and TB 
are common co-infections in sSA, worldwide in 2016 the majority of new TB 
cases and deaths occurred in HIV-negative individuals.242  
HIV is the most important risk factor for developing active TB in Malawi: the 
prevalence of TB climbed rapidly in parallel with HIV prevalence, peaking 
around 2004 when the national scale-up of anti-retroviral treatment (ART) 
began.244 Since then, TB cases have started to fall: in 2014 the national TB 
prevalence survey reported ~18,000 cases compared to ~28,000 in 2003.245  
TB is associated with considerable morbidity, with increasing recognition of 
the long-term consequences of infection.246 Up to half of TB survivors have 
some form of persistent respiratory dysfunction despite microbiological cure, 
with a wide range of structural abnormalities and consequent symptoms.247 
Cavitation, bronchiectasis and fibrosis are the main features seen on chest x-
ray, with nodules, consolidation and emphysema identified using CT 
imaging.248 Resulting lung function impairment may include both obstructive 
and restrictive patterns, with increasing evidence that TB plays a role in the 
development of COPD.247,249  
2.3.2.11 Emerging threats in sSA 
Research from HIC suggests that obesity increases an individual’s risk of 
developing asthma and may lead to more severe disease and resistance to 
asthma treatment.250 Although previously considered a problem of HIC, 
childhood obesity is now a growing concern across the globe, including 
LMIC.251 Childhood obesity rates are generally low in sSA, however southern 
Africa had the largest proportional rise in obesity among 5- to 19-year olds 
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between 1975 and 2016, globally.251 In southern Africa, 13.7% children under 
5-years age are overweight, compared to <5% in eastern, middle and west 
Africa.252 This increasing public health problem is likely to have a major impact 
on the prevalence of non-communicable diseases, including chronic 
respiratory conditions, across sSA. Further research is needed to explore 
obesity prevention interventions in LMIC, to impact on dietary behaviours and 
physical activity levels.252 
Another emerging global public health concern is the use of electronic 
cigarettes (e-cigarettes), particularly among young people. Lack of long-term 
safety data means that the effect of chronic exposure to e-cigarette 
emissions, containing nicotine, volatile carbonyls, reactive oxygen species, 
furans and metals on respiratory health is unknown.253 As discussed earlier, in 
utero exposure to nicotine may adversely affect lung development, and 
maternal e-cigarette use in pregnancy is therefore concerning.  At present e-
cigarette use is low in sSA; data from the 2016 South African Demographic 
Health Survey reported the prevalence of e-cigarette use as 2% and 3% in 
women and men respectively, compared to cigarette smoking rates of 7% and 
36%.  
The global impact of the COVID-19 pandemic has highlighted the fragility of 
overstretched health care systems, particularly in LMIC where even basic 
medical supplies and equipment are lacking. The long-term respiratory effects 
of novel pathogens, such as coronavirus SARS-CoV-2, are unknown. 
Longitudinal study of cohorts of infected individuals from diverse populations 





Having explored the literature relating to the epidemiology of NCD-L in sSA, 
and potential factors influencing lung health across the life course, I will now 
focus on the clinical management of asthma. The remaining sections will 
review literature of particular relevance to the studies comprising chapter 5 
and 6 of the thesis, and focus on monitoring asthma control (symptoms, 
airflow abnormalities and inflammation) and the treatment of asthma in LIC, 
including challenges and potential solutions.  
2.4 Asthma: clinical assessment of a heterogenous condition 
It is well recognised that asthma is a heterogeneous condition, and that the 
symptoms associated with asthma, can arise from a variety of underlying 
pathophysiology.36 Several phenotypes have been described including; 
allergic asthma, non-allergic asthma, late-onset asthma, asthma with fixed 
airflow limitation and asthma with obesity.44 Importantly, airway 
abnormalities which accompany the characteristic symptoms; airflow 
limitation, airway hyperresponsiveness and airway inflammation, are present 
in varying degrees, and in some cases may be absent. 
2.4.1 Monitoring asthma control  
Asthma control has two components; evaluation of current symptoms and 
future risk. GINA recommends the use of four questions to assess asthma 
symptoms over the previous four weeks and categorise patients into three 
levels of asthma control – see Table 2-5. There are a number of other 
questionnaires which have been developed to monitor asthma control; the 
Asthma Control Test (ACT) and Asthma Control Questionnaire are the most 
extensively validated.255 The ACT comprises five questions, giving a composite 
score ranging from 5-25.256 The ACT has been used in Nigeria, with 106 adult 
patients, and found to be an objective and reliable tool for determining 
asthma control, correlating with percentage predicted FEV1 and quality of life 
measures. In this study, 43% had good control (ACT ≥20), 32% poor control 
(ACT 16-19) and 25% very poor control (ACT ≤14).257 In Uganda, responses to 
the ACT and GINA assessment tool were similar; the ACT identified 17% 
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participants with good control, 43% with poor control and 40% with very poor 
control.258  
Table 2-5. GINA assessment of asthma symptom control 
In the past 4 weeks, has the patient had: Level of control 
Daytime asthma symptoms more than 
twice/week? 
None: well controlled 
1-2: partly controlled 
3-4: uncontrolled Any night waking due to asthma? 
Reliever needed for symptoms more than 
twice/week? 
Any activity limitation due to asthma? 
 
The Childhood ACT (cACT) has been developed for use with children aged 4-
11 years and includes seven questions; four answered by the child and three 
by their parent, giving a composite score ranging from 0-27.259,260  The 
questionnaire has been translated and validated in several languages, and 
used, although not validated, in South Africa.261-263 The mean (SD) cACT score 
was 19.86 (4.49) for 59 paediatric patients attending a tertiary hospital 
asthma clinic in Johannesburg, South Africa.263  
The minimal clinically important difference has been defined as 3-points for 
the ACT, although this has not been established for the cACT.264 
2.4.2 Measuring airflow limitation 
Asthma is characterised by variable expiratory airflow limitation, which can be 
measured objectively using spirometry. The variable nature of the condition 
means that the lung function of an affected individual can vary between 
completely normal and severely obstructed, depending on intrinsic and 
extrinsic factors. Within-day variability is greatest in patients with poor 
asthma control, whereas during acute exacerbations airflow obstruction 
increases steeply and response to bronchodilators may be impaired.265 
FEV1 is reported to predict subsequent asthma exacerbations in children: a 
percentage predicted FEV1 of <60% is associated with an OR 2.1 (95% CI: 1.3-
3.4) for an attack in the following year, and FEV1 60-80% OR 1.4 (95% CI: 1.2-
1.6).266 However, FEV1 percent predicted does not differ with asthma severity 
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(measured by symptom frequency and medication use) and many children 
with poorly controlled asthma have normal lung function in between 
exacerbations.267 FEV1/FVC appears to correlate more closely with symptoms, 
decreasing with increasing asthma severity.267 However, it is also recognised 
that patients with chronic airway obstruction, as opposed to an acute episode 
of wheeze, may have decreased perception of their symptoms.268 
Bronchodilator response is considered a key feature of asthma; defined for 
children as an increase in FEV1 of >12% predicted value, 10-15 minutes after 
bronchodilator administration.44 However, bronchodilator response 
discriminates poorly between asthmatic and healthy individuals and shows 
considerable within-subject variability; many asthmatic patients will have 
bronchodilator response values within the normal range.269  
Airway obstruction and hyperresponsiveness improve on inhaled 
corticosteroid (ICS) treatment, with the greatest benefits seen in the first 3-
months of treatment.270 
2.4.3 Measuring airway hyperresponsiveness 
Airway hyperresponsiveness or bronchial hyperreactivity is another aspect of 
asthma, which can be measured objectively using direct (inhaled histamine or 
methacholine) or indirect (exercise, mannitol, hyperosmolar saline) tests.271 
During an exercise test there is a transient dehydration of the airway surface, 
which causes the release of mediators (e.g. prostaglandins, leukotrienes and 
histamine) and subsequent contraction of airway smooth muscle.  
Standard protocols for exercise challenge tests involve a sustained effort for 
6-minutes, with sufficient intensity to raise the heart rate to a target value 
within the first 2-3 minutes of exercise.272 The American Thoracic Society 
defines exercise induced bronchoconstriction (EIB) as a ≥10% fall in FEV1 from 
the baseline value, measured within 30 minutes after exercise, but comments 
that studies in children have recommended a higher threshold of ≥15%.273 
GINA guidelines define a positive exercise challenge test in children as a fall in 
FEV1 of >12% predicted, or PEF>15%.44 However, the literature contains a 
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variety of exercise test protocols, summarised in Table 2-6 which makes direct 
comparison of results difficult. 
Table 2-6. Variation in exercise challenge test protocols.  
 Measure of lung function Timing Threshold for 
a positive test 
Haby 1994274 
Australia 
FEV1: 2 within 100ml 3,5,10 mins 13% 
Haby 1995275 
Australia 
FEV1: 2 within 100ml 3,5,10 mins 15% 
Powell 1996276 
UK 
PEFR: best of 3 attempts 5,10,15 mins 15% or 20% 
Addo-Yobo 200779 
Ghana 
PEFR: best of 3 attempts 5,8 mins 12.5% 
Mashalane 200678 
South Africa 
PEFR: best of 3 attempts 3,10 mins 10% or 15% 
Terblanche 199085 
South Africa 
FEV1: 2 within 5% 10-15 mins 10% 
Ng’ang’a 1998277 
Kenya 
FEV1: best of 3, within 
100ml 
5,10 mins 15% 
Perzanowski 200273 
Kenya 
FEV1: best of 3 
reproducible 
5,10 mins 15% 
 
Although airway hyperresponsiveness is a recognized airway abnormality 
among asthmatics, it may not be detectable in a significant proportion of 
patients.49 Airway hyperresponsiveness may also be present in individuals 
without a known diagnosis of asthma.273 Hence, although the detection of 
airway hyperresponsiveness may contribute to clinical assessment, it is no 
longer considered an essential screening tool in epidemiological studies.46   
2.4.4 Assessing airway inflammation 
The pathophysiology of school age asthma in HIC is well understood: there is 
a background of respiratory allergy with type-2 T-helper cell mediated 
eosinophilic inflammation of the lower airways and reversible airflow 
obstruction. Mast cells and antigen-specific type-2 T-helper cells produce 
cytokines, and interleukin-4, interleukin-5 and interleukin-13.278 An additional 
insult such as a viral or bacterial infection, or a sudden increase in allergen 
exposure results in an acute attack, with a rapid, marked increase in airway 
obstruction.279   
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However, allergic asthma may account for only half of asthma cases, with 
non-eosinophilic cases showing a picture of neutrophilic, mixed granulocytic 
(raised eosinophils and neutrophils) or paucigranulocytic (normal levels of 
eosinophils and neutrophils) airway inflammation.280-282 Among a birth cohort 
of UK children, similar proportions (~10%) were classified as having atopic and 
non-atopic wheeze at age 10 years.283 Among a cohort of Brazilian children, 
70% of asthmatics were nonatopic, defined by negative skin prick tests to a 
panel of six relevant aeroallergens.284 A subsample of this cohort underwent 
sputum induction: neutrophilic inflammation was reported as the 
predominant feature in sputum from the non-atopic asthmatic children.285  
Non-allergenic exposures including viral infections, bacterial endotoxins, 
particulate air pollution and ozone are potential contributors to neutrophilic 
airway inflammation.281 Features of airway remodelling, including epithelial 
loss, basement membrane thickening, increase in smooth muscle and blood 
vessel proliferation have been reported in children with both eosinophilic and 
non-eosinophilic asthma.286 
In adults, non-eosinophilic asthma is associated with a poor response to 
inhaled corticosteroid treatment.287,288 Information on airway inflammatory 
phenotype may therefore be useful in guiding treatment and predicting 
response. 
2.4.4.1 Sputum eosinophilia as a biomarker of airway inflammation 
Analysis of induced sputum from asthmatic children has demonstrated that 
atopic asthma and eosinophilic airway inflammation are associated with 
uncontrolled disease.284,289,290 In a Brazilian cohort, atopic children (defined by 
one or more positive skin prick tests) with current asthma were more likely to 
have ≥4 attacks during the previous year (OR 2.6, 95% CI: 1.04-6.4)284 Children 
classified as having eosinophilic asthma (with sputum eosinophils >2.5%) had 
increased symptoms and bronchodilator use during a 5-year follow-up 
period.290 A study of 146 asthmatic children found sputum eosinophilia was 
significantly associated with frequency of symptomatic episodes in the 
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previous 12-months, although the relationship with current symptoms (in 
past 2-weeks) and lung function was less strong.289  
The studies mentioned above collected sputum at only one time point: 
however longitudinal analysis including 59 children with mild, moderate and 
severe asthma demonstrated that sputum inflammatory phenotypes are not 
stable over time.291 Over a 6-12-month follow-up period, 63% of children 
demonstrated two or more phenotypes, with phenotype variability unrelated 
to asthma severity, symptom control or change in inhaled corticosteroid 
treatment.291 Only one paediatric study has explored using sputum 
eosinophils to adjust asthma medication: sputum was collected 3-monthly 
from 55 children with severe asthma and treatment altered according to 
either a conventional symptom-based strategy or an inflammation-based 
strategy (guided by sputum eosinophils).292 Exacerbation rates and daily 
symptoms were lower in the inflammatory management group, but not at a 
significant level. Increasing the frequency of sputum assessment may have 
yielded improved control, but this would likely be unacceptable to a 
paediatric population.  
2.4.4.2 Exhaled nitric oxide (FeNO) as a biomarker of airway inflammation 
In the lungs, nitric oxide gas (NO) is produced by two enzymes: constitutive 
nitric oxide synthetase, which continually generates low concentrations of NO 
in response to physiological stimuli, and inducible nitric oxide synthetase, 
which is influenced by various inflammatory cytokines, particularly 
interleukin-4 and interleukin-13.293 Exhaled nitric oxide (FeNO) is therefore 
thought to directly reflect type-2 T-helper cell-mediated inflammation, 
characteristic of allergic asthma, and has been explored as an attractive non-
invasive clinical tool to guide asthma diagnosis and treatment.294  
According to American Thoracic Society guidelines, a symptomatic, ICS naïve 
child with a FeNO <20 parts per billion (ppb) is unlikely to have eosinophilic 
airway inflammation and an alternative diagnosis should be explored; in 
contrast, a similar child with a FeNO level >35ppb is likely to have significant 
eosinophilic airway inflammation, and should respond well to ICS.295  
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The use of FeNO in guiding titration of ICS therapy has been evaluated in a 
meta-analysis of eight paediatric RCTs: children whose treatment was 
adjusted according to FeNO experienced significantly fewer exacerbations (OR 
0.58, 95% CI: 0.45-0.76), although there was no difference in symptom scores 
or quality of life measures.296 The largest multi-centre RCT included in the 
meta-analysis recruited 546 asthmatic patients in the USA, aged 12-20 years. 
The mean number of days with asthma symptoms did not differ between the 
FeNO monitoring group and the control group (difference 0.04 days, 95% CI: -
0.22 - 0.29), despite receiving significantly higher doses of ICS.297  The authors 
of the meta-analysis reported several limitations, including heterogeneity 
between studies relating to definition of exacerbation, cut-off levels for FeNO, 
and adjustment of medication.296 At present there is insufficient evidence to 
support the use of FeNO to guide treatment in routine clinical practice, 
although measurement may be beneficial in patients with frequent 
exacerbations.296  
FeNO may be useful in predicting loss of asthma control during ICS treatment 
reduction or cessation, however the evidence to date is limited.293 One small 
study monitoring FeNO levels in children after withdrawal of steroid 
treatment, reported that raised levels 2-4 weeks were seen in children who 
relapsed (n=9), although more children with raised FeNO did not relapse.298 
Another small study (n=40) monitored FeNO during a period of ICS reduction: 
exhaled FeNO ≥22 ppb was a significant predictor of failed treatment 
reduction, although FeNO as a continuous variable was not.299 Retrospective 
analysis found that excluding children with FeNO≥22 ppb from ICS reduction 
could have prevented an exacerbation in 11/14 (78%) children; conversely 
19/49 (39%) of children would have continued on ICS, when reduction would 
have been successful.   
2.5 Long term management of asthma: challenges in LMIC 
The goals of asthma management are to achieve good symptom control and 




2.5.1 Treatment guidelines for LMIC 
Treatment guidelines for LMIC are extrapolated from resource-rich settings, 
and advise a stepwise approach to asthma management; starting with inhaled 
short-acting β2-agonist (SABA), with the addition of regular ICS (e.g. 
Beclometasone), at escalating doses, if symptoms occur frequently – see 
Figure 2-3. However, these LMIC guidelines contrast greatly from the 
increasingly complex approach to asthma management now advocated in 
HIC, focusing on a personalised approach, considering individual risk factors, 
comorbidities and asthma phenotype. GINA recommends that all adolescents 
and adults, even those with mild asthma, should receive ICS, and there are a 
variety of inhalers combining short- or long-acting β2 agonists with ICS. 
Phenotypic investigation is advised for patients with severe asthma in HIC, to 
assess the appropriateness of add-on treatments such as; tiotropium, anti-IgE, 
anti-IL5, anti-IL5R or anti-IL4R.44  
 
Figure 2-3. The “4-step approach”.  
From Management of Asthma, IUATLD 2008300 
For children: HFA-Beclometasone 100µg daily dose; mild: 1 puff, moderate: 2 puffs, 
severe: 4 puffs 
 
Inhaled medication, from a pressurised metered dose inhaler (MDI) is best 
given using a spacer device; this is essential to optimise drug delivery. The 
spacer holds the suspended aerosol after MDI actuation, thus addressing the 
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difficulty of coordinating simultaneous MDI actuation and inhalation – a 
particular challenge in children and also during acute attacks.301  Research 
from South Africa has shown that a well-constructed “home-made” 500ml 
plastic bottle spacer is as effective as a conventional, commercially produced 
spacer for delivery of SABA via MDI for children with acute asthma.302 In 
children below 3 years of age, a bottle spacer can be used effectively with the 
addition of a flexible, well-fitting face mask.303 In order to be effective, home-
made spacers must be constructed and used correctly, and patients and 
families must understand how to do this.304,305 
Guidelines for asthma management in LMIC were first published in 1996 by 
the International Union Against Tuberculosis and Lung Disease – the most 
“current” version of these are over a decade old.300 The implementation of 
these guidelines has been evaluated in several LMICs; Algeria, Guinea, Ivory 
Coast, Kenya, Mali, Morocco, Syria, Turkey and Vietnam. These clinics were 
based in urban areas, with oversight by specialist lung physicians, and hence 
of limited generalisability. Practitioners underutilised PEF measurements to 
aid asthma diagnosis, underestimated disease severity and under prescribed 
inhaled steroids, recommended in steps 1-3 of the guideline.306 
Treatment outcomes, assessed after one year, for a total of 310 asthma 
patients from seven of these clinics, found that one-third of patients were 
successfully treated, but suffered from a high rate (37%) of defaulters.307  In 
those who adhered to treatment (n=167), asthma severity decreased for the 
majority of patients, with decreased emergency attendances and 
hospitalisation.308 The main challenge identified in these clinics, was 
adherence to treatment, with the availability of affordable treatment a major 
obstacle.  
2.5.2 Health care systems for chronic disease management 
Inhaled medication is the cornerstone of chronic respiratory disease 
management and recommended in global treatment guidelines for asthma 
and COPD. The WHO Essential Medicines List includes beclometasone and 
salbutamol inhalers, yet these medicines are often unavailable, unaffordable 
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or of unreliable quality in LMICs.19 In Malawi, salbutamol inhalers are often 
available at primary health centres, although staff may lack confidence to 
prescribe inhaled medication, particularly for children, preferring to give oral 
salbutamol and prednisolone instead. Beclometasone is usually only available 
at tertiary facilities; however, stock levels are unpredictable, and most 
families cannot afford to buy inhalers from private pharmacies.  
Chronic disease management requires more than medication alone; health 
care facilities require appropriate infrastructure, diagnostic tools, trained 
healthcare personnel and appropriate treatment guidelines and referral 
pathways.43 Information systems are also crucial to inform policy and 
planning, and engage government stakeholders.309 
2.5.3 Asthma awareness; patients, health care providers and communities 
A further barrier to treatment adherence is knowledge and understanding of 
asthma among patients, their families and the wider community. Adverse 
beliefs and suspicion regarding treatments, particularly inhaled medication, 
will lead to poor compliance and treatment failure.  
In Zambia, one third of participants surveyed believed that inhalers were 
addictive, and that tablets were a superior asthma treatment to inhalers. 
Furthermore, there was poor understanding that asthma symptoms can be 
managed with long-term treatment; only one third believed that 
hospitalizations were preventable and just over half thought that asthma 
symptoms are preventable with the correct medication.310  
Concerns regarding inhaled treatment were also reported from a cross-
sectional survey of carers of asthmatic children at a teaching and referral 
hospital in Kenya.311 Two-thirds of carers believed that inhalers were only for 
the very sick, a similar number preferred oral medication (syrups) over 
inhalers, and only one-third felt that preventer medications were necessary.  
A cross-sectional survey of asthmatic adults and children in South Africa, 
reported that one-quarter were experiencing daily symptoms, and that 
patients had considerable concerns about their inhaled medication.312 Almost 
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one-half of patients were worried about the side-effects and a similar number 
reported stopping their inhaled medication when they feel well. The authors 
concluded that under-treatment, inappropriate treatment and lack of patient 
education are all factors contributing to poor symptom control, and that 
education of patients and doctors should be prioritised. 
2.5.4 Asthma education interventions: patients and families 
Good patient education is key to empowering families to take an active role in 
long-term disease management. Empowerment of people and communities is 
one of the key approaches advocated by the WHO in addressing the global 
burden of NCDs.3  
Evidence from RCTs performed in high-income countries, suggests that 
educational interventions have a beneficial effect on a variety of asthma 
outcomes. A Cochrane review of 38 trials found that asthma education 
targeted at families presenting for emergency asthma care resulted in a 
reduced risk of subsequent emergency visits (RR 0.73, 95% CI: 0.65-0.81) and 
hospital admissions (RR 0.79, 95% CI: 0.69-0.92) compared to controls.313 An 
earlier systematic review of 32 trials, also including children without an 
emergency attendance in the past year, reported decreased emergency 
department visits, improved lung function, and reduced school absence and  
restriction of activities, although no effect on symptom scores.314 Meta-
analysis of asthma education interventions conducted in the USA only (37 
trials), found similar positive results, with decreased hospitalisation and 
emergency department visits in the intervention groups.315 
The majority of the RCTs included in these reviews were conducted in HIC: 
there were 2 trials reported from India.316,317 One RCT assessed the efficacy of 
an individualised written home management plan for children with moderate 
persistent asthma, reporting fewer exacerbations, decreased school absence, 
lower symptom scores and less nocturnal awakening in those children who 
received a written plan.317 Another RCT from an outpatient clinic in India, 
including asthmatic patients aged 10-45 years, reported a reduction in 
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hospital use following four group sessions relating to self-management of 
asthma.316 
The trials included in the three systematic reviews included a wide variety of 
educational interventions; targeting children, parents or both; with single or 
multiple sessions of varying durations; delivered to individual participants or 
in groups.313-315 It is therefore unclear which are the most important elements 
of an educational package, in achieving key treatment goals. The studies from 
the USA suggested that interventions comprising more sessions and with a 
more interactive format produced better outcomes.315 
Evidence from studies conducted in adults with asthma has shown that self-
management education reduces hospitalisation, emergency visits, days off 
work or school , night-time symptoms and quality of life.318 Key features of 
the educational interventions included self-monitoring (by either PEF or 
symptoms), in addition to regular medical review and a written action plan. 
Further analysis, exploring the key components of a written action plan found 
that the most effective plans were individualised, included 2-4 action points, 
and detailed how to adjust oral and inhaled corticosteroid treatment.319 
All the asthma education interventions cited previously were delivered by 
trained health personnel; nurses, health educators and social workers. There 
are limited studies reporting the outcomes of asthma education delivered by 
lay people, with none from LMIC. A small number of studies from high-income 
settings (USA, Australia and Jordan) have evaluated peer- and lay-led complex 
asthma interventions for adolescents, suggesting a small improvement in 
asthma-related quality of life, although the effect on asthma control, 
exacerbations and adherence are unclear.320,321 In the UK, self-management 
education delivered to adults with asthma by trained lay people, resulted in 
comparable clinical outcomes to patients seen by primary care based practice 
nurses, with similar associated costs.322,323 Qualitative exploration of the 
experiences of these lay educators highlighted the need for comprehensive 
support and monitoring, particularly at the start of the programme, and the 
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importance of training, with consideration of content, intensity, and 
interactive teaching methods, such as role play.324 
Among inpatients in the USA, asthma education delivered by trained lay 
volunteers to families of inner-city children with asthma, during an acute 
hospital admission, was associated with improved asthma management 
behaviours.325 
Asthma education is included in international guidelines as an essential 
component of asthma management, however it is recognised that limited 
time and resources may affect its delivery.44,326 
2.5.5 Asthma education: health care professionals 
The provision of good quality asthma education for patients and their families 
also requires that health workers are up-to-date and knowledgeable about 
both acute and long-term asthma management.  
A survey of paediatric clinicians from teaching hospitals in Nigeria found that 
despite familiarity with GINA guidelines, physicians frequently failed provide a 
self-management plan or check inhaler technique, as recommended.327 
Similarly, an audit of asthma guideline implementation in primary care 
facilities in South Africa found that asthma control was poor, despite 
reasonable availability of inhaled medications. Assessment of current 
symptom control, review of inhaler technique and provision of a self-
management plan occurred in only one in ten asthma consultations.328  The 
provision of educational programmes for health care professionals and the 
public are necessary to combat cultural misconceptions around asthma care, 
and to ensure widely accessible diagnosis and treatment.329  
Health workers in Malawi have described a need for training regarding 
chronic respiratory diseases such as asthma and COPD, particularly amongst 
primary health centre staff.330 
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2.5.6 Community awareness of chronic respiratory disease 
More broadly, community-wide, health promotion strategies are essential to 
address the growing rates of all NCDs in Malawi.15 Community education 
regarding the risks of exposure to indoor air pollution and tobacco smoke 
plays a key part in the prevention of chronic respiratory conditions. The use of 
highly polluting biomass fuels for energy requirements including cooking, 
lighting and heating is widespread in Malawi.188 Tobacco smoking rates are 
relatively low (~12%), however there are challenges in delivering anti-smoking 
public health policies in a country which is heavily reliant on the tobacco 
industry for domestic revenue.10,15  
Wider community understanding of chronic respiratory conditions may 
improve health seeking behaviour, encouraging early presentation and 
subsequent disease management, although there are many additional factors 
which affect access to healthcare.330 A recent cross-sectional survey in rural 
Malawi found that 23% of adults had chronic respiratory symptoms (cough, 
wheeze, shortness of breath); of these 88% had sought medical care but only 
5% had an appropriate diagnosis (TB, asthma, bronchitis or COPD) recorded in 
their patient-held medical records.331  That chronic respiratory conditions are 
diagnosed at such low rates, suggests a concerning lack of knowledge among 
health care staff. 
2.6 Human resource constraints in Malawi 
There is a global shortage of trained medical staff, but this deficit is most 
catastrophic in the poorest parts of the world where the mismatch between 
the healthcare need and available resources is greatest: the WHO African 
Region bears 24% of the global burden of disease, to be addressed with only 
3% of health workers and 1% of world health expediture.9 
Malawi suffers from a shortage of trained clinical staff with 2 physicians and 
28 nurses per 100,000 population, well below the WHO recommended ratio 
of 2.5 health professionals per 1000 population.8 Currently, there are three 
tertiary level referral hospitals (Blantyre, Lilongwe and Zomba), 27 secondary 
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level district hospitals, and 460 primary health care centres.10 Most patients 
with NCDs are managed in one of the tertiary care facilities, although there is 
growing interest in decentralising care, with management of common 
conditions at the primary health care level.11 However, appropriate diagnostic 
testing (spirometry) and long term treatments (inhaler therapy) for chronic 
respiratory conditions, are not available at district or primary care level 
facilities.331 
A survey of Malawi Ministry of Health personnel reported a lack of resources 
for NCD services including inadequate staff, equipment and supplies.332 
Furthermore, within the country there is a maldistribution of medical staff, 
with the staffing crisis particularly affecting the rural areas, where 80% of the 
population reside. The shortfall is addressed by the appointment of mid-level 
cadres; Clinical Officers and Medical Assistants, who complete a shorter 
duration of training than physicians completing a 5-year MBBS degree 
course.333 Medical Assistants complete a 2-year Certificate in Clinical 
Medicine, with a focus on primary care at the community level, while Clinical 
Officers complete a 4-year Diploma in Clinical Medicine, which includes 
surgical training. Medical Assistants staff primary health centres and Clinical 
Officers largely work in the district hospitals. 
Efforts to increase the number of health professionals in Malawi must keep 
pace with staff losses from the health sector. International migration or 
“brain drain” of doctors and nurses seeking opportunity for improved 
training, remuneration, working conditions or lifestyle is a constant challenge 
to the system.334 Furthermore, mid-level cadres may consider leaving their 
posts for an alternative career pathway as a result of demotivating 
experiences; particularly if staff feel undervalued, unfairly treated or unable 
to provide adequate patient care.335 
2.6.1 The potential for task shifting 
One possible strategy to address the huge shortfall of trained medical staff in 
LIC is task shifting: “the transfer of a task normally performed by a more 
highly trained health care worker to another with a different, usually lower 
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level of training.” 336 Tasks can also be transferred to non-medical staff, such 
as lay health workers, who have received training to perform tasks normally 
performed by health professionals with more education and higher 
qualifications.337 
Task shifting has been widely adopted in sSA in response to the HIV epidemic. 
A large RCT in South Africa reported comparable clinical outcomes of ART, 
whether care was monitored by an appropriately trained nurse or a doctor.338 
Several countries in sSA have reported improved quality of HIV care, by 
adopting a task-shifting approach.338-340 In Malawi, improved access to HIV 
services has been achieved through decentralisation of care to primary health 
centres and community sites, with task shifting of HIV testing and counselling 
and ART initiation and monitoring.341 Non-physician clinicians (clinical officers 
and medical assistants) and nurses are able to initiate ART, following a 
training course and short clinical attachment at an experienced ART site. Task 
shifting of HIV testing and counselling, from nurses to trained Health 
Surveillance Assistants (HSAs) has also been successfully employed. This 
approach is advocated by the WHO, to promote accessible, equitable and 
good quality health care for the rapidly expanding number of people living 
with HIV/ AIDS, who are now taking ART.336 Improved ART outcomes have 
also been reported where support has been provided by specifically trained 
community volunteers in rural Malawi.342 
Within Malawi, HSAs represent a health provider cadre that could potentially 
be rapidly expanded to address specific tasks within the health care system. 
HSAs are community health workers (or lay health workers), who have 
completed the Malawi School Certificate of Education and 12-weeks of pre-
service training. HSAs form 30% of the health workforce in Malawi and are 
largely responsible for delivering the Ministry of Health Essential Health 
Package, including the community case management of childhood illness. 
HSAs are considered the bridge between local communities and the health 
sector: the strength of these relationships relies heavily on mutual respect 
and trust.343 The initial role of HSAs focused on disease surveillance, 
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prevention and environmental health activities.344 However, over time the 
HSA role has extended to involve curative disease management, including 
maternal and newborn health tasks, such as prenatal care, postnatal care and 
neonatal assessment.337  Important considerations when extending the role of 
HSAs are: ensuring adequate remuneration and opportunities for career 
progression, strengthening training and supervision, monitoring and 
prioritising workload, providing adequate resources.345 Furthermore, 
community-based disease prevention work will suffer if HSAs spend time 
filling staffing gaps in health clinics, performing extended tasks such as 
microscopy, drug management, under-fives clinics and HIV testing and 
counselling.344  
Given the success of task-shifting for a broad range of health care  services in 
LMICs, the approach has been suggested as a potential strategy for the 
management of NCDs.339 However, there is limited quality research to assess 
this approach to NCD management; a systematic review of 22 studies 
(including 2 studies relating to asthma) reported successful task shifting for a 
variety of non-communicable diseases by non-physician health professionals 
(nurses, midwives, health workers).346 Asthma care was provided as part of a 
nurse-led primary-care intervention for multiple NCDs in rural South Africa: 
the authors reported improved treatment adherence, with asthma control 
achieved in 84% of patients using standardised treatment and referral 
protocols.347 A study from rural Cameroon reported decreased exacerbations 
over a median follow-up period of 5 months for patients attending nurse-led 
asthma clinics, although 41% were lost to follow-up.348 In Kenya, a 
programme has been successfully introduced, with nurse-led management of  
multiple NCDs (hypertension, type 2 diabetes, epilepsy, asthma and sickle cell 
disease) according to clinical protocols.349 Successful implementation of such 
task-shifting programmes require appropriate training programmes, access to 
standardised protocols, and supply of relevant equipment and medication.346 
Task shifting may present a potential solution to improve NCD management 
in Malawi, but further disease-specific research is needed to assess feasibility, 
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There is a lack of data relating to NCD-L in sSA, particularly for children and 
those living in rural areas. Limited data suggests that asthma and COPD are 
increasingly common, and that asthma symptoms may be poorly controlled in 
low-income settings. Uncontrolled disease may relate to lack of community 
and health provider awareness, and challenges with diagnosis, long-term 
monitoring, and availability and understanding of treatment, compounded by 
poorly equipped health care facilities with severe shortages of medical staff. 
Factors which may have an adverse effect on lung health can act at various 
points in the life course (in utero, during childhood, adolescence and 
adulthood). Potential risk factors for poor lung health are frequently 
encountered in LIC, such as Malawi; adverse antenatal environments lead to 
in-utero growth restriction and prematurity; HIV and respiratory infections, 
including TB are common; exposure to air pollution is widespread, including 
household air pollution from biomass fuel use. 
The original research presented in the following chapters attempts to address 
some of the existing gaps relating to NCD-L epidemiology in Malawi and 




3 Lung health and exposure to air pollution in Malawian 
children: a cross-sectional study 
 
3.1 Introduction 
Non-communicable lung diseases are major global health priorities across the 
life course.20,53 Asthma is the commonest chronic disease of childhood and 
one of the commonest chronic diseases of adulthood, affecting around 358 
million people whilst COPD affects 174 million people, worldwide.17 
Although most of the children and adults with these conditions live and die in 
low- and middle-income countries (LMICs), the majority of the research into 
these conditions is done in high-income countries. Research is especially 
scarce in the LMICs of sub-Saharan Africa where limited studies suggest the 
prevalence of childhood asthma is increasing in urban settings, and that 
children with symptoms of asthma are likely to be severely symptomatic. 51,67 
In adult populations, Burden of Obstructive Lung Diseases (BOLD) studies from 
countries in sub-Saharan Africa, including sites in urban and rural Malawi, 
have found a high burden of impaired lung function – particularly low Forced 
Vital Capacity (FVC)22,64,90 – which is concerning given the association between 
low FVC and mortality in other populations.24  
In these same sub-Saharan African populations, there is widespread reliance 
(by around 700 million people) on inefficiently burned solid fuels for cooking, 
heating and lighting.350 Studies in rural Malawi report exclusive biomass fuel 
use (wood, crop waste and charcoal) with households using traditional “open-
fire” cooking methods.26  The widespread exposure of children to pollutants 
such carbon monoxide (CO) and particulate matter, resulting from incomplete 
fuel combustion, is particularly concerning. Household air pollution has been 
suggested as a potential contributing factor in the development of non-
communicable lung diseases in low-income countries.190 However, the links 
between household air pollution exposure, new-onset asthma in children and 
obstructive lung disease in adults, are unclear, with controversy over the 
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interpretation of available data.96,191,194,230,231 Environmental exposures, 
including inhaled pollutants, during periods of lung growth and development 
may lead to irreversible long term deficits in adult lung function.55,178 
In this context, the Cooking and Pneumonia Study (CAPS) was done to 
determine whether an intervention comprising two cleaner burning biomass-
fuelled cookstoves and a solar charger would reduce the incidence of 
Integrated Management of Childhood Illness (IMCI)-defined pneumonia in 
children under the age of 5 years in rural Malawi compared to continuation of 
traditional cooking methods.26 CAPS recruited households from village 
clusters in Chikhwawa between December 2013 and February 2016. The 
primary intention-to-treat analysis found no difference in pneumonia 
incidence between the two trial arms. Recently reported secondary analyses 
in adults from a sub-set of CAPS households found no difference in chronic 
respiratory symptoms, lung function or personal air pollution exposures 
between participants from the intervention and control groups.23 That said, 
median exposure to fine particulate matter (PM2.5) was 71 g/m3, well above 
WHO annual and 24-hour guidelines. 
Is it not known whether the same pattern of respiratory symptoms, 
spirometric abnormalities and air pollution exposures would be seen in 
children as in adults or whether the CAPS intervention would have beneficial 
effects on any of these outcomes in children. In this paper we report the 
findings of a cross-sectional study, conducted in the same village communities 
as CAPS, which set out to: 1) measure the prevalence and determinants 
(including measured exposure to household air pollution) of non-
communicable lung disease in a population representative sample of children 
in rural Malawi and 2) conduct an analysis comparing lung function between 





3.2.1 Study design 
We conducted a cross-sectional study of the prevalence and determinants of 
non-communicable respiratory disease among children living in Chikhwawa 
District, Malawi.  
3.2.2 Setting 
Chikhwawa is a rural area, located in the Southern Region of Malawi on the 
Shire River, 50 kilometres from the nearest city, Blantyre. The population 
consists largely of subsistence farmers living in village communities and is 
highly vulnerable to climatic shocks, having experienced flooding, crop 
failures, and famine in recent years. Infectious diseases (malaria, pneumonia 
and gastroenteritis), HIV/AIDS, malnutrition, and limited access to basic 
healthcare contribute to high childhood mortality rates, although a 
considerable reduction in the mortality rate for children under 5 years old  has 
been seen in Malawi over the past 25 years.42  
3.2.3 Participants 
Following widespread community engagement events, children aged between 
6 and 8 years, living in households that had taken part in CAPS and BOLD-
Chikhwawa were identified by local community advisors and invited to 
participate if the child’s parent/guardian gave written informed consent (or 
witnessed thumbprint for those unable to read and write). Verbal assent was 
sought from the children. Exclusion criteria were current treatment for 
tuberculosis, current acute respiratory infection (defined as cough of <1-week 
duration, associated with fever and/or increased work of breathing) and other 
contraindications to spirometry (chest or abdominal pain, haemoptysis). We 
recruited all children from the study area meeting the eligibility criteria. 
3.2.4 Procedures 
Fieldworkers visited the children in the community to administer an electronic 
questionnaire, and assess anthropometry, lung function, and personal 
exposure to household air pollution. An electronic questionnaire was 
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administered in Chichewa, the local language; parents answered questions 
detailing respiratory symptoms and potential contributing factors. Core 
written questions from the International Study of Asthma and Allergy in 
Children (ISAAC) were included, which had been forward and back-
translated.52 Height, weight and mid-upper arm circumference (MUAC) were 
measured according to standardised protocols. Height and weight were 
interpreted using the WHO 2007 child growth standards.351 MUAC was used 
to assess nutritional status.352  
Pre and post-bronchodilator spirometry was performed by BOLD centre-
certified technicians, according to American Thoracic Society/European 
Respiratory Society (ATS/ERS) standards using an Easy On-PC Spirometer (ndd 
Medical Technologies; Zurich, Switzerland).58 Regular calibration was 
performed according to the manufacturer’s instructions. The highest Forced 
Expiratory Volume in 1 s (FEV1) and FVC measurements for each participant 
were selected (from a maximum eight attempts), before and after 
administration of 400 µg inhaled salbutamol, via Volumatic spacer. 
Reversibility was defined as ≥12% improvement between pre- and post-
bronchodilator FEV1. 
Spirometry overreading was performed by two independent reviewers. Two 
sets of ATS/ERS standards (aged 4-6 years and aged 7 and above) are relevant 
for the children in this study.58,353 As the age range of our study children 
overlaps both sets of standards, and to maximise the use of spirometric data 
collected, we defined acceptable (grade C) quality as two traces within 150 ml 
or 10% (Table 3-1). 
Table 3-1. Quality grading for spirometry  
Quality grade FEV1 or FVC 
A 3 acceptable trials within 5% or 100ml 
B 2 acceptable trials within 5% or 100ml 
C 2 acceptable trials within 10% or 150ml 
D One acceptable trial 
F No acceptable trials 
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Carboxyhaemoglobin level (COHb) was measured at a single time-point using 
a Rad-57 pulse CO-oximeter (Masimo Corporation, California, USA). 
Performance verification was ensured at study outset, according to the 
manufacturer service manual. To assess personal carbon monoxide (CO) 
exposure levels, children wore an EasyLog CO USB data logger (Lascar 
Electronics Ltd., Wiltshire, UK), for up to 48 hours, starting immediately after 
the field visit.  
3.2.5 Variables 
Clinical outcomes were presence or absence of symptoms, as assessed by the 
following questions; Chronic cough: defined by a positive response to both 
“Does your child usually have a cough when they don’t have a cold?” and “Are 
there months in which they cough on most days?”; Current wheeze: “Has your 
child had wheezing or whistling in the chest in the past 12-months?”; Severe 
asthma: current wheeze, and ≥4 attacks of wheeze, or ≥1 night per week 
sleep disturbance from wheeze, or wheeze affecting speech, in the past 12 
months; Shortness of breath: a composite outcome, positive if children were 
reported to be breathless during normal daily activities or on minimal 
exertion; Any respiratory symptom: a composite outcome, positive if a 
participant was reported to have any of the previously described symptom 
outcomes. 
Continuous FEV1 and FVC values were used in the primary analysis. 
Standardised z-scores and lower limits of normal for FEV1, FVC and FEV1/FVC 
were derived from the GLI 2012 reference equations for African-Americans, 
which provide race- and sex-specific reference values, taking into account 
height and age.57  
Personal CO exposure monitoring data were not analysed if <24 hours were 
recorded. To allow comparison of varying lengths of recording, all data were 
truncated at 24 hours for the final analysis.  




3.2.6 Study size 
We calculated a sample of 600 participants (300 male, 300 female) would 
estimate the prevalence of non-communicable lung disease (chronic 
respiratory symptoms) in each sex stratum with a precision (95% CI) of ±3.3 to 
±5.0% (assuming a prevalence of 10 to 25%). To allow for unequal sex 
distributions, refusals and inability to provide spirometry of acceptable 
quality, we aimed to recruit 1000 children.   
3.2.7 Statistical analysis 
Descriptive analysis was performed, using Student’s t-test and Pearson’s chi-
square to compare continuous and categorical data. For population 
proportions, Wald-type standard errors were calculated, assuming a binomial 
distribution. Bivariate associations between spirometric and clinical 
outcomes, and variables including CO, COHb, hospital admission for 
respiratory illness during infancy, and CAPS allocation were explored. 
Harmonic regression was used to account for any possible effect of 
seasonality on the outcome measures.  This was implemented by including 
sinusoidal functions (sine and cosine terms) of time with a period of 1 year. 
Linear multivariable regression was used to estimate the association between 
exposures and continuous lung function values (FEV1 and FVC). Multivariable 
logistic regression models were constructed for dichotomous clinical 
outcomes. All models included age, sex, height and weight a priori, and 
variables with a p value <0.2 on bivariate analysis. A backward stepwise 
regression technique was used to develop multivariable models. An analysis 
was conducted to compare FEV1, FVC and FEV1/FVC, symptom prevalence and 
exposure variables between the intervention and control groups of CAPS. CO 
was log10 transformed for inclusion in linear models to ensure normality of 
residuals. 




3.2.8 Ethical approval 
Ethical approval was given by the College of Medicine Research Ethics 
Committee in Malawi (reference P.07/16/1994) and Liverpool School of 
Tropical Medicine Research Ethics Committee in the UK (reference 16-040) 
 
3.3 Results 
Between February-December 2017 we approached 886 children of whom 804 
were confirmed to be eligible and were recruited (79/82 were outside the 
eligible age range; 3/82 guardians declined to consent). Questionnaire data 
were collected for all but one participant who withdrew from the study 
shortly after giving consent. Anthropometry, spirometry, COHb measurement 
and personal CO monitoring were done on 99.9% (802/803), 99.9% (802/803), 
99.4% (798/803) and 99.3% (797/803) of these participants, respectively. 
Grade A-C pre-bronchodilator traces were achieved in 65% (522/802) of the 
children. The duration of CO monitoring was 24 and 48 hours for 91.9% 
(738/803) and 79.5% (638/803) children, respectively. There were 476 (260 





Figure 3-1. CLHS participant recruitment flow diagram 
 
 
The mean age (SD) of participants was 7.13 (0.77) years and 417 (51.9%) 
participants were female. Most (700 (87.2%)) were attending primary school. 
The mean (SD) height-for-age and weight-for-age z-scores were -1.04 (0.90) 
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and -1.10 (0.89), respectively.  Mean (SD) MUAC was 15.98 (1.26) cm (Table 
3-2). No children met the criteria for severe or moderate acute malnutrition, 
but 11/789 (1.4%) children were “at risk for acute malnutrition”, with a MUAC 
of 12.5-13.5cm. 
Table 3-2. Demographics and clinical characteristics of CLHS participants (n=803) 
 n (%) 
Female, n (%) 417 (51.9) 
Age, mean (SD) years 7.13 (0.77) 
School attendance, n (%) 700 (87.2) 
Anthropometry  
Weight-for-age z-score, mean (SD) -1.10 (0.89) 
Height-for-age z-score, mean (SD) -1.04 (0.90) 
MUAC, mean (SD) cma 15.98 (1.26) 
Chronic respiratory symptoms  
Wheeze ever 97 (12.1) 
Current wheeze (in the past 12 months) 57 (7.1) 
Severe asthma (in the past 12 months) 31 (3.9) 
Wheeze with exercise 44 (5.5) 
Dry cough at night 145 (18.1) 
Chronic cough 64 (8.0) 
Chronic sputum production 13 (1.6) 
Chronic shortness of breath 49 (6.1) 
Any chronic respiratory symptom 133 (16.6) 
a MUAC measurement available for 789 participants 
 
Chronic respiratory symptoms were reported by 133 (16.6% (standard error 
(SE) 1.3)) children, most commonly cough (8.0% (SE 1.0)), and current wheeze 
(7.1% (SE 0.9)) (Table 3-2). One-fifth (159/803) of children had been admitted 
to hospital with respiratory symptoms in the past; on one (9.7%), two (6.1%), 
and three or more (4.0%) occasions. Admission for a respiratory problem 
during the first year of life was reported for 70 (8.7%) children. Antibiotic use 
for a chest problem in the last year was common, reported for 112 (13.9%) 
children, with 69 (8.6%) receiving these on more than one occasion. Half 
(54.4%) of children with current wheeze had symptoms of severe asthma, 
representing 3.9% of children overall. Of these, 22 (71.0%) had a previous 
hospital admission, and 10 (32.2%) missed school due to breathing problems. 
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Very few (0.4%) children had previously been treated for tuberculosis, and 
2.0% (6/307) of children who had been tested for HIV were HIV-positive.  
Children producing grade A-C were older than those with unacceptable traces 
(mean age 7.23 vs. 6.96 years, p<0.001); otherwise there were no significant 
differences in growth parameters and respiratory symptoms between the two 
groups (Table 3-3).  
 
Table 3-3. Comparison of growth measurements and respiratory symptoms for 





p value * 
Age, mean (SD) years 7.23 (0.78) 6.96 (0.72) <0.001 
Growth parameters 
Weight-for-age z-score, mean (SD) -1.13 (0.89) -1.04 (0.87) 0.17 
Height-for-age z-score, mean (SD) -1.04 (0.92) -1.04 (0.87) 0.93 
MUAC, mean (SD) cm 15.96 (1.28) 16.02 (1.23) 0.50 
Prevalence of chronic respiratory symptoms 
Chronic cough, % 8.6 6.8 0.44 
Current wheeze, % 7.3 6.8 0.91 
Severe wheeze, % 4.2 3.2 0.61 
Chronic SOB, % 6.7 5.0 0.42 
*comparison of means using Student’s t-test; comparison of proportions using Pearson’s chi-
squared test 
 
Overall, participants had a mean (SD) FEV1 z-score -0.48 (0.93) and mean (SD) 
FVC z-score of -0.30 (0.96). Children from CAPS intervention households had 
higher FVC z-scores than those from control households (-0.22 vs -0.44, 
p=0.05). Pre-bronchodilator spirometric abnormalities were found in 68/522 
(13.0%) of children; 7.1% with low FVC and 6.3% obstruction (Table 3-4). Post-
bronchodilator spirometry was attempted by 706 children, with 72% 
(505/706) producing grade A-C traces. Both pre- and post-bronchodilator 
traces were available for 432 children, 26 of whom had a pre-bronchodilator 





Table 3-4. Pre-bronchodilator lung function parameters for participants with grade A-













vs control * 
FEV1 z-score,  
mean (SD) 
-0.48 (0.93) -0.41 (0.92) -0.60 (0.97) P=0.10 
FVC z-score,  
mean (SD) 
-0.30 (0.96) -0.22 (0.97) -0.44 (0.98) P=0.05 
FEV1/FVC z-score, 
mean (SD) 
-0.38 (0.90) -0.40 (0.91) -0.34 (0.93) P=0.57 

















Abnormal spirometry  
(low FVC, obstruction, 








a Mixed pattern in 2 participants; b Mixed pattern in 1 participant 
*comparison of means using Student’s t-test; comparison of proportions using Pearson’s chi-
squared test 
 
Personal CO monitoring showed considerable variation in exposure 




Figure 3-2. Example of a typical 48-hour CO monitoring trace.  
 
Mean exposure levels ranged from 0- 15.1 parts per million (ppm), with a 
median CO exposure of 0.20 ppm (interquartile range (IQR) 0.07-0.54). Peaks 
exceeding the 15-minute indoor WHO guideline (81 ppm; 100 mg/m3) were 




Figure 3-3. Maximum CO levels recorded during monitoring period for 738 
participants.  
Dashed line represents WHO recommended indoor exposure guideline for a 15-
minute time period.355 
 
 
Median %COHb was 4.00 (IQR 1.50-6.50). 68.5% of participants had a level 
greater than 2%, and 6.0% greater than 10% (Figure 3-4).  
 
Figure 3-4. %COHb level for 798 participants.  
Dashed line represents the WHO COHb guideline.355 
 
We found no association between respiratory symptoms or spirometric 
indices and personal CO and COHb measurements in bivariate analyses and 
therefore these variables were not carried forward into multivariable analysis. 
In logistic multivariable analysis, chronic cough (OR 2.63 (95% CI: 1.13, 6.12)), 
current wheeze (OR 5.48 (95% CI: 2.45, 12.26)) and symptoms of severe 
asthma (OR 6.36 (95% CI: 2.34, 17.28)) were all associated with hospital 
admission during infancy (Table 3-5). We found no association between 
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respiratory symptoms and spirometric indices in bivariate or multivariable 
analysis (Table 3-5).  
 
Table 3-5. OR (95% CI) for chronic respiratory symptoms estimated by multivariable 
logistic regression (n=522) 
 
 Cough Current 
wheeze 
Severe asthma Shortness of 
Breath 






Sex - - - - 


















Significant at; a 0.001, b 0.01, c 0.05 level 
 
In the analysis comparing intervention and control groups, we found 
statistically significant associations between the intervention arm and both 
FVC (coefficient estimate 0.04 (95% CI: 0.00, 0.07)), and COHb level 
(coefficient estimate -0.89 (95% CI: -1.53, -0.26)) (Table 3-6).  
We found no significant differences between CAPS arms for growth 




Table 3-6. CAPS secondary trial analyses: mean or median values, with linear model 
coefficient estimates (95% CI) for continuous outcomes 





mean (SD) litresa 
1.02 (0.18) 0.97 (0.19) 0.02 (-0.01, 0.06) 0.135 
FVC,  
mean (SD) litresa 
1.16 (0.21) 1.09 (0.21) 0.04 (0.00, 0.07) 0.033 
FEV1/FVC,  
mean (SD) a 






















score, mean (SD)b 




score, mean (SD)b 
-1.10 (0.84) -1.06 (0.93) -0.04  
(-0.20, 0.12) 
0.624 
MUAC, mean (SD) 
cmd 
15.92 (1.29) 15.94 (1.30) -0.02  
(-0.26, 0.21) 
0.846 
a Spirometry data for 300 participants; 167 intervention, 133 control. FEV1, FVC and FEV1/FVC 
adjusted for age, sex, height and weight in regression model 
b COHb, height, and weight data for 476 participants; 260 intervention, 216 control 
c 24-hour CO monitoring for 436 participants; 239 intervention, 197 control 
d MUAC for 466 participants; 260 intervention, 206 control 
e Adjusted for seasonality in linear regression model 
f Log10 CO values used in linear regression model 
† Mean exposure was estimated over the monitoring period per individual, the median of 
















30 (7.7%) 18 (8.3%) 0.92 (0.47-1.78) 0.797 
Current wheeze,  
n (%) 
19 (7.3%) 17 (7.9%) 0.92 (0.47, 1.82) 0.817 
Severe asthma,  
n (%) 
11 (4.2%) 10 (4.6%) 0.91 (0.38, 2.19) 0.833 
Shortness of 
breath, n (%) 
13 (5.0%) 14 (6.5%) 0.75 (0.34, 1.63) 0.471 
Any respiratory 
symptom, n (%) 




3.4   Discussion 
This is one of the first studies to report lung function and personal household 
air pollution exposure, measured concurrently in young children, and it was 
conducted in the context of the largest trial of a cleaner-burning cookstove 
intervention to date. Among children living in rural Malawi, we found that; 
one in six reported chronic respiratory symptoms; over half with current 
wheeze had severe symptoms; anthropometric and lung function parameters 
were generally decreased compared to global reference ranges; the majority 
of children had COHb levels above WHO recommended guidelines; and half of 
children exceeded WHO guidelines for CO exposure (100mg/m3), during 24-
hour monitoring.350 Overall, we found no evidence of an association between 
CO exposure and respiratory symptoms or lung function. However, children 
from CAPS intervention households had higher FVC z-scores and lower COHb 
levels than controls. 
There are limited data regarding chronic respiratory symptoms in children 
from Africa, and particularly rural settings. One study from rural Senegal 
reported similar rates with 9% current wheeze and 5% severe asthma among 
children aged 5 to 8 years.72 Studies from urban settings in sub-Saharan 
Africa, including ISAAC sites, reported rates of current wheeze in 5 to 16% of 
young children, with symptoms of severe asthma in half of these.51,69,70,76 
Globally 11.5% of children aged 6-7 years have current wheeze, and 4.9% 
have symptoms of severe asthma; severe symptoms are seen in one third of 
children with current wheeze in Europe.51 The high rates of severe symptoms 
seen in low-income countries are concerning, and likely reflect multiple 
challenges within healthcare systems, which are better equipped to manage 
acute episodes relating to infectious diseases, rather than chronic non-
communicable conditions. In keeping with this, recent research from Nigeria 
and South Africa has reported high rates of under-diagnosed and untreated 
asthma in schoolchildren.356,357 
We found decreased lung function parameters in this study, comparable to 
values reported for community controls in a recent study exploring long-term 
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outcomes after severe acute malnutrition, at the referral hospital in Blantyre, 
Malawi.171 Mean (SD) FEV1 and FVC z-scores were comparable to those of 
adults from the same community (-0.49 (0.93) and -0.30 (0.96) for children; -
0.38 (1.14) and -0.19 (1.09) for adults) adding to evidence that spirometric 
abnormalities in adults have their origins in early life. These lung function 
deficits, when compared to international reference ranges, may reflect host 
and environmental factors such as undernutrition, frequent respiratory 
infections, low birth weight, exposure to pollutants in utero and early life, 
which can have adverse effects on lung growth and 
development.126,133,134,358,359 No children in this study were acutely 
malnourished (as defined by MUAC measurement), although other 
anthropometric parameters (weight- and height-for-age z-scores) were 
reduced compared to international standards, suggesting a level of chronic 
undernutrition in this community. There are limited data regarding normal 
lung function in healthy African paediatric populations, and consequently it is 
difficult to understand the clinical significance of these apparent spirometric 
deficits.173 Further research is needed to describe optimal lung growth in 
African populations, and determine the morbidity and mortality associated 
with lung function abnormalities.66   
Consistent with our previous findings in Chikhwawa, we noted exposure to 
high peaks of CO, reaching up to three times the WHO guidelines around 
cooking times, although mean and median levels were low; median CO 1.23 
ppm (IQR: 0.79-1.93) in adults and mean CO 1.27 ppm (SD 2.79) in younger 
children.23,360 Median CO exposure levels were lower (0.20 ppm (IQR: 0.07-
0.54) in our older paediatric population perhaps reflecting long periods of 
time that children spend away from the home environment during the school 
day. Cookstove trial analyses exploring adult lung function as a secondary 
outcome have found no evidence of intervention benefit.23,233,234 Paediatric 
lung function outcomes in cookstove trials are inconclusive, but signal a 
possible beneficial effect of the interventions. Secondary analysis from the 
RESPIRE trial found decreased lung growth at around 5-years of age 
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(measured by peak expiratory flow), associated with delayed chimney stove 
installation, although there was no association between lung function at age 5 
and measured personal CO exposure during the first 18 months of life.361 The 
GRAPHS birth cohort in rural Ghana recently reported an association between 
prenatal CO exposure and infant lung function at 30 days of life, with an 
increased effect of exposure on female infants.40 Cross-sectional studies from 
Nigeria have described decreased lung volumes (FEV1 and FVC) and increased 
asthma symptoms in children with self-reported exposure to biomass cooking 
fuels.357,362 
The association between CAPS intervention group and higher FVC is 
interesting, given the lack of evidence for an association between lung 
function and CO exposure or COHb level. This positive finding must be 
interpreted cautiously as it is the result of exploratory secondary analyses, 
unadjusted for multiplicity and therefore may be due to chance. However, 
when taken with the second signal of a potential effect, lower COHb observed 
in the intervention group, the results may be evidence of a genuine impact. 
We may have observed a benefit among our participants, who were aged 3-6 
years during the CAPS trial period, in contrast to findings from adult 
populations, because the early childhood years represent a key period for 
lung development. There is rapid alveolar expansion and resulting lung 
growth during the first 2 years of life, which stabilises around 8 years of 
age.112 Alveolar number is reflected by FVC in childhood and so it is 
biologically plausible that we might see improved lung function in children 
from the intervention arm; the apparent difference of 70 ml in mean FVC 
between CAPS groups represents approximately 6% of a child’s lung volume. 
Furthermore, young children have increased susceptibility to air pollutants, 
exhibiting increased deposition of particles in the lung, due to physiological 
and anatomical factors.195 CO exposure measures do not appear to be 
associated with lung function or respiratory symptoms – perhaps CO is an 
inadequate proxy for other pollutants of interest, such as PM2.5 and nitrogen 
dioxide. Our previous air pollution monitoring work in Chikhwawa has 
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demonstrated that monitored CO exposure correlates weakly with COHb, 
PM2.5 exposure, and measured black carbon in airway cells from induced 
sputum.23,360,363 
This study was conducted in the context of the largest cookstove intervention 
trial to date – a major strength enabling us to assess the effect of a cookstove 
intervention on childhood spirometry and air pollution exposure outcomes. 
Cookstove use declined during the CAPS follow-up period, with one-quarter of 
households using the cookstoves for two or more meals per day after 24-
months. Cookstove and solar panel malfunctions were common, with four 
repairs/replacements per intervention household during the 2-year trial 
period.26 It seems unlikely that many households would continue to use the 
cookstoves in 2017, without the maintenance support provided by the trial: 
from anecdotal reports however, we believe that increased awareness of the 
adverse effects of smoke led to altered cooking behaviours among study staff 
and participants. These altered behaviours, such as cooking away from the 
house and in better ventilated areas may have been responsible for the lower 
COHb observed in our “intervention” participants.  
Other strengths of this study include high participation rates for spirometry 
and CO exposure monitoring, and good quality spirometry in a representative 
sample of children, despite the highly challenging research environment of a 
rural area in a low-income country. We achieved our sample size, even though 
field work was disrupted by vampirism hysteria in the community; periodically 
there are reports of “blood-suckers” in Malawi – people are fearful of 
strangers during these times and research activities were suspended to avoid 
fuelling the mass hysteria, particularly those studies collecting samples or 
using unfamiliar equipment  We acknowledge limitations to our study 
including that personal monitoring of CO for 48 hours provides only a 
snapshot of exposure to a single pollutant. There are substantial limitations to 
the methods currently available for monitoring personal exposure to other 
pollutants in this young age group; the Lascar CO-monitoring device 
represents one of the best options available, at present. Monitoring during a 
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48-hour exposure period may not describe individual variation in daily and 
seasonal routines but reflected a compromise in terms of feasibility and 
acceptability in this large study population. Questionnaire data may have 
been subject to recall bias, with limited information on contributing factors 
such as birthweight, gestation at birth, HIV-status, and exposure to passive 
smoking. 
In conclusion, the substantial burden of chronic respiratory symptoms, 
abnormal spirometry and air pollution exposures in children in rural Malawi is 
concerning and calls for strategies to maximise healthy lung development and 
to effectively manage chronic respiratory conditions. To achieve this, research 
will be needed to develop ways to increase awareness of non-communicable 
lung diseases, such as asthma, at a community level to inform health care 
seeking behaviours and ensure access to appropriately trained health care 
providers and effective long-term treatment such as inhaled medication. Our 
finding of a potential beneficial effect of a cleaner burning biomass-fuelled 
cookstove on lung function (FVC) calls for further research into clean-air 
initiatives, tackling multiple sources of air pollution in a community-wide 
approach to promote lung health in children. 
3.5 List of appendices for chapter 3 
• Ethical approval from College of Medicine Research Ethics Committee 
(Malawi) 
• Ethical approval from Liverpool School of Tropical Medicine (UK) 
• Participant information sheet – English 
• Consent form – English 
• Questionnaire – English 
• Chichewa versions of study documents and SOPs available on request; 
o SOP – data collection 
o SOP – COHb measurement with Rad57 
o SOP – Spirometry 
o SOP – CO measurement with EasyLog
82 
 
4 Non-communicable respiratory disease and air pollution 
exposure in Malawi: a prospective cohort study   
 
4.1 Introduction 
Non-communicable respiratory diseases including chronic obstructive 
pulmonary disease (COPD) and asthma are a growing global concern, 
particularly in low- and middle-income countries (LMIC).53,43,87 Air pollution, 
including exposure to tobacco smoke, outdoor and household air pollutants, 
and occupational exposure to dust and fumes, is considered a major risk 
factor for non-communicable respiratory disease development and 
exacerbations.53,190 However, conflicting findings from recent studies have 
cast uncertainty over the specific role of household air pollution in COPD 
development.96,231 Approximately 3 billion people worldwide rely on highly 
polluting biomass fuels for cooking, heating and lighting.350 It is therefore a 
global public health priority to better understand the impact of household air 
pollution on non-communicable respiratory disease morbidity and mortality. 
The lung function trajectories of adults from sub-Saharan Africa (sSA) are 
largely undescribed; limited published data relate to cohorts from South 
Africa with HIV-infection and occupational silica dust exposure.239,364 There 
are no data from population-representative cohorts in sSA; it is not known 
whether adults exposed to biomass-related air pollution would experience 
accelerated age-related decline in lung function and therefore an increased 
risk of developing obstructive airways diseases as occurs in those exposed to 
tobacco smoke.220,222 
The cross-sectional BOLD (Burden of Obstructive Lung Disease) study, 
conducted in urban Blantyre, Malawi found unexpectedly high rates of 
decreased FVC and high levels of self-reported exposure to biomass smoke.22 
The finding of a high burden of low FVC was concerning given the association 
between this and increased mortality.24 To further explore this phenomenon, 
we did a second study in rural Chikhwawa, Malawi (entitled BOLD-
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Chikhwawa) with the same protocol as the Blantyre BOLD study, but with the 
addition of measurement of personal exposure to air pollutants: carbon 
monoxide (CO) and fine particulate matter ≤2.5µm (PM2.5).23 We found 
comparably high rates of spirometric abnormalities, with decreased FVC seen 
in 35% of participants, but no association between spirometric outcomes and 
exposure to CO or PM2.5 despite high levels of air pollution. Participants were 
from village communities which also participated in the Cooking and 
Pneumonia Study (CAPS), a cluster randomised trial of a cleaner-burning 
biomass-fuelled cookstove.26 Secondary analysis of adults from a sub-set of 
CAPS households found no difference in respiratory symptoms, lung function 
or personal air pollution exposures between intervention and control groups, 
but these analyses were done using cross-sectional data that were collected 
only a short time after introduction of the intervention – it is not known 
whether the rate of decline in lung function over time would be different 
between the trial arms.23 
This longitudinal study, the Adult Lung Health Study (ALHS) reports lung 
function and personal air pollutant exposure measurements from 3-years of 
follow-up for the BOLD-Chikhwawa cohort, to explore the determinants of 
lung function trajectories, including the effect of the CAPS cookstove 
intervention, in adults living in rural Malawi. 
4.2 Methods 
4.2.1 Setting 
Chikhwawa is a rural district, approximately 50km south of Blantyre, on the 
Shire river valley. During the study period, this district experienced severe 
flooding and crop failures. CAPS recruited children aged <4.5 years in 
Chikhwawa between December 2013 and August 2015; intervention 
households received two cleaner-burning biomass-fuelled cookstoves, a solar 
panel to charge the stove-fan battery and user training at the time of 
randomisation. Those in the control arm continued using traditional cooking 
methods, mostly open fires, but received cookstoves at the end of the CAPS 
follow-up in May 2016. 
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BOLD-Chikhwawa was a separate study, recruiting adults from the same 
village communities as CAPS: not all BOLD-Chikhwawa participants were 
enrolled in CAPS. Figure 4-1 shows the timeline of CAPS and BOLD-Chikhwawa 
activities. 
 
Figure 4-1. Timeline showing CAPS and BOLD-Chikhwawa activities 
 
4.2.2 Participants 
Following community engagement events, a list of all adults living in each of 
the 50 villages participating in CAPS in Chikhwawa was obtained from local 
community health workers. An independent statistician at the BOLD-centre in 
London used these collated lists to obtain a population-representative sample 
of adults aged >18 years, stratified by age and sex. All potential participants 
were invited to participate, with information provided in the local language, 
Chichewa, and written informed consent (or witnessed thumbprint) obtained 
from those who agreed.23 
4.2.3 Procedures 
Fieldworkers conducted follow-up visits in the community, approximately one 
and two years after enrolment, according to BOLD study standardised 
operating procedures, to collect questionnaire, spirometry and personal air 
pollution exposure data.21 Fieldworkers administered an abbreviated version 
of the BOLD study questionnaire in Chichewa, and measured height and 
weight.  
BOLD-centre certified fieldworkers conducted spirometry according to 
European Respiratory Society /American Thoracic Society (ERS/ATS) standards 
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using an EasyOne Spirometer (ndd Medical Technologies; Zurich, Switzerland), 
before and after administration of 200 micrograms of Salbutamol via 
Volumatic spacer.58 Spirometry overreading was performed by an 
independent technician, according to the BOLD criteria for acceptability and 
repeatability. 
After completing the questionnaire and spirometry assessment, participants 
were given an Indoor Air Pollution (IAP) 5000 Series Monitor (Aprovecho 
Research Centre, Oregon, USA) which they were instructed to wear in a small 
backpack during the day and to keep beside their sleeping mat at night, to 
estimate personal exposure to PM2.5 and CO over a 48 hour period. These 
monitors continuously sample air from the breathing zone, and PM2.5 and CO 
are measured using a light-scattering photometer and electrochemical cell CO 
sensor, respectively. Fieldworkers encouraged compliance with personal 
exposure monitoring during frequent community visits. IAP traces with 
outlying PM2.5 or CO values (extremely high or low) were visually inspected for 
expected daily variation in exposure: traces without variability, suggesting 
that backpacks had not been worn, were excluded from the analysis. 
4.2.4 Variables 
Clinical outcomes were assessed by the questions detailed in Table 4-2. Raw 
FEV1 and FVC values were used as continuous variables in the longitudinal 
analysis. Lung function parameters were compared with age, sex and height-
standardised Global Lung Initiative (GLI) reference ranges for African-
Americans and NHANES III reference ranges for Caucasians and African-
Americans.57,61 Restriction was defined as FVC below the lower limit of normal 
(LLN), and obstruction as FEV1/FVC ratio below the LLN; values below the 5th 
centile in a healthy, non-smoking reference population. 
Exposures included estimated personal exposure to PM2.5 and CO, and 
questionnaire assessment of smoking status and previous tuberculosis. At 
baseline, first and second follow-up, participants were classed as having 
access to a cookstove if their household had been given a cleaner-burning 
biomass-fuelled cookstove by the CAPS study team prior to data collection. 
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Baseline PM2.5 and CO levels were zeroed at the 0.1th percentile of values 
obtained during each monitoring period. Observations were included if >24-
hours were recorded, with recording truncated into 24-hour periods to reflect 
daily variation in personal exposure patterns, and only full 24-hour periods 
analysed. Log mean 24-hour PM2.5 and CO estimates were used for mixed-
effects modelling.  
Potential effect modifiers: Body Mass Index (BMI) and/or height and weight, 
age, years of education and sex, were evaluated as fixed covariates in the FEV1 
and FVC linear mixed-effects models. 
4.2.5 Study size 
3000 adults were initially invited to enrol in the baseline BOLD-Chikhwawa 
cohort. Participants were followed up if they had completed a baseline 
questionnaire (1481 participants) and were included in the longitudinal lung 
function analysis if they had at least two valid spirometry assessments during 
the study period. 
4.2.6 Statistical methods 
Descriptive analysis was performed, with Student’s t-test and Pearson’s chi-
square to compare continuous and categorical data.  
Participants with incomplete data (lost-to-follow-up or failing to complete 
spirometry) were compared to those with complete data using chi-square and 
Student’s t-test. Positive associations (p<0.2) on bivariate analysis were 
explored in multivariable logistic regression. 
Two separate mixed-effects models were developed for analysis of repeated 
exposure and lung function outcomes. In the log-linear exposure models, 
repeated estimates (mean 24-hour CO and PM2.5) from individuals were 
accounted for using an individual level random effect, with an additional 
random-effect accounting for clustering of 24-hour measurements within 48-
hour monitoring periods. Fixed effect covariates were selected sequentially to 
determine the optimum model fit by likelihood ratio testing under maximum 
likelihood estimation (MLE), with calculation of parameter estimates, 
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standard errors and p-values. Harmonic terms were included in the exposure 
models to account for any possible effect of seasonality on the outcome 
measures. This was implemented by including sinusoidal functions (sine and 
cosine terms) of time with a period of 1 year.  
Longitudinal lung function (FEV1 and FVC) linear models included the fitted CO 
and PM2.5 values from the exposure model as fixed covariates; an average 
value was calculated where participants had multiple periods of exposure 
monitoring. Fixed effect covariates were sequentially assessed by likelihood 
ratio testing under MLE, with interaction terms to explore the change in lung 
function over time. The final regression equations used in the exposure and 
lung function analysis are included in section 4.2.7. Analyses were conducted 
using R version 3.4.1 statistical software. 
4.2.7 Regression equations for mixed-effects exposure models 
4.2.7.1 CO model 
 𝑙𝑜𝑔𝑌𝑖𝑗𝑡 = 𝛼 + 𝑏𝑖𝑗𝑡𝛽1 + 𝑐𝑖𝑗𝑡𝛽2 + 𝑑𝑖𝑗𝑡𝛽3 + 𝑒𝑖𝑗𝑡𝛽4 + 𝑈𝑖 + 𝑉𝑖𝑗 + 𝑍𝑖𝑗𝑡 
where: 
𝑌𝑖𝑗𝑡  = exposure measurement for participant i, during 48-hr monitoring period j, 
on day t  
𝛽1, 𝛽2, 𝛽3, 𝛽4 = fixed effects parameter estimates 
b = sex (female=1, male=0) 
c = current smoker (yes=1, no=0) 
𝑑 = cos (
2𝜋
365
∗ day of year)   
𝑒 = sin (
2𝜋
365
∗ day of year)   
𝑈𝑖 ∼ 𝑁(0, 𝜎𝑢
2), random effect for the ith participant 
𝑉𝑖𝑗 ∼ 𝑁(0, 𝜎𝑣
2), random effect for jth 48-hour monitoring period in the ith 
participant 
𝑍𝑖𝑗𝑡~𝑁(0, 𝜎𝑥
2), error term associated with the tth measurement in the jth 48-




4.2.7.2 PM2.5 model 
𝑙𝑜𝑔𝑌𝑖𝑗𝑡 = 𝛼 + 𝑏𝑖𝑗𝑡𝛽1 + 𝑐𝑖𝑗𝑡𝛽2 + 𝑈𝑖 + 𝑉𝑖𝑗 + 𝑍𝑖𝑗𝑡 
where: 
𝑌𝑖𝑗𝑡  = exposure measurement for participant i, during 48-hr monitoring period j, 
on day t  
𝛽1, 𝛽2 = fixed effects parameter estimates 
𝑏 = sex (female=1, male=0) 
𝑐 = access to cookstove (yes=1, no=0) 
𝑈𝑖 ∼ 𝑁(0, 𝜎𝑢
2), random effect for the ith participant 
𝑉𝑖𝑗 ∼ 𝑁(0, 𝜎𝑣
2), random effect for the jth 48-hour monitoring period in the ith 
participant 
𝑍𝑖𝑗𝑡~𝑁(0, 𝜎𝑥
2), error term associated with the tth measurement in the jth 48-
monitoring period for the ith participant. 
4.2.7.3 FEV1 and FVC models 
𝑌𝑖𝑡 = 𝛼 + 𝑏𝑖𝑡𝛽1 + 𝑐𝑖𝑡𝛽2 + 𝑑𝑖𝑡𝛽3 + 𝑒𝑖𝑡𝛽4  + 𝑓𝑖𝑡𝛽5 + 𝑔𝑖𝑡𝛽6 + 𝑈𝑖 + 𝑍𝑖𝑡 
where: 
𝑌𝑖𝑗𝑡  = lung function measurement for participant i, on day t  
𝛽1, 𝛽2, 𝛽3, 𝛽4, 𝛽5, 𝛽6 = fixed effects parameter estimates 
b = time in years 
c = age in years 
d = sex (female=1, male=0) 
e = height in cm  
f = previous tuberculosis (yes=1, no=0) 
g = Body Mass Index in kg/m2 
𝑈𝑖 ∼ 𝑁(0, 𝜎𝑢
2), random effect for the ith participant 
𝑍𝑖𝑡~𝑁(0, 𝜎𝑥





4.2.8 Ethical approval 
The study was approved by Malawi College of Medicine Research Ethics 
Committee (reference P.11/12/1308) and the Liverpool School of Tropical 
Medicine Research Ethics Committee (reference 12.40). 
4.3 Results 
Between August 2014 and July 2015, 1481 adults were enrolled in the study at 
baseline and followed up on two subsequent occasions.23 Three-quarters 
(75%, n=1090) were re-assessed during the first follow-up period (August 
2015–November 2016) and two-thirds (67%, n=989) during the second follow 





Figure 4-2. Participant flow diagram. 
 
Demographic data for participants with or without questionnaire, spirometry 
or exposure monitoring are shown in Table 4-1. Participants completing the 
second follow-up visit were more likely to be female (odds ratio (OR) (95% CI), 





Table 4-1. Availability of data (questionnaire, exposure monitoring and spirometry) for 
1481 participants at baseline, first and second follow-up. 
 Data available Data not available 













Baseline 1481 43.8 
(17.8) 
57.0 - - - - 
Follow-up 1 1090 43.6 
(17.5) 
60.6 26.4 391 44.5 
(18.5) 
46.8 
Follow-up 2 989 44.0 
(17.6) 




Baseline 1029 44.0 
(17.9) 
57.1 30.5 452 43.4 
(17.4) 
56.6 
Follow-up 1 830 44.0 
(17.4) 
61.8 44.0 651 43.7 
(18.3) 
50.8 
Follow-up 2 811 44.4 
(17.2) 


















Baseline 886 40.9 
(15.3) 
51.1 40.2 595 48.2 
(20.2) 
65.7 
Follow-up 1 594 39.0 
(14.1) 
51.5 59.9 887 47.1 
(19.2) 
60.7 
Follow-up 2 537 37.1 
(13.8) 


















Spirometry was attempted by 950/1481 (64%), 628/1090 (58%) and 571/989 
(58%), and personal air pollution exposure monitoring completed for 
1029/1481 (69%), 830/1090 (76%) and 811/989 (82%) at baseline, first and 
second follow-up, respectively (Figure 4-2). Multiple spirometry 
measurements were available for 654/1481 (44%) of participants whilst 413 
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(28%) had only one spirometry measurement and 413 (28%) had none. 
Personal air pollution exposure was estimated on more than one occasion for 
929/1481 (63%) of participants whilst 401 (27%) had only one episode of 
monitoring and 151 (10%) had none. 
At baseline, the cohort included 424 participants from CAPS households: this 
rose to 523 participants (271 from intervention and 252 from control 
households) as CAPS continued to recruit until August 2015.  
The baseline demographics of the cohort have been previously reported.23 In 
brief, at baseline the mean (SD) age of participants was 43.8 (17.8) years, 57% 
were female and all households (99.8%) used biomass fuels for cooking. One 
third had never attended school and half had not been educated beyond 
primary school level. 
The frequency of reported respiratory symptoms increased greatly over the 
course of the study (Table 4-2): overall 13.6% (95% CI, 11.9-15.4) of 
participants reported respiratory symptoms at baseline compared to 36.2% 
(95% CI, 33.3-39.4) at final follow-up. Self-reported rates of smoking and TB 
did not change over time; current smoking was reported by 13.9% and 12.9%, 
and previous TB infection reported by 3.2% and 2.6%, at baseline and final 




Table 4-2. Respiratory symptoms and exposures reported by participants at baseline, 
first and second follow-up. 







Respiratory symptoms    
Cough: Do you usually cough when 







Sputum: Do you usually bring up 
phlegm from your chest when you 







Wheeze: Have you had 
wheezing/whistling in your chest in 








MRC dyspnoea II: Are you troubled 
by shortness of breath when 








Functional limitation: Have breathing 








Any respiratory symptom (any of the 

























4.3.1 Personal exposure monitoring 
A total of 1768 personal exposure monitoring episodes lasted >48 hours, and 
a further 902 lasted between 24 and 48 hours. Within episodes of >48 hours, 
there was fair correlation between the first and second 24-hour periods, for 
both PM2.5 (adjusted R2=0.68) and CO (adjusted R2=0.59). Correlation between 
exposures to the two air pollutant measures (mean PM2.5 and CO), analysed 
for a total of 4438 24-hour monitoring periods was poor (adjusted R2=0.027). 
Overall, the 24-hour median personal PM2.5 and CO exposures were 77.0 
µg/m3 (interquartile range [IQR], 42.8-153.1) and 1.27 ppm (IQR, 0.79-2.05), 
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respectively. Personal PM2.5 (median (IQR)) was 71.7 µg/m3 (42.8-128.0), 84.6 
µg/m3 (45.9-175.7) and 75.9 µg/m3 (40.1–176.4) at baseline, first and second 
follow-up, respectively. Personal CO exposure (median (IQR)) was 1.26 (0.79-
2.07) ppm, 1.33 (0.81-2.22) ppm and 1.22 (0.75-1.90) ppm, at baseline, first 
and second follow-up, respectively. 
In total, 4377 24-hour monitoring periods with complete covariate data from 
1304 individuals were included in mixed effects exposure models, with CO and 
PM2.5 as the response variables. In the final CO model, we found strong 
evidence that female sex, current smoking status and seasonality were 
associated with CO level (Tables 4-3 and 4-4). In the final PM2.5 model, female 
sex was associated with increased PM2.5 and access to a cookstove with 
decreased PM2.5 (risk ratio 0.85 (95% CI, 0.75-0.97) (Tables 4-3 and 4-5). 
Table 4-3. Estimated risk ratios and 95% confidence intervals for fixed effects 
covariates included in final air pollutant exposure log linear mixed-effect models 
 PM2.5 (µg/m3) CO (ppm) 
Sex 1.27 (1.13, 1.42) 1.60 (1.51,1.72) 
Current smoking - 1.22 (1.12, 1.34) 
Seasonality: cosine function - 0.85 (0.81, 0.89) 
Seasonality: sine function - 0.99 (0.96, 1.03) 
Access to cookstove 0.85 (0.75, 0.97) - 
 
Table 4-4. Likelihood ratio comparison of increasingly complex mixed-effects logCO 
response models 
 Fixed effects 
parameters 
Comparison LogLikelihood Likelihood 
ratio test 
df p-value 
1 None - -4371.4    
2 Seasonality 1,2 -4344.8 53.2 2 <0.001† 
3 Seasonality, sex 2,3 -4256.2 177.2 1 <0.001† 
4 Seasonality, sex, age 3,4 -4256.1 0.1 1 0.768 
5 Seasonality, sex, 
smoker 
4,5 -4246.6 19.1 1 <0.001† 
6 Seasonality, sex, 
smoker, cookstove 
5,6 -4246.5 0.2 1 0.698 
†Significant at 0.05 level and included in final model. Final fixed effects covariates 
highlighted in grey. 
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Table 4-5. Likelihood ratio comparison of increasingly complex mixed-effects logPM2.5 
response models 
 Fixed effects 
parameters 
Comparison LogLikelihood Likelihood 
ratio test 
df p-value 
1 None - -6923.7    
2 Seasonality 1,2 -6923.2 1.1 2 0.574 
3 Sex 1,3 -6915.4 16.7 1 <0.001† 
4 Sex, age 3,4 -6914.7 1.3 1 0.256 
5 Sex, smoker 3,5 -6913.6 3.4 1 0.064 
6 Sex, cookstove 3,6 -6912.2 6.2 1 0.013† 
†Significant at 0.05 level and included in final model. Final fixed effects covariates 
highlighted in grey. 
 
4.3.2 Spirometry 
Of those attempting spirometry, ERS/ATS standards were achieved by 
886/950 (93.3%), 594/628 (94.6%) and 537/571 (94.0%) at baseline, first and 
second follow-up visits, respectively (Figure 4-2). On bivariate analysis, factors 
associated with failing to complete spirometry were: older age, lower BMI, 
female sex, current smoking, cough or any respiratory symptoms. In logistic 
multivariable analysis, participants who were female (OR (95% CI), 0.52 (0.39-
0.71)), older (OR (95% CI), 0.97 (0.96-0.98)) or with a lower BMI (OR (95% CI), 
1.09 (1.04-1.14)) were significantly less likely to complete spirometry. 
Participants with longitudinal spirometry data had reduced lung function at 
baseline, compared to those who performed spirometry on only one occasion: 
mean (SD) FEV z-score -0.48 (1.03) vs -0.22 (1.28), mean (SD) FVC z-score -0.33 
(1.01) vs 0.03 (1.19), respectively. 
Best post-bronchodilator traces were analysed for 1068 participants who 
completed at least one spirometry session to ERS/ATS standards. Overall, 
mean (SD) FEV1 and FVC were 2.55 (0.64) litres and 3.16 (0.73) litres, 
respectively, with a mean (SD) FEV1/FVC ratio of 0.80 (0.09) (Table 4-6). When 
compared to GLI African-American reference ranges, mean (SD) FEV1, FVC and 
FEV1/FVC ratio z-scores were -0.38 (1.14), -0.19 (1.09) and -0.37 (1.04), 
respectively, with spirometric obstruction seen in 11.2% (95% CI, 9.4-13.2%) 
and low FVC in 8.1% (95% CI, 6.5-9.9%). Rates of obstruction were similar 
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when NHANES Caucasian reference ranges were used (11.5% (95% CI, 9.6-
13.5%)), but considerably more - approximately 50% - of participants were 
classified as having a low FVC (49.7% (95% CI, 46.7-52.8%). 
Table 4-6. Best post-bronchodilator spirometry values* and classification by GLI and 
NHANES reference ranges for 1068 participants. 
*For participants with spirometry measured at more than one timepoint, the best FEV1 
and FVC values were analysed  
† z-scores calculated using GLI African-American reference ranges 
 
 
Overall, the annual rate of lung function decline was 30.9ml (95% CI, 21.6-
40.1) for FEV1 and 38.3ml (95% CI, 28.5-48.1) for FVC (Table 4-7). Age, sex, 
height, previous TB infection, and BMI were included in the final mixed-effects 
models as significant fixed effect covariates for FEV1 and FVC (all p<0.001, 
Tables 4-8 and 4-9), although they did not affect rate of lung function decline. 
Current smoking, access to a cookstove, PM2.5 and CO exposure levels did not 
significantly improve either model. Decreased FEV1 and FVC were associated 
with increasing age, female sex, previous TB infection and decreased height 
and BMI (Table 4-7). 
Spirometry value 
Raw Mean (SD) FEV1, litres 2.55 (0.64) 
 
Mean (SD) FVC, litres 3.16 (0.73) 
 
Mean (SD) FEV1/FVC ratio 0.80 (0.09) 
Z-scores† Mean (SD) FEV1 z-score -0.38 (1.14) 
 
Mean (SD) FVC z-score -0.19 (1.09) 
 
Mean (SD) FEV1/FVC ratio z-score -0.37 (1.04) 
Classification % of population (95% CI) 
Obstruction FEV1/FVC <LLN GLI African American 11.2 (9.4-13.2)  
 
FEV1/FVC <LLN NHANES African American 11.5 (9.6-13.5)  
 
FEV1/FVC <LLN NHANES Caucasian 9.8 (8.1-11.7)  
Restriction FVC <LLN GLI African American 8.1 (6.5-9.9)  
 
FVC <LLN NHANES African American 7.7 (6.2-9.5)  
 
FVC <LLN NHANES Caucasian 49.7 (46.7-52.8)  
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Table 4-7. Parameter estimates for multiple fixed-effects covariates included in final 
FEV1 and FVC linear mixed-effect models*. 
 FEV1 ml  FVC ml  
 Estimate 95% CI Estimate 95% CI 
Time (years) -30.9 -40.1, -21.6 -38.3 -48.1, -28.5 
Age (years) -18.7 -20.4, -16.9 -11.0 -13.0, -9.1 
Sex (female) -500.1 -566.6, -433.6 -678.0 -751.4, -604.7 
Height (cm) 23.6 19.9, 27.3 32.8 28.7, 36.9 
Previous TB (yes) -404.9 -539.7, -230.2 -334.2 -526.6, -141.8 
BMI 21.9 13.8, 30.0 21.3 12.4, 30.2 
*Models include post-bronchodilator FEV1 and FVC data from 950 individuals, 




Table 4-8. Comparison of increasingly complex mixed-effects FEV1 response models 





0 None - -13723 - - - 
1 Time 0,1 -13704 38.7 1 <0.001† 
2 Time, age 1,2 -13602 203.0 1 <0.001† 
3 Time, age, sex 2,3 -13379 446.0 1 <0.001† 
4 Time, age, sex, height 3,4 -13312 134.7 1 <0.001† 
5 Time, age, sex, height, 
smoker 
4,5 -13310 3.2 1 0.072 
6 Time, age, sex, height, TB 4,6 -13299 25.5 1 <0.001† 
7 Time, age, sex, height, TB, 
BMI 
6,7 -13285 28.9 1 <0.001† 
8 Time, age, sex, height, TB, 
BMI, years at school 
7,8 -13284 1.3 1 0.248 
9 Time, age, sex, height, TB, 
BMI, cookstove 
7,9 -13285 0.14 1 0.706 
10 Time, age, sex, height, TB, 
BMI, CO 
7,10 -13285 0.08 1 0.777 
11 Time, age, sex, height, TB, 
BMI, PM 
7,11 -13284 2.1 1 0.146 
12 Time, age, sex, height, TB, 
BMI, time*age 
7,12 -13284 0.87 1 0.352 
13 Time, age, sex, height, TB, 
BMI, time*sex 
7,13 -13285 0.12 1 0.726 
14 Time, age, sex, height, TB, 
BMI, time*TB 
7,14 -13285 0 1 0.998  
15 Time, age, sex, height, TB, 
BMI, time*PM 
7,15 -13283 2.94 2 0.230 
16 Time, age, sex, height, TB, 
BMI, time*CO 
7,16 -13284 0.34 2 0.842 
 
†Significant at 0.05 level and included in final model.  
Final fixed effects covariates highlighted in grey. 





Table 4-9. Comparison of increasingly complex mixed-effects FVC response models 





0 None - -13912 - - - 
1 Time 0,1 -13885 54.08 1 <0.001† 
2 Time, age 1,2 -13862 45.96 1 <0.001† 
3 Time, age, sex 2,3 -13560 604.00 1 <0.001† 
4 Time, age, sex, height 3,4 -13454 212.11 1 <0.001† 
5 Time, age, sex, height, 
smoker 
4,5 -13454 0.08 1 0.775 
6 Time, age, sex, height, TB 4,6 -13446 15.04 1 <0.001† 
7 Time, age, sex, height, TB, 
BMI 
6,7 -13435 22.69 1 <0.001† 
8 Time, age, sex, height, TB, 
BMI, years at school 
7,8 -13435 0.001 1 0.973 
9 Time, age, sex, height, TB, 
BMI, cookstove 
7,9 -13435 0.12 1 0.732 
10 Time, age, sex, height, TB, 
BMI, CO 
7,10 -13434 1.89 1 0.170 
11 Time, age, sex, height, TB, 
BMI, PM 
7,11 -13434 1.33 1 0.249 
12 Time, age, sex, height, TB, 
BMI, time*age 
7,12 -13433 3.34 1 0.068 
13 Time, age, sex, height, TB, 
BMI, time*sex 
7,13 -13435 0.08 1 0.78 
14 Time, age, sex, height, TB, 
BMI, time*TB 
7,14 -13434 0.79 1 0.37 
15 Time, age, sex, height, TB, 
BMI, time*PM 
7,15 -13434 2.70 2 0.259 
16 Time, age, sex, height, TB, 
BMI, time*CO 
7,16 -13434 1.96 2 0.376 
†Significant at 0.05 level and included in final model.  
Final fixed effects covariates highlighted in grey. 






This is the first prospective cohort study to report longitudinal lung function 
and personal exposure to air pollution in a sub-Saharan African population. 
The main findings were that: FEV1 and FVC were determined by age, sex, 
height, previous TB and BMI, whilst there was no evidence of accelerated lung 
function decline (30.9ml FEV1 and 38.3ml FVC annual decrease) as might have 
been expected in this population compared to the natural age-related decline 
reported in populations from Europe and the USA.222 Mean (SD) FEV1 and FVC 
z-scores (-0.38 (1.14) and -0.19 (1.09)) were comparable to those previously 
reported for children from this community adding to evidence that 
spirometric abnormalities in adults have their origins in early life.365 Lung 
function was not associated with exposure to CO, PM2.5 or access to a 
cookstove. Estimated CO and PM2.5 correlated poorly and were associated 
with different covariates. Exposure to PM2.5 was increased in females and 
decreased by a factor of 0.85 (95%CI, 0.75-0.97) in those with access to a 
cookstove. Exposure to CO was increased in females and current smokers and 
showed a seasonal trend. 
We did not find evidence of accelerated lung function decline despite 
exposure to high levels of PM2.5. Previous studies exploring the impact of 
PM2.5 on lung function in high income settings have focused on PM2.5 from 
ambient air pollution, particularly traffic-related air pollution. Faster lung 
function decline was associated with increasing PM2.5 in  longitudinal cohorts 
from the USA and Taiwan, the effects of other pollutants were not 
reported.366,367 A large multi-centre metanalysis from the European ESCAPE 
cohorts did not find an association between air pollution and lung function 
decline but noted that NO2 was negatively associated with lung function.368 It 
is possible that the emissions from incomplete biomass combustion are less 
harmful to the airways than the many constituents (including nitrogen oxides) 
of traffic-related air pollution. 
Previous work from Malawi has reported lung function relative to NHANES III 
Caucasian reference values, to facilitate comparison with other BOLD 
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studies.22,23 In this analysis, we have additionally compared our data to 
African-American reference ranges (NHANES and GLI). The prevalence of 
reduced FVC varies greatly depending on which reference equation is used.64 
The prognostic significance of markedly different predicted values in different 
ethnic populations is unclear.66 Reduced FVC is seen in restrictive lung 
disease, however more detailed assessment of total lung capacity by 
plethysmography is needed to further characterise the pattern of lung defect 
seen in African populations. 
Use of GLI reference ranges permitted direct comparison with spirometry data 
from children living in the same community. We recently reported lung 
function for children aged 6-8 years, living in Chikhwawa; FEV1, FVC and 
FEV1/FVC ratio z-scores were -0.48 (0.93), -0.30 (0.96) and -0.38 (0.90), 
respectively, compared to GLI African American reference ranges.365 The 
finding of similar z-scores in both the children and adults living in this 
community, suggests that factors which influence lung growth and 
development act in early childhood before 6 years of age, perhaps even 
starting in-utero. 
We found an increase in self-reported respiratory symptoms over the 3-year 
follow-up period but no changes in exposures (self-reported TB or smoking 
status, or measured PM2.5 or CO). We speculate this is due to changes in 
reporting behaviour rather than a true change in symptom prevalence. During 
the CAPS period, the local community were exposed to messages about the 
health impact of air pollution and may have become sensitized to the issues of 
clean air and respiratory health. Participants became familiar with the same 
questions asked on repeated occasions: this may have led a positive reporting 
bias. Alternatively, responses at baseline may have underreported symptom 
prevalence: a community survey in two rural districts in Central Malawi 
reported chronic respiratory symptoms in 22.5% of the population.331  
Previous cookstove intervention trials have explored lung function in adult 
women only.233,234 The RESPIRE randomised controlled trial in Guatemala, 
reported a reduction in 48-hour personal CO exposure in the intervention 
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group using a plancha woodstove but no effect on women’s lung function at 
12-18 months in an intention-to-treat analysis.234 A subsequent exposure-
response analysis did find a significantly decreased rate of decline with 
decreased exposure to CO.235 Use of a Patsari stove in rural Mexico was 
associated with a significantly decreased rate of lung function (FEV1) decline in 
women compared to those cooking on open fires (31ml vs 62ml), over one 
year of follow-up, but this effect was not observed on intention-to-treat 
analysis.233 This decrease in decline is comparable to that reported among ex-
smokers, in the first year after quitting; their FEV1 trajectory showed half the 
rate of annual decline compared to those who continued to smoke ((mean ± 
SD) 31±48 vs 62±55ml).223 Our finding of FEV1 annual decline of 30.9ml is 
consistent with the ranges seen in non-smokers from various studies.220 
Our findings would suggest that low lung volumes seen in Malawian adults are 
not a result of accelerated decline in lung function, but more likely a failure to 
reach maximal lung volumes in early adulthood, either due to low lung 
function at birth or suboptimal lung growth during early childhood. Low-birth 
weight and prematurity are of particular relevance in Malawi; the country has 
the highest rate of preterm birth worldwide, and intrauterine growth 
restriction, in both term and preterm infants, is common in low-income 
countries due to maternal factors including young maternal age, short-
interpregnancy intervals and congenital infections.152,153 Adverse effects of 
prenatal exposure to household air pollution on infant lung function has been 
suggested by the recent GRAPHS trial in Ghana.40 The adverse effect of early 
respiratory infections on lung health in adulthood has long been recognised; 
such infections are common in sub-Saharan Africa, particularly during the first 
year of life.129,369 
Several studies have used CO levels as a proxy for particulate matter, which is 
challenging to measure in the field in low-resource settings. However, 
respirable particulate matter ≤2.5µm (PM2.5) can reach the alveolar level in 
the lungs and is of greater interest when considering adverse respiratory 
effects of air pollution. We found no association between PM2.5, CO or access 
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to a cookstove and lung function. In keeping with findings from Peru, Nepal 
and Kenya, we observed poor correlation between CO and PM2.5 
measurements and different explanatory covariates for the two pollutants in 
our exposure models.370 Although observed levels of exposure to both CO and 
PM2.5 exceeded WHO upper safety limits, the duration of these high exposures 
was brief, and we speculate that adverse pulmonary effects are limited by the 
low intensity of exposure in rural Malawi where most cooking is done 
outdoors. Similarly, we found that current smoking was not associated with 
FEV1 in this population, likely reflecting the low intensity of tobacco use 
among smokers in this community; less than one-fifth of current or ex-
smokers at baseline reported cigarette consumption of greater than 10 pack 
years. 
Strengths of our study include the collection of longitudinal lung function and 
personal air pollution exposure data in a rural cohort in one of the world’s 
poorest countries; high quality spirometry performed by BOLD-certified 
technicians, with external quality control of traces by an independent expert 
reviewer. Limitations include potential recall bias and highly variable 
responses to questionnaires, and bias introduced by those not attempting 
spirometry or lost to follow-up. Participants performing spirometry were 
younger and hence it is likely that spirometric abnormalities, such as 
obstruction, which are associated with increasing age are likely to be 
underrepresented. Throughout the study the team struggled with cultural 
beliefs that older members of the community were “too weak” or “physically 
unable” to attempt spirometry. One third of participants from baseline were 
lost to follow-up by the end of the study; we were unable to ascertain the 
reasons for this due to limitations of the data collected, but comparison of the 
demographic data for those who remained in the study at each phase 
suggested that men and those with better education were more likely to be 
lost, reflecting the more economically active, mobile sector of society. We 
recognise that 3 years is a relatively short time period to track longitudinal 
changes in lung function but believe we would more likely observe any effect 
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of the intervention during the CAPS study period, when the use of the 
cookstoves was actively supported by a repair and maintenance programme. 
Given that the rate in decline in lung function we observed over 3 years was 
consistent with the rate of decline seen in healthy adults in Europe and North 
America it seems likely that this observation is accurate and that a longer 
period of follow up would not have yielded additional useful rate of decline 
information. 
In conclusion, in our cohort of adults living in rural Malawi, we observed a) 
reduced FVC compared to Caucasian reference populations, similar in relative 
magnitude to what we previously reported in children living in the same 
communities, b) no evidence of accelerated decline in FEV1 or FVC and c) no 
effect of access to cleaner-burning cookstoves on lung function decline. We 
suggest that future efforts to improve the lung health of those living in the 
poorest parts of the world should focus on antenatal and early childhood 
interventions to maximise lung growth and development. Further research is 
required to define the prognostic significance of reaching adulthood with 
suboptimal lung volumes, regardless of comparative reference range in terms 





5 Task-shifting to improve asthma management in 
children in Malawi: a randomised controlled trial 
 
5.1 Introduction  
Asthma is the most common chronic condition in childhood and is a growing 
concern in Africa.20 Asthma causes an estimated 1000 deaths worldwide every 
day, and is a major cause of morbidity in children, ranking in the top ten 
causes of disability adjusted life years.19,20 Asthmatic adults in sub-Saharan 
Africa (sSA) suffer frequent acute exacerbations, and have symptoms which 
are poorly controlled.257,258,371 Limited data from asthmatic children living in 
sSA suggest higher rates of severe symptoms compared to high-income 
settings, likely due to challenges with diagnosis and quality of asthma care.51 
The Malawi Standard Treatment Guidelines for asthma management are 
extrapolated from global guidelines, adopting a step-wise approach centred 
on inhaled corticosteroid (ICS) therapy.372,44 These guidelines are appropriate 
where steroid-responsive, allergen-driven, eosinophilic asthma predominates: 
it is unknown whether this is true for Malawi. Limited evaluation of asthma 
guideline implementation in selected low- and middle-income countries 
(LMICs), found that physicians often underutilise ICS treatment, and that 
patient adherence to treatment is a challenge.306,307 Reasons for poor 
adherence are likely to be multifactorial, including unreliable supplies of 
affordable medication, and misconceptions regarding effective asthma 
treatments.308,310 
Asthma education and the use of an Asthma Action Plan (AAP) are considered 
important elements of chronic asthma management in high-income countries 
(HIC) and are recommended in international guidelines.44 Studies 
demonstrating a beneficial impact of asthma education in HIC include a wide 
range of interventions, with variable content, duration and delivery 
methods.313,315 AAPs facilitate the early detection and treatment of an 
exacerbation, and have been shown to improve asthma health outcomes in 
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HIC.319 However, the provision of asthma education can be time consuming 
and human resources constraints in Malawi limit the quality of care available. 
Task shifting, defined as “the transfer of a task normally performed by a more 
highly trained health care worker to another with a different, usually lower 
level of training,” is a possible solution, but research exploring this approach 
to asthma management in LIC is lacking.336,348 
We implemented a package of enhanced asthma care, appropriate for a LIC, 
which included a standardised clinical assessment, optimisation of locally 
available inhaled asthma treatment, and asthma education delivered by non-
clinical staff. 
We aimed to assess the feasibility of the intervention and describe baseline 
levels of asthma control and exacerbation rates in asthmatic children living in 
urban Blantyre, Malawi. Furthermore, we planned to; evaluate the effect of a 
package of enhanced asthma care over a 3-month period; to describe clinical 
and airway inflammatory phenotypes; to identify clinical features which might 




Queen Elizabeth Central Hospital (QECH), a government-run, tertiary hospital, 
located in Blantyre, Malawi’s second largest city, receives referrals from 
throughout the Southern Region. Children attending the general paediatric 
clinic are referred from primary health centres, and from within QECH 
following emergency department attendance or ward admission. 
5.2.2 Trial design  
We did a non-blinded, individually randomised controlled trial comparing the 





All children aged 6-15 years attending the general paediatric outpatient clinic 
at QECH with a doctor-diagnosis of asthma recorded in their health passport 
were invited to participate in the study. Children with symptoms suggestive of 
tuberculosis were excluded; productive cough, haemoptysis, weight loss, 
recurrent fevers or night sweats. Study visits were postponed if children were 
acutely unwell, or had a respiratory infection, asthma exacerbation or 
received oral corticosteroids in the previous 4-weeks. 
5.2.4 Consent and randomisation procedure 
Study information was provided in the local language (Chichewa). Following 
written informed consent from the parent or guardian and assent from the 
child, a baseline electronic questionnaire was completed; children were 
stratified according to their level of asthma control, as assessed by the 
childhood Asthma Control Test (cACT), into two groups (cACT≥20 or 
cACT≤19).259 Within each group, individuals were allocated 1:1 to intervention 
or standard care arms using pre-generated variable length, permuted block 
randomisation codes. Allocation information was not accessible to any staff 
prior to electronic questionnaire completion. 
5.2.5 Study procedures 
The intervention comprised 3 components; detailed clinical assessment, 
optimisation of locally available inhaled asthma treatment, and asthma 
education delivered by non-clinical staff.  
5.2.5.1 Intervention: Clinical assessment 
Participants in the intervention arm attended the hospital shortly after 
recruitment for an assessment visit at which clinical examination, 
anthropometry, exhaled nitric oxide (FeNO) measurement, pre-and post-
bronchodilator spirometry, and exercise challenge were done. All study 
procedures were performed according to standardised operating procedures, 
with regular quality control monitoring by the study clinician. Asthma 
symptoms were assessed using Global Initiative for Asthma (GINA) and 
International Study of Asthma and Allergies in Childhood (ISAAC) 
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questionnaires.44,51 Spirometry was conducted by experienced technicians, 
using an Easy On-PC spirometer (ndd Medical Technologies), according to 
American Thoracic Society/European Respiratory Society (ATS/ERS) 
guidelines.58 Lung function was measured before and after 400µg salbutamol 
administered by metered-dose inhaler via a Volumatic spacer. Lung function 
parameters; forced expiratory volume in one second (FEV1), forced vital 
capacity (FVC), FEV1/FVC ratio and bronchodilator responsiveness, were 
interpreted with reference to the African American Global Lung Initiative 2012 
equations.57 
Carboxyhaemoglobin (COHb) was measured non-invasively using a Rad-57 
Pulse CO-Oximeter (Masimo Corporation). FeNO was measure using an 
NObreath machine (Bedford Scientific Ltd.), following ATS/ERS guidelines.373 
Provided their FEV1 was >75% predicted value, participants underwent 
exercise challenge, running at maximum effort for 6-minutes with FEV1 
monitored at five- and ten-minutes post-exercise.  
5.2.5.2 Intervention: Optimisation of inhaled asthma treatment 
Following the clinical assessment, ICS treatment was started or escalated to a 
maximum daily dose of 400µg of beclometasone dipropionate, for children 
with poor control or obstructive spirometry (as indicated by cACT≤19 or 
FEV1/FVC ratio below the lower limit of normal (LLN) respectively). These 
participants were reviewed after 6-weeks to assess their response and to 
encourage treatment adherence. Participants with cACT≥20 and FEV1/FVC 
above the LLN continued their previous medication. 
5.2.5.3 Intervention: Asthma education delivered lay educators 
Non-clinical “lay educators” delivered a 1-hour asthma education session to 
the child and carer, including discussion of a personalised AAP (Figure 5-1), 
with oversight by the study clinician or nurse. Before study initiation, 
educators completed a structured training programme (Table 5-1) and were 
required to pass a formal assessment of their knowledge and skills. Each 
asthma education session followed a structured approach, with checklist, to 
ensure consistency within and between educators (Table 5-2).  
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Pre-study training programme 
Before the study started, four “lay educators” received training by the study 
doctor. These staff had completed secondary school, with a Malawi School 
Certificate of Education, but had no previous medical experience or training. 
The lay educators spent time with the study doctor in the paediatric clinic to 
gain experience with asthma patients and their families. Formal training 
comprised four hour-long tutorials (Table 5-1), with an accompanying training 
manual for self-study, after which the educators were required to gain at least 
80% in a knowledge test (comprising 20 true/false questions) and 
demonstrate competence at delivering the asthma education session in a 
role-play session. The educators were supported by the study medical staff 
and encouraged to seek advice throughout the study period. 
 
Table 5-1. Pre-study asthma training for lay educators 
Session Key content 
1) What is 
asthma? 
Chronic inflammation of airways and airway narrowing 
Recurrent symptoms; cough, wheeze, difficulty breathing 
Impact of poor asthma control, including death with severe attack 
Symptoms can be well controlled with inhaled treatment 
Common triggers for asthma symptoms 
2) Asthma 
treatment 
Types of inhaler: relievers (β2 agonist) and preventers (steroid) 
Use of a spacer to improve drug delivery 
Importance of long-term adherence 
3) Self-
management 
Monitoring of symptoms 
What to do in an asthma attack 
Asthma Action Plans 
4) Practical 
session 
Inhaler technique – how to demonstrate 





Education session content  
Study participants received a 1-hour individualised asthma education session, 
delivered to the child and their carer by lay educators, with oversight by the 
study doctor or nurse. A structured approach, with checklist (Error! Reference 
source not found.Table 5-2), was followed to ensure intra- and inter-educator 
consistency. Education sessions were conducted in Chichewa, and patients 
received a written asthma action plan, also in Chichewa (Figure 5-1).  
 
Table 5-2. Asthma education checklist 
 Please tick 
General approach 
Establish good rapport with child and family  
Establish what is known already about asthma, treatments etc.  




What is asthma?  
What symptoms does asthma cause?  
Rationale for treatment – differences between “relievers” and 
“controllers” 
 
Encourage adherence, even when control is good  
Inhaler/spacer skills training  
• Including demonstration of inhaler/spacer technique 
by fieldworker 
 
• Observe participant’s technique  
Discuss possible triggers and avoidance  
How to recognise worsening symptoms and what to do  
Discuss and provide written asthma action plan  
Arrange next medical review  





Figure 5-1. Asthma Action Plan  
 
Patients with poor control (cACT≤19) or airway obstruction (FEV1/FVC below 
lower limit of normal) at the time of the first education session, attended a 




5.2.5.4 Standard care 
Participants in standard care continued with their asthma treatment and 
follow-up schedule as prescribed by the QECH clinic staff (paediatric specialist 
of registrar or consultant level). 
All study participants received their medication from the QECH pharmacy: 
salbutamol and beclometasone dipropionate inhalers are included in the 
Malawi Standard Treatment Guidelines, and usually available, free of charge. 
At times when inhalers were out of stock, children received their inhalers 
from a private supply, purchased by the Paediatric department to prevent 
treatment interruptions. 
5.2.6 Outcomes 
All participants were invited to attend a study review at 3-months for 
assessment of primary and secondary outcomes. The primary outcome, 
asthma symptom control, was measured by the cACT, a 7-item questionnaire, 
translated into Chichewa according to linguistic validation guidelines.374 
Secondary outcomes were asthma exacerbations requiring hospitalization, 
emergency health care use or treatment with oral corticosteroid; school 
absence; lung function; FeNO. Serious adverse events were reported within 
72-hours to a Data Safety and Monitoring Board, which also met at regular 
intervals. 
5.2.7 Follow-on care 
At the end of the 3-month study period, those in the intervention arm 
returned to care in the general clinic. Participants in the standard care arm 
were invited to attend an assessment visit, including the asthma education 
intervention and were reviewed again after 3-months, with a questionnaire 
and FeNO and spirometry assessment. 
5.2.8 Sample size 
We planned to enrol 120 participants, aiming for a sample of at least 90 
children with complete data, after loss-to-follow-up and technical difficulty 
with clinical procedures. Using two-tailed Student’s t-test, 45 children in each 
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arm will detect a difference in cACT of 3 points; an effect size of 0.6, given 
standard deviation 5, with 80% power at a 5% significance level. 
5.2.9 Statistical methods 
Intention-to-treat analysis compared primary and secondary outcomes 
between the intervention and standard care arms using two-tailed Student’s 
t-test and Wilcoxon Signed-Rank test for normally distributed and non-
parametric continuous data, respectively. Pearson’s Chi-squared tests were 
used to compare proportions. Pearson and Spearman correlation coefficients 
were calculated to explore associations between parametric and non-
parametric continuous variables, respectively. Predictors of change in cACT 
over 3-months were explored in a multivariable linear regression model, using 
a backward stepwise regression technique, including variables with a p-value 
<0.2 on bivariate analysis. Analyses were conducted using R version 3.4.1 
statistical software. 
5.2.10 Approvals and registration 
The study was approved by the College of Medicine, Malawi (reference 
P.04/18/2384) and Liverpool School of Tropical Medicine, UK (reference 18-
018) Research Ethics Committees. The trial was registered with the Pan 
African Clinical Trials Registry (reference PACTR201807211617031). 
5.3 Results 
We recruited 120 children between September 2018 and December 2019; 59 
were randomised to receive enhanced care, and 61 to receive standard care. 
Mean age (SD) of participants was 9.8 (2.8) years with 65.8% males. 115 
participants attended for review at 3-months, with data collected as shown in 
Figure 5-2.  Mean (SD) duration of follow-up, to RCT completion, was 96.6 
(12.0) days and 91.0 (10.1) days for enhanced and standard care participants, 
respectively. Following completion of the initial 3-month follow-up, 58 
participants from standard care attended for assessment, asthma education 





Figure 5-2. Participant recruitment and follow-up for the RCT analysis 
 
 





5.3.1 Asthma symptoms and treatment at enrolment 
Eighty percent of participants reported previous hospital admission with 
asthma symptoms. In the preceding 3-months, 28/120 (23.3%) were admitted 
to hospital, 39/120 (32.5%) attended a health facility, but did not require 
admission, and 79/120 (65.8%) missed school due to asthma symptoms. 
Median (IQR) school absence was 3 (2-5) days, with 58.2% (46/79) of 
absentees seeking medical review. Baseline clinical characteristics were 
similar for both study arms (Table 5-3). 
Table 5-3. Baseline characteristics of study population (n=120) 




Age, mean (SD) years  10.1 (2.8) 9.4 (2.9) 
Sex: female, n (%) 18 (30.5) 23 (37.7) 
Hospital admission ever, n (%) 47 (79.7) 49 (80.3) 
Hospital admission in past 3 months, n (%) 14 (23.7) 14 (23.0) 
Health facility attendance in past 3 months, n (%) 18 (30.5) 21 (34.4) 
School absence in past 3 months, n (%) 40 (67.8) 39 (63.9) 
School absence in past 3 months, median days 
(IQR) 
3 (2-5) 3 (2-5) 
Reported using salbutamol inhaler 45 (76.3) 51 (83.6) 
Reported using steroid inhaler regularly 21 (35.6) 28 (45.9) 
Daily dose beclometasone 238 µg (n=21) 273 µg (n=28) 
GINA: Well controlled (score* 0) 12 (20.3) 7 (11.5) 
GINA: Partly controlled (score* 1-2) 20 (33.9) 21 (34.4) 
GINA: Uncontrolled (score* 3-4) 27 (45.8) 33 (54.1) 
cACT, mean (SD) 20.4 (2.9) 20.3 (2.3) 
cACT ≥20 (well controlled) 37 (62.7) 40 (65.6) 
cACT ≤19 (poor control) 22 (37.3) 21 (34.4) 
Pre-bronchodilator lung function   
Mean (SD) % predicted FEV1 † 88.1 (18.4) - 
Mean (SD) % predicted FEV1/FVC ratio‡ 89.0 (10.0) - 
FEV1/FVC ratio below LLN, no. children (%)‡ 17/43 (39.5) - 
Fractional concentration of exhaled nitric oxide (FeNO) 
Median (IQR) FeNO, ppb# 44.5 (27.5-
66.5) 
- 
High (>35 ppb), no. children (%) 34 (59.6) - 
Intermediate (20-35 ppb), no. children (%) 15 (26.3) - 
Low (<20 ppb), no. children (%) 8 (14.0) - 
* Score 1 for each positive response to: In the past 4-weeks, has the patient had: a) 
Daytime asthma symptoms more than twice/week? b) Any night waking due to 
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asthma? c) Reliever needed for symptoms more than twice/week? d) Any activity 
limitation due to asthma? 
 †Technically acceptable FEV1 data available for 48 participants at baseline 
‡Technically acceptable FEV1/FVC data available for 43 participants at baseline 
#FeNO available for 57 participants at baseline 
Most children (106/120, 88.3%) reported wheezing in the past year; overall 
68.3% (82/120) experienced ISAAC-defined severe asthma symptoms, with at 
least one of; ≥4 attacks (64/106, 60.4%), wheeze-related sleep disturbance 
more than once per week (34/106, 32.1%), or wheeze affecting speech 
(38/106, 35.8%), in the past year. By GINA criteria, asthma symptoms were 
well controlled in 19 (15.8%), partly controlled in one third (41/120) and 
uncontrolled in half (60/120) of participants. The baseline mean (SD) cACT 
score was 20.3 (2.6), with 43 (35.8%) participants stratified as having poor 
control (cACT≤19) and 77 (64.2%) with good control (cACT≥20). Responses to 
individual cACT questions are shown in Table 5-4. 
At enrolment 96/120 (80.0%) participants reported using a salbutamol 
inhaler, with 67/96 (69.8%) using a spacer; 41/120 (34.1%) participants 
reported using a beclometasone inhaler (+ spacer) regularly, with a mean 
daily dose of 258µg and self-reported adherence of 89.6%. 
None of the participants had been previously treated for tuberculosis. Of 105 
participants who had been tested for HIV, all were HIV-negative. Half of 
participants (62/120, 51.7%) reported a family history of asthma, including 
47/120 (39.2%) with asthma in a first-degree relative. The majority of 
participants experienced wheezing in early childhood; 52/120 (43.3%) 
reported wheeze onset before age 3 years, 41/120 (34.2%) aged 3-6 years, 
and 27/120 (22.5%) after age 6 years. Atopic symptoms were common; with 
self-reported rhinitis, hay fever, and eczema in 72/120 (60.0%), 37/120 




Table 5-4. Baseline responses to cACT questionnaire from participants and carers. 





  How is your asthma 
today? 
0 (very bad) 1 (0.8) 
1 (bad) 8 (6.7) 
2 (good) 58 (48.3) 
3 (very good) 53 (44.2) 
How much of a problem 
is your asthma when 
you run, exercise or play 
sports? 
0 (it’s a big problem)  7 (5.8) 
1 (it’s a problem and I don’t like it) 24 (20.0) 
2 (it’s a little problem but it’s OK) 71 (59.2) 
3 (it’s not a problem) 18 (15.0) 
Do you cough because 
of your asthma? 
0 (yes, all the time) 3 (2.5) 
1 (yes, most of the time) 15 (12.5) 
2 (yes, some of the time) 102 (85.0) 
3 (no, none of the time) 0 
Do you wake up during 
the night because of 
your asthma? 
0 (yes, all the time) 0 
1 (yes, most of the time) 10 (8.3) 
2 (yes, some of the time) 90 (75.0) 




r  During the last 4-weeks, 
how many days did your 
child have any daytime 
asthma symptoms? 
0 (everyday) 0 
1 (19-24 days) 0 
2 (11-18 days) 4 (3.3) 
3 (4-10 days) 28 (23.3) 
4 (1-3 days) 69 (57.5) 
5 (not at all) 19 (15.8) 
During the last 4-weeks, 
how many days did your 
child wheeze during the 
day because of asthma? 
0 (everyday) 0 
1 (19-24 days) 0 
2 (11-18 days) 1 (0.8) 
3 (4-10 days) 18 (15.0) 
4 (1-3 days) 42 (35.0) 
5 (not at all) 59 (49.2) 
During the last 4-weeks 
how many days did your 
child wake up during 
the night because of 
asthma? 
0 (everyday)  0 
1 (19-24 days) 0 
2 (11-18 days) 4 (3.3) 
3 (4-10 days) 16 (13.3) 
4 (1-3 days) 53 (44.2) 
5 (not at all) 47 (39.2) 
 
5.3.2 Clinical outcomes at 3-month follow-up 
At 3-months, children in the intervention arm had a mean (SD) cACT of 22.9 
(2.3), compared to 20.8 (3.0) in standard care (p<0.001). Children receiving 
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the intervention had a greater mean (SD) change in cACT score from baseline; 
2.7 (2.8), compared to 0.6 (2.8) for standard care participants, a difference of 
2.1 points (95% CI: 1.1-3.1) (p<0.001) – see Table 5-5. Participants receiving 
enhanced care reported improvement in symptoms and GINA score, with little 
change for those receiving standard care (Figure 5-4 and Figure 5-5). 
Baseline 3-month follow-up 
  
Figure 5-4. (left) Comparison of GINA categories at baseline (n=120) 
Figure 5-5. (right) Comparison of GINA categories at 3-month follow-up (n=114) 
Standard care is shown in dark grey and enhanced care in light grey. 
 
Hospital admission and health facility attendance fell in both arms, compared 
to baseline. Compared with standard care, the enhanced care arm reported 
lower rates of admission (3.6% vs 10.2%, p=0.32), overall emergency health 
facility attendance (7.3% vs 25.4%, p=0.02), and school absence (20.0% vs 
62.7%, p<0.001) (Table 5-5). Oral prednisolone was given during 8/30 (26.7%) 
exacerbations requiring emergency health care use. 
FeNO levels and spirometry results were similar for both study arms at 3-
months (Table 5-5). There were no significant differences in age, sex, study 
arm and baseline cACT between those with and without spirometry results 
(Table 5-6).   
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Primary outcome: cACT score    
cACT score, mean (SD) 22.9 (2.3) 20.8 (3.0) P<0.001 
Change in cACT score from baseline, mean 
(SD) 
2.7 (2.8) 0.6 (2.8) P<0.001 
Secondary outcomes    
Health care use    
Exacerbations with hospitalization, no. 
children (%) 
2 (3.6) 6 (10.2) P=0.32 
Exacerbations with health facility 







Exacerbations with any emergency health 
care use, no. children (%) 
4 (7.3) 15 (25.4) P=0.019 
School absence    
School absence, no. children (%) 11 (20.0) 37 (62.7) P<0.001 
Pre-bronchodilator lung function    
Mean (SD) % predicted FEV1 † 86.9 (18.0) 92.0 (17.5) P=0.15 
Mean (SD) % predicted FEV1/FVC ratio‡ 90.9 (12.5) 92.8 (10.3) P=0.42 





Fractional concentration of exhaled nitric oxide (FeNO) 





High (>35 ppb), no. children (%) 33 (58.9) 31 (55.4) P=0.85 
Intermediate (20-35 ppb), no. children (%) 11 (19.6) 15 (26.8) P=0.50 
Low (<20 ppb), no. children (%) 12 (21.4) 10 (17.9) P=0.81 
†Technically acceptable FEV1 data available for 99 participants  
‡Technically acceptable FEV1/FVC data available for 92 participants 





Table 5-6. Comparison of those with and without spirometry data at 3-month follow-
up 






Age, mean (SD) years 9.7 (2.7) 9.2 (3.3) p=0.56† 
Sex: female, n (%) 35 (35.4) 3 (20.0) p=0.38‡ 
Baseline ACT, mean (SD) 20.3 (2.6) 19.7 (2.5) p=0.43† 
Study arm: intervention, 
n (%) 
50 (50.5) 6 (40.0) p=0.63‡ 
†Student’s t-test for continuous data, ‡Pearson’s χ2 for categorical data 
 
5.3.3 Asthma treatment at 3-month follow-up 
At 3-months, 98.1% (54/55) children in enhanced care were using a 
salbutamol inhaler with a spacer compared to 83.1% (49/59) in standard care. 
Daily ICS use was more common in enhanced care (47/55, 85.5% participants) 
compared to standard care (41/59, 69.5% participants), with enhanced care 
participants prescribed a higher mean (SD) daily beclometasone dose: 331µg 
(121) vs 266 µg (99). Self-reported adherence was 85.4% and 85.5% among 
enhanced and standard care participants, respectively. Four carers (3 from 
enhanced care, 1 from standard care) reported non-availability of inhalers at 
QECH during the trial period. 
5.3.4 Clinical predictors of response to “enhanced care” intervention 
Overall, 115 participants were assessed before receiving the enhanced care 
package, with post-intervention outcome data collected for 104 participants. 
Mean (SD) percentage of predicted FEV1 was 90.1 (17.9) and mean percentage 
predicted FEV1/FVC ratio 91.0 (10.3), with one-third (30/88, 34.1%) of 
participants having a FEV1/FVC ratio below the lower limit of normal. Thirteen 
participants had FEV1/FVC<0.7, of which five had cACT ≥23. The distribution of 





Figure 5-6. Distribution of percentage predicted FEV1 measurements (n=97) 
 
Figure 5-7. Distribution of percentage predicted FEV1/FVC ratio (n=88) 
 
Of participants with baseline FEV1>75%, eligible for exercise challenge, half 
(37/74, 50.0%) had an FEV1 fall of >12% predicted. Post-bronchodilation, 
45/115 (39.1%) participants showed an improvement in FEV1 >12% predicted 
and overall 54.6% (53/97) participants demonstrated variability in FEV1 of 
>12% during the visit. FeNO levels were high, with a median (IQR) of 41.5 
(25.0-63.0) ppb and over half of participants (65/113, 57.5%) with a FeNO >35 




Figure 5-8. Distribution of FeNO levels measured pre-intervention (n=113) 
Dashed line shows threshold for high FeNO (>35ppb)  
Median carboxyhaemoglobin was 3.5% (IQR 1.5-6.5) and this was not 
associated with cACT score or FEV1/FVC on bivariate analysis. 
The correlation between clinical measurements was weak, with correlation 
coefficients of 0.24, -0.15 and -0.26 for cACT and FEV1/FVC ratio, cACT and 
FeNO level, and FEV1/FVC ratio and FeNO level, respectively – see Figures 5-9, 
5-10 and 5-11. 
   
Pearson coefficient 0.24,  
p=0.026 
Spearman coefficient -0.15, 
p=0.13 
Spearman coefficient -0.26, 
p=0.01 
 
Figure 5-9. (left) Correlation between percentage predicted FEV1/FVC and cACT score 
(n=88) 
Figure 5-10. (centre) Correlation between FeNO level and cACT score (n=113) 





On bivariate analysis, age of wheeze onset, pre-intervention cACT score, FeNO 
level and FEV1/FVC ratio, showed potential association (p<0.2) with a greater 
change in cACT over the 3-month intervention period and were explored in a 
multivariable linear regression model (Table 5-7). On multivariable analysis, 
lower pre-intervention cACT score and FEV1/FVC ratio were both significantly 
associated with a greater response to the intervention (Table 5-7), other 
variables were dropped from the model. 
Table 5-7. Predictors of response to intervention: change in cACT score. 
 Bivariate linear regression Multivariable linear regression 
Covariate Coefficient 
estimate (95% CI) 
p-value Coefficient 
estimate (95% CI) 
p-value 
Age 0.09  
(-0.13 - 0.32) 
0.42 -  
Sex (male) -0.47 
(-1.80 – 0.85) 
0.49 -  
Age of wheeze onset 
3-6 years 
1.04 
(-0.39 – 2.47)  
0.16 -  
Age of wheeze onset 
>6 years 
1.49  
(-0.11 – 3.09) 
0.07 -  
Positive family 
history of asthma 
-0.18 
(-1.47 – 1.11) 
0.78 -  
ICS naive -0.39 
(-0.39 to 0.67) 
0.56 -  
Pre-intervention measurements 
cACT score -0.70  
(-0.89 - -0.53)  
<0.001 -0.56 
(-0.74 - -0.38) 
<0.001 
FeNO level, ppb 0.02 
(-0.01 – 0.04) 
0.16 -  
FEV1/FVC ratio % 
predicted 
-0.08 
(-0.16 - -0.01) 
0.03 -0.07 
(-0.13 - -0.02) 
0.008 
 
In the 3-months following the education intervention, 9/104 (8.7%) 
participants attended a health facility with an asthma attack on a total of 15 
occasions, including four hospital admissions. The clinical details of these nine 
participants are included in Table 5-8. There were no clinical features 
significantly associated with emergency health care use on bivariate logistic 
regression, although the study was not powered to this outcome.  
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Table 5-8. Clinical information for participants with emergency health care attendance 

















































































P136 1 2 13 M 21 34 84 400 
G457 1 0 8 M 22 54 92 0 
G453 0 1 9 M 21 24 - 400 
P108 0 2 6 F 17 34 88 200 
G416 1 1 10 M 23 72 100 200 
P104 1 1 7 F 14 15 92 200 
G415 0 1 9 M 22 58 90 0 
P130 0 1 6 F 15 23 97 400 
G460 0 2 7 M 22 28 - 200 
 
5.3.5 Adverse events 
During the study period, six participants (3 from each arm) reported hospital 
admission for exacerbation of asthma. There were no other adverse events. 
 
5.4 Discussion 
To our knowledge, this is the first randomized controlled trial of a task-shifting 
intervention using non-medically trained asthma educators on asthma 
outcomes in sSA. The key finding was a clinically and statistically significant 
improvement in asthma control in the intervention vs standard care group  
(increase in mean (SD) cACT score of 2.7 (2.8) vs 0.6 (2.8) points, p<0.001)). 
We found a high burden of symptoms among asthmatic children attending an 
outpatient clinic at baseline; in the preceding 3-months, one-quarter of 
participants had been admitted to hospital, a further one-third had attended a 
health facility, without overnight admission, and two-thirds had missed school 
due to acute asthma symptoms. The overall mean (SD) cACT was 20.3 (2.6), 
with 85% of participants reporting sub optimal asthma control, by GINA 
criteria. Despite a high burden of symptoms and previous engagement with 
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the health care system, one fifth had no salbutamol inhaler, and less than half 
had received ICS treatment, with relatively low mean daily doses. 
In addition to improved asthma control, fewer children in the enhanced care 
group experienced asthma exacerbations requiring emergency health facility 
attendance (7.3% vs 23.7%, p=0.03), and school absence (20.0 vs 61.0%, 
p<0.001). There were also fewer hospital admissions among enhanced care 
patients, although the admission rates in both groups were too small to 
detect a significant reduction. 
Participants demonstrated raised FeNO levels, confirming that ICS treatment 
is highly appropriate in this population. Self-reported ICS use was greater in 
the enhanced care group, with more children taking daily beclometasone, and 
participants prescribed a significantly higher daily dose.  Despite apparently 
greater ICS use, there was no difference in median FeNO levels at 3-months, 
suggesting unchanged levels of airway inflammation. Self-reported adherence 
rates were high (>85%), however adherence rates are frequently below 50% 
when steroid inhaler use is assessed objectively in HIC: low ICS adherence 
would explain the unaltered levels of inflammation in our participants.375 
Improved outcomes maybe due to increased confidence to intervene early in 
an attack, with self-management of symptoms at home, using inhaled 
Salbutamol. Participants were generally able to collect inhalers, free of 
charge, from the hospital pharmacy, however inhaled treatment has very 
limited availability outside of tertiary health facilities in Malawi. 
Lower pre-intervention cACT and decreased FEV1/FVC ratio were associated 
with a greater response to the intervention which may represent the greater 
potential for improvement from baseline in children with more severe initial 
symptoms. However, our findings suggest that spirometry was a useful 
additional assessment tool. We identified several children with severe airway 
obstruction but normal cACT scores; symptom perception may be impaired in 
children with chronic airflow obstruction and the poor correlation between 
self-reported symptoms and spirometry is well-recognised.267,268 Spirometry is 
unlikely to be available outside of the research setting in most LMIC, but peak 
flow meters can provide a useful alternative and may be a more appropriate 
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component of future interventions.44 We did not include peak expiratory flow 
rate (PEFR) monitoring in the individual management plans as peak flow 
meters are not currently available in QECH: further research to explore the 
feasibility and effectiveness of this approach in LMICs is needed. 
We found relatively high levels of reported asthma control (64.2%), defined by 
cACT≥19, compared to other studies in sSA, although most published data 
relate to adult patients. Among Ugandan patients, aged 5-93 years, attending 
tertiary care, only one third had controlled asthma (ACT>19), and 
exacerbation rates were high (59.6% patients had one exacerbation and 
33.4% had 3 or more, during one year of follow-up).371 In a teaching hospital 
respiratory clinic in Nigeria, 43.4% of adult patients had good control 
(ACT≥20).257 Among paediatric patients attending a tertiary clinic in 
Johannesburg, South Africa, 55.7% had controlled asthma (ACT/cACT >19).263 
However, despite the baseline cACT for our participants suggesting 
reasonable control of asthma symptoms, the burden of exacerbations 
requiring health facility attendance and school absence was high. 
In the absence of a locally validated assessment tool, the choice of outcome 
measurement for this study was challenging. The cACT is validated for use 
with children aged 4-11 years; with four questions for the child and three for 
their accompanying adult.259 It has been used, although not validated, in 
South Africa: mean (SD) cACT score was 19.9 (5.5) for asthmatic children 
attending a tertiary hospital clinic in Johannesburg.263 We chose to use the 
cACT for all participants, rather than separate tools for children 4-11 years 
and ≥12 years, for logistical reasons, and to collect complementary 
information from both the child and their caregiver. However, there are 
challenges to obtaining responses which truly reflect the child’s clinical 
condition; younger children may have difficulty recognising and articulating 
their symptoms and have a poor perception of symptoms over time, and 
children of all ages may be reluctant to answer, often deferring to the 
opinions of their elders in a culture which promotes hierarchical respect. 
Changing caregivers, meant that adults were sometimes unsure of the child’s 
symptoms over the preceding month, particularly at night or during the school 
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day. To date, a clinically meaningful difference in cACT has not been 
established; in adults the minimally important difference in ACT (a 5-item 
questionnaire, with a response range of 5-25 points) is 3 points.264 
Given the lack of other studies using non-medical staff for task-shifting, we 
deliberately set a short follow-up period for this pilot study, to minimise loss 
to follow up and maximise the chances of identifying a benefit or harm from 
this novel approach. Overall completeness of data collection was good, 
including acceptable and repeatable spirometry data for over 75% of 
participants. We were unable to collect RCT outcome data for six (5%) 
participants, and post-intervention outcome data for a further 10 participants 
as study activities were disrupted by the global COVID19 pandemic in April-
May 2020. 
We relied upon self-report of symptoms, exacerbations and inhaler use: recall 
bias is a potential limitation of our study. We tried to quantify medication use 
by weighing inhalers but abandoned this approach as very few participants 
brought their inhaler cannisters, despite timely reminders. Our study 
recruited patients attending outpatient follow up at a tertiary hospital – we 
would expect a high rate of previous hospital admissions and attendances, 
since many patients are referred to this clinic from paediatric wards and the 
emergency department, and our findings may not represent asthmatic 
children more broadly in Malawi. Despite these limitations, our findings 
suggest that optimisation of inhaled treatment, supported by asthma 
education, delivered by non-clinical staff, can have a beneficial effect on 
asthma outcomes. 
Malawi suffers from a shortage of trained medical staff with 2 physicians and 
28 nurses per 100,000 population, well below the WHO “critical shortage” 
threshold of 2.5 health professionals (including doctors, nurses and midwives) 
per 1000 population.8,9 This huge deficit in workforce requires an alternative 
approach to health care delivery: task shifting has been successfully employed 
in the community case management of childhood illnesses, and to improve 
access to HIV screening and treatment in Malawi.341,376 Considering asthma 
management specifically, a study from rural Cameroon, reported decreased 
128 
 
asthma attacks over time in a group of mostly adult patients attending a 
nurse-led asthma clinic, although over 40% of patients were lost to follow 
up.348 Task-shifting asthma education to non-medical cadres has been 
explored in high-income settings. Comparable outcomes were reported for 
asthma education delivered by lay people and nurses to adult patients, 
however among adolescent asthmatics the evidence for lay-led peer support 
interventions is weak.320,322 The use of lay educators has not previously been 
evaluated in LMIC: we propose that the potential impact may be greater than 
in HIC, due to lower baseline education and health literacy levels among 
poorer populations. 
 
These promising pilot data require further exploration of task-shifting in low-
income settings, with asthma education delivered to children and adults 
attending a range of health care settings, and assessment of outcomes 
extending beyond 3-months. The reliable and affordable supply of inhaled 
medication, across all levels of health facilities, is also a key component to 
reducing the burden of asthma symptoms on patients and their families and is 
a major issue which must be addressed in many low-income countries.19 
Furthermore, there is a pressing need to assess the clinical and cost-
effectiveness of current therapeutic approaches, using combination 
corticosteroid and beta-agonist inhalers, as-needed or regularly depending on 
symptoms, which are becoming widely used in high-income countries.377 
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5.5 List of appendices for Chapter 5 
• Ethical approval from College of Medicine Research Ethics Committee 
(Malawi) 
• Ethical approval from Liverpool School of Tropical Medicine (UK) 
• Registration with Pan African Clinical Trials Registry 
• Participant information sheet for children – English 
• Participant information sheet for parents – English 
• Assent form - English 
• Consent form – English 
• cACT – English 
• Baseline Questionnaire – English/Chichewa 
• Review Questionnaire – English/Chichewa 
• Chichewa versions of study documents and SOPs available on request 
o SOP – enrolment, consent and randomisation 
o SOP – study visits 
o SOP – safety monitoring 
o SOP – FeNO measurement with NOBreath 
o SOP – COHb measurement with Rad57 
o SOP – spirometry 
o SOP – exercise challenge 
130 
 
6 Task-shifting to improve asthma education at a tertiary 
hospital in Malawi: a qualitative analysis 
 
6.1 Introduction 
This chapter describes a qualitative sub-study of the randomised-controlled 
trial (RCT) reported in Chapter 5, designed to provide a complementary 
evaluation of the task-shifting asthma education component specifically. 
Asthma education is central to Global Initiative for Asthma (GINA) 
recommendations, which emphasise the importance of a strong partnership 
between patients and health care providers.44 Achieving good symptom 
control is a primary goal in asthma management and adherence to treatment 
plays a key role.44 Children are more likely to take their medication regularly if 
their family have a positive view of asthma, understand the need for regular 
inhalers and trust the medication.375 During childhood, parents or carers are 
primarily responsible for medication administration, identification and 
avoidance of triggers and obtaining prescriptions.378 However, older children 
can take an increasingly active role is self-management of their asthma.379 
Successful asthma care then requires that both children and parents receive 
adequate information on asthma, triggers, medication and self-management 
of symptoms. 
Asthma care in LMIC is delivered in overburdened health care settings, with 
conflicting clinical priorities, human resource constraints and inadequate 
infrastructure. The general paediatric clinic at Queen Elizabeth Central 
Hospital (QECH), provided the “standard care” received by our RCT 
participants and was the sole recruitment site for the study. Children with a 
wide range of clinical conditions, in addition to asthma, are reviewed in this 
clinic, including; epilepsy, recurrent anaemia, jaundice, neurodevelopmental, 
renal, rheumatological, behavioural and psychological conditions. Within this 
busy and unstructured clinical environment, clinical staff have very limited 
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time to spend on each patient consultation, or to dedicate to asthma 
education. 
Considering this, we designed an intervention, described in section 5.2.5, to 
improve asthma care at QECH, with individualised asthma education delivered 
by non-clinical staff. Task-shifting has been suggested as an effective and 
affordable strategy to improve the management of non-communicable 
diseases in LMIC, however there are limited data relating to asthma care 
specifically, and the use of non-clinical personnel has not been explored.346,348 
This qualitative sub-study aimed to explore the experiences of the children, 
carers and study staff involved in the asthma education sessions, in order to: 
1) assess the acceptability of using non-clinical staff to deliver asthma 
education; 2) understand facilitators and barriers to asthma education; 3) 
assess the perceived value of the education sessions to children and their 
carers. 
 
6.2  Methods 
6.2.1 Study site and context 
Details of the study site, participants and RCT intervention have been 
reported in Chapter 5, section 5.2, including specific information regarding the 
asthma education intervention; pre-study training programme for the lay 
educators (Table 5-1), asthma education session content and checklist (Table 
5-2), and Asthma Action Plan (Figure 5-1). 
In total, 120 participants were recruited to the RCT between September 2018 
and December 2019; 113 child-adult pairs participated in the asthma 
education session, either as part of the RCT intervention group or, for those in 
the RCT standard care group, in the 3-months following RCT completion. The 
qualitative assessment of the asthma education intervention was conducted 
between August 2019 and March 2020.  
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Children were most frequently accompanied to the education session by their 
mother (85/113, 75.2%), followed by their father (10/113, 8.8%), with the 
remaining adults a mix of other family members or guardians (Table 6-1).  
Table 6-1. Details of adults participating in the asthma education session 
 N (%) 
Relationship to patient  
Mother 85 (75.2) 
Father 10 (8.8) 
Grandmother 8 (7.1) 
Grandfather 1 (0.9) 
Other female relative / guardian 3 (2.7) 
Other male relative / guardian 6 (5.3) 
Total female carers 96 (85.0) 
Total male carers 17 (15.0) 
Level of education attended  
None 3 (2.7) 
Primary 37 (32.7) 
Secondary 52 (46.0) 
College 21 (18.6) 
 
For one-third of accompanying adults, the highest level of education attended 
was primary school (37/113, 32.7%), with 52/113 (46.0%) attending secondary 
school and 21/113 (18.6%) attending college. 
6.2.2 Study design 
The sub-study used qualitative research methods including focus group 
discussions (FGDs) with study participants and their carers and key informant 
interviews with study staff (Table 6-2).380 These aimed to gain deeper insight 
into the facilitators and barriers to the educational aspect of the intervention. 
FGDs and interviews were conducted in Chichewa, facilitated by a fluent 
Chichewa-speaker who had no previous involvement in the study intervention 
(LN); recordings were transcribed verbatim and translated into English for 




Table 6-2. Details of study participants and qualitative data collection methods 





Focus Group Discussions 
Mothers and other 
female carers 
21 (3 FGDs) Exploring the children’s and carers’ 
experience of the asthma education including 
facilitators and barriers to the intervention, 
their perceptions of the lay educators as non-
clinical staff delivering asthma education, 
their perceived value of the asthma 
education, and recommendations for future 
interventions 
Fathers and other 
male carers 
7 (1 FGD) 




Key informant interviews 
Lay educators 4, 
individual 
interviews 
Lay educators’ experience of delivering 
asthma education, their training and 
mechanisms for support, perceived benefits 
to the participants, facilitators and barriers to 
delivery, and recommendations 
Research nurse 1, 
individual 
interview 
Exploring her experience in supervising the lay 
educators, facilitators and barriers to the 






Participants were approached following completion of the intervention: 
children and their carers were purposively sampled to ensure that key 
participant characteristics, including age, sex, and asthma severity, and a 
range of views were represented. Children over the age of 10 years were 
invited to attend: we were concerned that younger children would be too 
nervous or inhibited to participate freely. Only parents or carers who 
attended the asthma education sessions were included. Male and female 
carers and children attended separate FGDs to encourage free participation. 
Individual interviews were conducted with each of the “lay educators” and 
with the research nurse who had supervised the sessions. Interviews took 
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place in a private location, with full confidentiality assured to encourage 
honest and open participation. 
6.2.3 Data analysis  
Data analysis was conducted iteratively alongside data collection, to allow 
exploration of emerging issues in later interviews and FGDs. A thematic 
approach was adopted, with transcripts reviewed by three independent 
researchers (SR, LN and FL). A coding framework was developed (SR, LN and 
FL) which was used to manually code all the transcripts through identification 
of informative texts and quotations, with senior oversight by a post-doctoral 
social scientist (FL).381 The codes were grouped into key themes derived from 
study objectives (deductively) and emerging from the transcripts 
(inductively).382 
6.2.4 Ethical approval 
Ethical approval was obtained in Malawi and the UK, as per section 5.2.10. 
Written informed consent was obtained from the carers and the study staff, 
with additional assent from the children. 
 
6.3 Results 
Four key themes emerged from the FGDs and in-depth interviews, discussed 
in the following sub-sections; 1. challenges with asthma care in Blantyre; 2. 
acceptability of using non-clinical staff as educators; 3. perceived value of 
asthma education; 4. facilitators and barriers to asthma education, including 
recommendations. We have synthesized the sub-themes, to illustrate the 
dimensions of an ideal task shifting asthma education intervention in Figure 
6-1, at the end of the results section. 
6.3.1 Challenges with asthma care in Blantyre  
6.3.1.1 Clinical environment 
Participants reported several previous challenges in accessing asthma care. 
Both parents and children commented that health care workers did not have 
enough time to explain the various aspects of asthma management, both 
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during admissions and outpatient attendances, largely due to the busy clinical 
environment. Parents felt unable to ask all the questions they had about their 
child’s medication and asthma more generally. 
“…the explanation there is really brief, and you will be lucky if you 
find a person that is able to answer any question that you have 
because they are very busy.” Mother of 12-year-old asthmatic 
child, FGD. 
In addition, some parents and children also expressed their concerns about 
hostile attitudes they had encountered from some medical staff previously, 
which affected their willingness to ask for clarification when needed. Children 
also reported they were given conflicting information from different doctors, 
which was confusing. 
“Some doctors get really angry and annoyed when you keep 
asking questions.” Mother of 11-year-old asthmatic child, FGD. 
“We kept on meeting different doctors at the clinic, that was 
really disturbing me because you end up being told different 
things by different people.” 13-year-old male asthmatic, FGD. 
6.3.1.2 Access to information  
Another challenge reported by both parents and children was the lack of 
asthma information provided by health care staff. Some parents expressed 
their lack of knowledge of what the disease (asthma) is and how it affects the 
human body. Specific areas of concern were what to do during an asthma 
attack and how to administer inhaled medication. Children said they were not 
aware of the triggers of their asthma or the importance of using inhaled 
treatments. 
“When I go to the hospital, I don’t even know what exactly 
asthma is. But then I can’t start asking the doctor because he is 
already busy with so many kids to be helped so I can’t sit down 
and start asking him “Doctor please tell us what exactly asthma is 
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and what should I do to help my child?”” Mother of 6-year-old 
asthmatic child, FGD.  
 “In fact, I didn’t even know that asthma causes the airways to 
close but when we came here, they started teaching us from 
there” Father of 7-year-old child, FGD.  
6.3.1.3 Access to medication  
Access to inhaled medication was also expressed as a challenge, especially by 
parents, with inhaled medication largely unavailable at primary health 
centres. Parents described extremely stressful situations when they had no 
medication to use at home during a severe attack. 
“She was attacked at around 10 in the night, we didn’t have an 
inhaler. So, we tried making phone calls to try and find an inhaler 
from other people, but we didn’t find it. And then we tried looking 
for transport, we still didn’t find it. We were only able to get to the 
hospital at 4 in the morning.” Father of 14-year-old asthmatic 
child, FGD. 
6.3.2 Acceptability of using non-clinicians as educators  
6.3.2.1 Perspectives of patients and families  
The parents did not express any concerns that the education sessions were 
delivered by non-medical personnel. Some of the parents said they assumed 
the educators had some medical training because of their professional 
manner. Many parents praised the educators’ overall competence and 
asthma-related expertise. The children said the lay educators were friendly 
and caring and that they felt free to ask questions without fear of being 
shouted at. Parents also said the openness and friendliness of the educators 
made the children look forward to coming back for the next study 
appointment. 
“The kids were very happy and comfortable around them and 
were not afraid of them.…. They were not scaring them but made 
them feel like they have found a friend.” Mother of 9-year-old 
asthmatic child, FGD. 
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6.3.2.2 Perspectives of the study team  
The lay educators said they were initially nervous to conduct the asthma 
education sessions with patients and their families. They reported that their 
knowledge on asthma was very limited before they participated in the 
training, after which they understood more about the disease and how to 
deliver the sessions. The educators also commented that they gained 
confidence to deliver the education sessions over time, with ongoing 
experience. 
6.3.3 Perceived value of asthma education  
Participants described various aspects of their lives before the asthma 
education intervention and the subsequent impact of the education they had 
received (Table 6-3). 
Children who previously were frequently sick and often missed school due to 
their asthma described a great improvement since implementing what they 
had learnt during the asthma education sessions. The improvement in clinical 
condition had a positive impact on daily family life, with families reporting 
reduced school absence and increased productivity at work. 
“When it’s time for me to go to the village to farm, seeing that she 
won't be able to stay without being monitored, I was withdrawing 
her from her school here in town and I would go with her to the 
village. But all that stopped now - I am able to leave her.” Mother 




Table 6-3. Participant’s perceptions of the impact of asthma education on knowledge 
levels, symptom control and aspects of daily life.  
 
Parents were previously stressed about how to manage their child’s asthma, 
particularly during an attack, and how to use their medication but reported 
increased confidence and a feeling of control, as a result of their increased 
knowledge levels. 
Before asthma education intervention After asthma education intervention 
Participants’ reports of asthma knowledge 
No clear understanding of asthma, 
common triggers and inhaled 
medications. 
Unable to identify asthma symptoms. 
Improved knowledge of asthma, 
common triggers and inhaled 
medications. 
Greater understanding of what to do in 
an emergency. 
Confidence to identify symptoms of 
asthma and manage appropriately. 
Participants’ reports of asthma symptoms 
Difficulties breathing at night, often 
interfering with sleep. 
Frequent cough and wheeze. 
Frequent visits to health facilities. 
Frequent school absence. 
Families able to manage asthma 
symptoms more effectively. 
Fewer attacks, school absence and 
hospital visits. 
Interaction between asthma and family life 
Disruption to sleep for whole family. 
Stressful situations during 
deteriorating symptoms. 
Staying home to care for child. 
Removing child from school to allow 
closer monitoring. 
Greater control of asthma. 
Knowledge of asthma triggers and self-
management has reduced child’s 
symptoms and enabled parents to be 
more productive. 
Improved asthma knowledge among 
wider family, including other asthmatic 
individuals. 
Interaction between asthma and school life 
Stigmatised by peers. 
Lack of understanding among school 
community. 
Belief that asthma is contagious. 
Children gaining support from peers 
through greater openness and 
understanding. 
Interaction between asthma and the community 
Negative attitudes towards inhaled 
treatment. 
Belief in healing through traditional 
medicines and prayers. 
Parents keen to act as asthma 
advocates and share their new 
knowledge with the wider community. 
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“Most times…. when the child starts to get sick, we would not do 
anything. We would wait till maybe two days pass and then start 
off to the hospital. But when we were taught, it really helped…. 
When he gets sick again, before it reaches the point of taking him 
to the hospital, because of what we learnt in the research we are 
able to help him control the asthma before it gets worse.” Mother 
of 7-year old asthmatic child, FGD  
Both parents and children reported misconceptions and negative opinions 
relating to asthma and inhaled medication which they had experienced from 
family members, school peers and the wider community. 
“When I am at school and I have asthma symptoms, my friends 
tell me that I am bewitched and when I am trying to play with 
them, they tell me that I will spread my asthma to them.” 11-year-
old asthmatic male, FGD. 
“Some of my friends scared me saying "That is a bad drug, if your 
child starts using inhalers now, his asthma will never improve and 
will be dependent on inhalers all his life." I was really scared so 
much that when I got home with him, I didn’t use the inhalers, I 
just kept them.” Mother of 6-year-old asthmatic child, FGD 
6.3.4 Facilitators and barriers to asthma education  
6.3.4.1 Intervention design: training, resources and support  
The lay educators and the study nurse mentioned specific resources which 
were helpful in ensuring the education sessions were delivered effectively. 
The lay educators explained that the pre-study training they received was one 
of the main activities that helped them gain knowledge and confidence to 
deliver the sessions effectively. 
“I am not a medical person but because we were specially trained, 
and we paid attention to the things we were being taught during 
the training, we were able to teach these people the same things.” 
Asthma educator, interview 
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The educators also reported that that education session checklist ensured 
that everyone was teaching information uniformly, was helpful in reminding 
the educators of their own training and helped staff to focus while teaching 
the participants. 
“We also need to have a paper which has the guidelines ….which 
helps us follow through as we are talking to them to see what has 
been discussed and what hasn’t been mentioned yet and we tick 
what we have already said… it helps us not to forget because 
without the guidelines, it’s easy to forget.” Lay educator, interview 
Some parents highlighted the importance of providing additional written 
information, to reinforce the asthma education they had received. Written 
information would allow participants to revisit the information at a later date 
and also help share the knowledge with the wider community. 
Both the educators and study nurse mentioned that the support given by 
supervisors and peers was also essential in ensuring the educators delivered 
the sessions effectively. The study nurse reported that she was available to 
the educators to help answer any questions and provide any additional 
support as needed. The educators also described the positive and motivating 
effect of words of appreciation from the study participants. 
“The other form of support was from the patients, if a person 
compliments and appreciates the work you have done for them…, 
you get motivated because you feel that you have done a good 
job, that encourages you in the next session… so when we are 
working we need to encourage each other.” Study nurse, 
interview. 
6.3.4.2 Individual and open approach to education sessions 
Both children and their carers said the lay educators were very approachable, 
patient and friendly which helped in understanding the asthma education 
sessions. The parents also said the educators ensured they felt comfortable to 
ask any questions that they had about their child’s condition or asthma more 
generally. The educators described the importance of building a good rapport 
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with their patients when meeting them for the first time as this ensured that 
everyone was open and free to learn and ask questions. 
“First of all, we build a rapport in order to create an environment 
for both participant and guardian to feel that they are free…. they 
shouldn’t be afraid of anything.” Lay educator, interview. 
Lay educators said the difference in levels of education of the parents was one 
of the main barriers to the delivery of asthma education. Although the session 
was delivered in Chichewa, which parents appreciated, some still found it 
challenging to follow the content. 
The educators explained that due to different baseline education levels 
among parents and children, they made sure that information was delivered 
according to an individual’s ability to understand and paused frequently to 
check comprehension and give clarification. Parents appreciated the physical 
demonstration of inhaler administration techniques, using a bottle spacer. 
 “…something else that that slows us down is the level of 
understanding of the parents. This is mostly because of the level of 
education that most of them have because you may explain to 
them clearly then ask them to explain what you just explained but 
you find that they are finding it hard to do that. So, we still take 
some time to explain again because we just have to spend that 
time to teach these parents so that they understand.” Lay 
educator, interview.  
6.3.4.3 Logistics: Location and schedule  
Both the parents and children recommended that asthma education sessions 
should be conducted in a private and well-sheltered location. 
Some of the children reported that the education sessions interrupted their 
school schedule, and that this was problematic – however, others commented 
that this disruption was acceptable, due to the beneficial nature of the 




Figure 6-1. Task shifting of asthma education to lay educators: dimensions of an ideal intervention  
 
Context: Standard Asthma Care 
 
Intervention Design 
• Participatory training for educators  
• Provision of guidelines/checklists 
• Supervision and clinical support 
• Effective referral system 
 
Education Approach 
• Building good rapport 
o Friendly, open and caring 
• Paced delivery of information 
• Opportunity for questions 
• Demonstration of practical skills 
  
 
Environment and Timing 
• Privacy and confidentiality 
• No conflict with school schedule 
• Brief and uninterrupted sessions 
• Appropriate supporting materials 
 
Intervention Outcomes  
• Improved knowledge of asthma 
• Capacity to self-manage asthma symptoms 
• Reduced school absence and hospital visits 
• Advocacy for improving asthma care 
❖ Clinics with few clinical staff and 
high patient numbers 
❖ Limited time during clinic 
consultations  
❖ Limited availability of medication  
❖ Lack of asthma knowledge among 
patients and their families  




To our knowledge this is the first evaluation of an asthma education task-
shifting intervention in sSA, in which asthma education is delivered by lay 
educators with no medical or nursing background. Patients and their parents 
expressed high levels of satisfaction and described the positive impact of 
asthma education on their knowledge levels, frequency of asthma symptoms 
and daily life. Families reported increased confidence to self-manage asthma 
attacks at home, resulting in less absence from school and work, and fewer 
emergency health facility attendances. The educators emphasized the 
importance of building a good rapport with the patient and their family, and 
pacing the delivery of information, considering the participants’ background 
educational level. Young people and their families appreciated the open and 
friendly approach of the educators, and the time and patience that were 
taken to ensure understanding and address all their questions. We found that 
asthma education can be delivered successfully by non-clinical personnel, 
given adequate training and ongoing support from clinical staff, and that this 
approach was popular with young people and their families.  However, 
educators and participants encountered challenges with limited space for the 
study activities, compromising privacy, and leaving the sessions open to 
interruptions and distractions. 
The rationale for task-shifting, in a country with a critical shortage of health 
care providers has been previously discussed in section 5.4. 
In Malawi, task shifting of HIV screening to non-medical cadres has been 
successfully deployed with lay counsellors delivering HIV counselling and 
testing with good programme outcomes.341 Health Surveillance Assistants 
(HSAs: non-clinician health workers, with 10-weeks of basic training) have also 
been employed to deliver community case management of childhood 
illnesses; in common with our findings and others, the importance of ongoing 
support and supervision were highlighted in an evaluation of this 
scheme.337,376 Also in common with our study, recognition by the community 
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and positive feedback were also mentioned as motivating factors for the 
HSAs.345 
In high-income settings, a small number of studies have evaluated peer- and 
lay-led complex asthma interventions for adolescents, suggesting a small 
improvement in asthma-related quality of life, although the effect on asthma 
control, exacerbations and adherence are unclear.320 Self-management 
education delivered to adults with asthma by trained lay people, resulted in 
comparable clinical outcomes to patients seen by primary care based practice 
nurses in the UK.322 Qualitative exploration of the experiences of these lay 
educators reinforced several of the points raised in our study; the need for 
comprehensive support and monitoring, particularly at the start of the 
programme, and the importance of training, with consideration of content, 
intensity, and interactive teaching methods.324 
In the USA, asthma education delivered by trained lay volunteers to families 
of inner-city children with asthma, during an acute hospital admission, was 
associated with improved asthma management behaviours.325 Improved 
asthma outcomes have been associated with greater health literacy and 
asthma knowledge among asthmatic children’s parents, consistent with our 
participants’ responses; however, research exploring health literacy in 
children is scarce.383,384 Our educators experienced particular challenges with 
carers who had a lower level of general education; one-third of accompanying 
adults had only attended school at primary level. However, compared to 
national levels, our participants were relatively well educated, reflecting the 
population of urban Blantyre. Overall in Malawi, among those aged 15-49 
years, 26% of women and 36% of men have at least some secondary 
education, compared to 46% among our carers, with only 3% women and 5% 
men attending tertiary education, compared to 19% among our carers.10 
Our qualitative sub-study sampled the experiences of a range of participants 
involved in the asthma education sessions, exploring the perspectives of those 
receiving and those providing education, and deliberately sought to include 
male and female carers, allowing triangulation of our findings. It is possible 
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that those agreeing to participate in this sub-study had a more positive view 
of the intervention; however, participants were purposively sampled and only 
three parents declined to participate, with the main reason given being time 
constraints. To ensure that participants felt comfortable to freely express 
their opinions of the study, the FGDs and interviews were facilitated by an 
independent researcher, with no previous connection to the RCT participants. 
In conclusion, asthma education delivered by lay educators was well received 
by children and their families, with reported positive benefits on asthma 
knowledge levels, symptoms, and daily life, and increased confidence relating 
to asthma self-management. Further research is needed; to evaluate the 
wider implementation of this approach, including both clinical and cost-
effectiveness, beyond a tertiary hospital setting, and to explore optimal ways 
to train, support and motivate lay educators in LMIC settings. 
 
6.5 List of appendices for Chapter 6 
• Ethical approvals and study documents (consent, assent, participant 




7 Summary and implications 
This thesis includes four studies, designed to address some of the knowledge 
gaps relating to NCD-L in Malawi. The broad aims were; 1. To explore the 
prevalence of non-communicable lung disease and air pollution associated 
determinants in children and adults in rural Malawi 2. Evaluate a novel task 
shifting approach to asthma management for children. 
This chapter summarises the rationale for the studies, the main findings and 
implications for policy and decision making, including recommendations for 
further research. 
Conducting research can be challenging in low-income settings, particularly in 
rural areas where infrastructure is lacking, communication is difficult and 
health literacy levels are low. In rural Malawi, the setting for the Chikhwawa 
studies (Chapters 3 and 4), most adults have only spent approximately 3-years 
at school (median length of schooling; 2.7 years for women, 3.4 years for 
men).10 Less than half of all rural households own a mobile phone, and only 
3.9% of households have electricity to charge it.10   
Research activities can arouse considerable suspicion among local 
communities, especially in rural areas. Field work was disrupted during late 
2017 due to unrest among many communities in southern Malawi, relating to 
concerns of vampirism. This impacted negatively on the final phases of data 
collection for both Chikhwawa studies. We also observed that many 
participants, especially older people, were reluctant to perform spirometry. 
Participants voiced fears relating to the spirometry equipment and there was 
a concern that older individuals were “too weak” to participate, despite 
having no objective contraindications. 
Poor rural communities rely heavily on subsistence farming and are highly 
vulnerable to climatic shocks. During the 3-year follow-up of the adult 
Chikhwawa cohort, the region experienced severe flooding, crop failures and 
famine. Many homes were destroyed, including personal possessions and 
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study documentation, and families relocated. Tracing of participants was 
particularly challenging, hence the relatively high rates of loss to follow-up. 
The field team also experienced challenges in explaining to community 
members the differences between Malawi-Liverpool-Wellcome Trust, as a 
research organisation, and the various aid agencies that were operating in the 
area as part of disaster relief activities.    
Despite these considerable challenges, we collected and published the first 
data from sSA relating to lung function and personal air pollution exposure in 
children, and longitudinal lung function and personal air pollution exposure in 
adults, as summarised in section 7.1.   
For health systems and policy makers to address the growing global burden of 
NCDs, it is essential to understand the size and nature of the problem. Due to 
shortcomings in information systems and routine record keeping, it is often 
difficult to gain such insight. Within routine clinical care, it has previously 
proved impossible to accurately quantify the number of asthmatic children 
attending the general Paediatric outpatient clinic at Queen Elizabeth Central 
Hospital (QECH), or to assess the extent of their symptoms or responses to 
treatment. Shortages in staffing and a large and unpredictable workload mean 
that routine care adopts a “firefighting” approach; the target is to review all 
patients who have attended, suffering a wide variety of medical conditions, 
and ensure they have received appropriate medications within the clinic and 
hospital pharmacy opening hours. Structured clinical assessment and 
subsequent adjustment of asthma treatment, and patient education are 
frequently suboptimal. The randomised-controlled trial and qualitative sub-
study described in Chapters 5 and 6 aimed to provide baseline information on 
the clinical characteristics of asthmatic children in Blantyre, and to assess the 
feasibility, acceptability and effectiveness of a task-shifting intervention on 
asthma outcomes. This is the first comprehensive description of a paediatric 
asthmatic cohort from a low-income sSA country, and the first trial of task 
shifting asthma education to non-clinical staff in a resource-limited setting, as 
summarised in section 7.2 
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7.1 Prevalence and determinants of NCD-L in children and adults in 
rural Malawi 
The cross-sectional and cohort studies presented in Chapters 3 and 4 
respectively, aimed to assess the prevalence and determinants of chronic 
respiratory symptoms, spirometric abnormalities and personal exposure to air 
pollution in children and adults living in Chikhwawa, Malawi. Furthermore, we 
aimed to explore the lung function trajectories of adults, over a period of 3-
years, to assess whether biomass smoke exposure causes an accelerated 
decline in lung function, in the same way as tobacco smoke exposure.  
Adults and children were recruited from the same rural communities that had 
participated in the Cooking And Pneumonia Study (CAPS), which facilitated 
secondary analyses to explore the effect of the cookstove intervention. During 
the CAPS trial (2013-2016), intervention households received two cleaner-
burning biomass-fuelled cookstoves, while control households continued 
cooking using traditional methods, mostly open fires.26 We compared lung 
function between children in the CAPS intervention and control households 
and explored adult lung function trajectories, with “access to a cookstove” 
included as a covariate in the mixed-effects lung function model. 
Children reported a high burden of chronic respiratory symptoms, mainly 
cough (8.0%) and wheeze (7.1%), with half of wheezing children experiencing 
severe symptoms, according to ISAAC definitions. In keeping with previous 
reports from Malawi, we found high rates of chronic respiratory symptoms 
(13.6% at baseline), particularly cough (11.1%) among the adult cohort.22,23  
Using GLI African-American reference equations, we found similar lung 
function z-scores for children and adults; mean (SD) FEV1 -0.48 (0.93) and -
0.38 (1.14), and mean (SD) FVC -0.30 (0.96) and -0.19 (1.09), for children and 
adults respectively.57 This suggests that lung function deficits in adulthood are 
likely to have origins in early childhood, before the age of 6 years. The 
prevalence of decreased FVC in the adult population is highly dependent on 
the comparative reference range used: the prevalence is much lower when 
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Malawian lung function data are compared to African-American reference 
ranges (either NHANES III or GLI) supporting ancestral differences in lung 
physiology, the prognostic significance of which is unknown. 
Both children and adults were exposed to high peak levels of personal air 
pollution exposure. In children, maximum CO exposure and COHb levels 
exceeded WHO guidelines in 50.1% and 68.5% of participants, respectively, 
however median CO exposure was 0.20 ppm (IQR, 0.07-0.54).350 In adults, 
median CO exposure was 1.27 ppm (IQR, 0.79-2.05) and median personal 
PM2.5 77.0 µg/m3 (IQR, 42.8-153.1), almost three times the WHO air quality 
24-hour exposure limit.350  
Overall, we found no evidence of an association between respiratory 
symptoms, spirometric indices and measures of personal air pollution 
exposure (CO and COHb in children, CO and PM2.5 in adults). It is possible that 
exposure to biomass smoke, largely from intermittent cooking activities, does 
not deliver a sufficiently sustained or concentrated dose of harmful pollutants 
to lead to adverse respiratory effects. 
Exploring the longitudinal lung function data, we found no evidence of 
accelerated lung function decline among this cohort of biomass smoke 
exposed adults. Annual rates of FEV1 and FVC decline were 30.9ml (95% CI: 
21.6-40.1) and 38.3ml (95% CI: 28.5-48.1) respectively, comparable to healthy 
non-smokers in HIC.222 Previous TB and BMI were significantly associated with 
lung function. Although exposure to PM2.5 was decreased in those with access 
to a cookstove, we found no evidence that having access to a cookstove 
affected adult lung function.    
In children, however, results signalled a benefit from the cookstove 
intervention: children from the CAPS intervention households had lower 
median COHb levels (3.50% vs 4.85%, p=0.006) and higher FVC z-scores (-0.22 
vs -0.44, p=0.05) than controls. These results of exploratory secondary 
analyses are interesting, given the apparent lack of association between 
personal air pollution exposure and lung function, and require cautious 
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interpretation. However, it is plausible that the cookstove intervention had a 
positive effect during a critical period of lung growth and development in 
younger children: the CLHS participants were aged 3-6 years during the CAPS 
trial period. 
Neither CLHS or ALHS were designed to assess the impact of the cookstove 
intervention on personal air pollution exposure or lung function: the primary 
outcome reported in CAPS was WHO Integrated Management of Childhood 
Illness defined pneumonia in children aged under 5 years.26 Since CAPS, CLHS 
and ALHS recruited participants from the same village communities in 
Chikhwawa, we have taken the opportunity to explore secondary research 
questions relating to the cookstove intervention, permitted by overlapping 
study participation.  
Several factors may have influenced the impact of the cookstove intervention 
on air pollution exposure and respiratory outcomes. Most households in 
Chikhwawa cook outdoors; only households with an eligible child (aged ≤4½ 
years) were recruited from the village clusters and so their local environment 
may have been contaminated by emissions from neighbouring households not 
included in the CAPS trial. Furthermore, other sources of ambient air 
pollution, such as burning rubbish and clay brick ovens are common in 
Chikhwawa. Cookstove malfunction was relatively common during the trial 
period, and cookstove use waned among intervention households, with most 
households using a combination of cooking methods (both cookstove and 
traditional open-fire).26     
In summary, the novel findings in Chapters 3 and 4 suggest that, in a rural 
Malawian community;  
• Lung function deficits in adulthood are more likely due to early life 
factors (acting before age 6 years) than accelerated age-related 
decline 
• Biomass smoke (measured by PM2.5 and CO personal exposure levels) 
does not appear to affect lung function or respiratory symptoms 
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• A cleaner-burning cookstove intervention did not influence lung 
function in adults although there was a signal of benefit in younger 
children which warrants further investigation 
Future public health interventions to promote lung health must address 
factors acting in early life (in utero and early childhood) and consider multi-
faceted clean air interventions. 
 
7.2 Evaluation of a task shifting approach to asthma management for 
children in Malawi 
7.2.1 Clinical characteristics of asthmatic children in urban Blantyre 
To my knowledge, there is no previously published data relating to asthmatic 
children in Malawi. The first aim of the study presented in Chapter 5 was to 
describe the clinical characteristics of children attending outpatient follow-up 
at a tertiary hospital in urban Blantyre. We recruited 120 children, aged 6-15 
years with a previous “doctor-diagnosis” of asthma from the general 
paediatric clinic at QECH, Blantyre and assessed asthma symptoms, recent 
exacerbations, asthma treatment, and potential risk factors. We found a high 
baseline level of asthma symptoms and exacerbations. In the previous 3-
months; one-quarter of children had been admitted to hospital, a further 
third had attended a health facility for emergency care, although not requiring 
admission, and two-thirds had missed school, due to asthma symptoms. By 
GINA criteria, 85% of participants had uncontrolled or partly controlled 
symptoms. Despite the high burden of symptoms, less than half had been 
prescribed regular ICS and the mean daily beclometasone dose was relatively 
low.    
We measured pre-intervention FeNO levels in 113 children; levels were high 
(median FeNO 41.5 ppb [IQR 25.0-63.0]) suggesting that eosinophilic asthma 
is the predominant phenotype in Malawian children, and that treatment with 
ICS is appropriate. Spirometric abnormalities were common with one-third of 
152 
 
patients demonstrating airway obstruction pre-intervention (FEV1/FVC ratio 
below LLN) and weak correlation between symptom score and FEV1/FVC. 
7.2.2 Can an enhanced asthma care package improve asthma outcomes? 
Chapter 5 reports an RCT, which aimed to assess the feasibility and 
effectiveness of an enhanced asthma care package, including 1) a 
standardised assessment of asthma control, 2) optimisation of treatment 
according to standard guidelines and 3) an education intervention for children 
and their carers, delivered by non-clinical staff. 120 children were stratified 
according to their baseline level of asthma control and randomised to either 
continue with standard care in the general paediatric clinic at QECH, or to 
receive an enhanced care package, with clinical outcomes compared at 3-
months.  
We found a significant difference between groups in the primary outcome, 
asthma control (measured by cACT score); a mean (SD) increase in cACT score 
of 2.7 (2.8) points for intervention patients compared to 0.6 (2.8) points for 
those receiving standard care. Fewer children in the enhanced care group 
experienced asthma exacerbations requiring hospital admission, emergency 
health facility attendance, and school absence. Children in the enhanced care 
group were prescribed a significantly higher daily dose of beclometasone at 3-
months, although there was no difference in FeNO levels between the two 
groups. Children with lower pre-intervention cACT score or FEV1/FVC ratio 
showed a greater response to the intervention. 
7.2.3 Experiences of asthma education delivered by non-medical personnel 
The qualitative sub-study of the RCT, aimed to assess to acceptability and 
perceived value of the asthma education intervention, and explore facilitators 
and barriers to this approach. Young people, carers and study staff expressed 
high levels of satisfaction relating to the education sessions. Participants 
described the positive impact of asthma education on their knowledge levels; 
increased confidence to self-manage symptoms resulted in less absence from 
school and work, and fewer emergency health care attendances. Good 
rapport, with open dialogue between the educators, children and carers, was 
153 
 
essential and an individualised approach allowed educators to tailor the 
education session to the participants’ background level of knowledge and 
understanding. Educators highlighted the importance of adequate training, 
written resources and ongoing supportive supervision. 
In summary, the novel findings of chapters 5 and 6 suggest that among 
asthmatic children attending a hospital outpatient clinic in Blantyre, Malawi; 
• The burden of asthma symptoms is high, with frequent school absence 
• Eosinophilic airway inflammation is common, and therefore treatment 
with ICS is highly appropriate 
• Task shifting of asthma education to lay educators is a feasible, 
acceptable and effective approach to improve asthma outcomes 
Further research is needed to see if our task shifting approach to asthma 
education could be more widely employed, across all levels of health care 
facility. Alternative approaches to empower asthmatic patients and their 
families, and educate the wider community are also needed.  
 
7.3 Towards solutions 
There remain large gaps in our knowledge relating to NCD-L across the life 
course in Malawi, and sSA more widely, with key questions regarding effective 
disease prevention strategies and health care delivery. 
Potential multi-sectoral public health interventions to tackle early life risk 
factors and optimise lung growth and development (Figure 7-1) could include; 
• Strategies to improve engagement with antenatal and postnatal care 
at health facility level; group antenatal care, involvement of fathers, 
health promotion (breastfeeding, improved hygiene practices, seeking 
early medical care) by non-medical staff 
• Targeted antenatal nutritional interventions e.g. vitamin D  





Figure 7-1 Risk factors for poor lung health in sSA and potential interventions. 
ETS, environmental tobacco smoke; HAP, household air pollution; IUGR, intrauterine growth 
restriction; PMTCT, prevention of mother-to-child transmission; SDG, sustainable 
development goal; TB, tuberculosis; TRAP, traffic-related air pollution; WASH, water, 
sanitation and hygiene  
 
There are many unanswered questions relating to the management of NCDs 
in the poorest parts of the world including; 
• How best to engage communities and empower patients and their 
families? 
• How to improve access to effective clinical care, including appropriate 
diagnosis, treatment and monitoring of chronic conditions?  
• Can task shifting and the use of lay educators be deployed more 
widely, across a range of medical conditions and community settings?  
Future research to inform health care practice and policy in LIC must address 
local priorities and include all relevant stakeholders. In this way, patients, 
health care providers, policy makers and researchers can explore strategies to 
deliver effective clinical care of chronic conditions, such as asthma, with direct 
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Dr Sarah Rylance 






Friday, 02 December 2016 
Dear Dr Rylance, 
Research Protocol (16-040) Child lung health and exposure to household air pollution in rural 
Malawi 
Thank you for your letter of 1st December 2016 providing the necessary in-country approvals for this 
project. I can confirm that the protocol now has formal ethical approval from the LSTM Research 
Ethics Committee. 
 
The approval is for a fixed period of three years and will therefore expire on 1st December 2019.  The 
committee may suspend or withdraw ethical approval at any time if appropriate.  
Approval is conditional upon: 
 Continued adherence to all in-country ethical requirements. 
 
 Notification of all amendments to the protocol for approval before implementation.  
 
 Notification of when the project actually starts. 
 
 Provision of an annual update to the Committee. 
Failure to do so could result in suspension of the study without further notice. 
 
 Reporting of new information relevant to patient safety to the Committee 
 
 Provision of Data Monitoring Committee reports (if applicable) to the Committee  
 
Failure to comply with these requirements is a breach of the LSTM Research Code of Conduct and 
will result in withdrawal of approval and may lead to disciplinary action. The Committee would also 
like to receive copies of the final report once the study is completed. Please quote your Ethics 
Reference number with all correspondence. 
Yours sincerely 
 
Dr Angela Obasi 
Chair 
LSTM Research Ethics Committee 
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Child Lung Health Study – a cross sectional survey of children aged 6-8 years living in Chikhwawa, 
Malawi. 
1. Introduction. 
We would like to learn more about lung problems which affect young children in Malawi. There is 
very little research in Africa looking at problems such as ongoing cough, wheeze and breathlessness 
in this age group.  
We will study how much of a problem ongoing cough, wheeze and breathlessness is in children and 
what the causes might be. This work will help us develop solutions to the problems we find.  
2.  Why has your child been chosen? 
Your household is in one of the villages that took part in a trial called the Cooking And Pneumonia 
Study (CAPS). CAPS investigated whether using a new type of cookstove might improve the health of 
young children and adults. The Child Lung Health Study will include children living in households in 
villages that took part in CAPS. Your household has been chosen because your household is in one of 
the villages that took part in CAPS and your child has been chosen because he or she is in the age 
range (6 to 8 years) making him or her suitable.  
3. Does your child have to take part in the study? 
We will only ask you to participate in this study if your village leaders have agreed for your village to 
participate. You do not have to take part even if other members of the village agree to take part. 
Your agreement to help with this research study is completely optional and if you would prefer not 
to participate, this will be without penalty or loss of benefits to which you would be otherwise 
entitled. You can choose to leave the study at any time, without providing a reason. 
4. What will be involved if you agree for your child to take part in this study? 
We will make an appointment to visit you and your child at home. 
We will ask you some questions about your child’s health and record the results on a small 
computer. These will include questions about symptoms such as cough and wheeze, previous TB or 
chest infections and your child’s HIV status.  
We will measure your child’s weight using scales, height using a ruler and upper arm circumference. 
We will ask your child to blow into a machine which measures how their lungs are working. The 
study staff will then give them 4 puffs of a Salbutamol inhaler to try and improve the way their lungs 
work. We will then ask your child to blow into the machine again. It can take a little while to get a 
good result and we will ask your child to repeat the blowing test at least 3 times, up to a maximum 
of 8 attempts. 
We will place a small peg-like device on your child’s finger for a few moments to take a 
measurement of the levels of carbon monoxide in their body. This measurement does not involve 
taking a blood sample and does not hurt.  
We will place a small air pollution monitor on your child’s clothing for 2 day to allow us to measure 
air pollution exposure. This will not interfere with their usual daily activities. 
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We do not need to take any blood samples for this study. 
5. Will there be any risks involved in the study?  
You and your child may be inconvenienced by the time commitment involved in taking part in the 
study, the information we need to record and the measurements we need to take. All of the study 
procedures are routine and involve minimal risks. Your child may feel a bit light headed when they 
blow hard into the machine, but they will be sitting securely in a chair for the test and the nurses are 
trained to look out for this. The medicine (called Salbutamol) that your child will be given to improve 
their lung function is regularly taken by children with asthma. The dose is very low and therefore 
side effects such as racing heart and jitteriness are very unlikely. 
6. Will there be any benefits involved in being in the study? 
Our overall aim is to improve the care of children with ongoing respiratory symptoms. If we find your 
child has a lung problem we can refer them to a health centre for further investigation and 
treatment.  
To thank your child for taking part, we will give them a school bag. We will also provide the 
household with items such as sugar and salt, as compensation for the time and effort involved 
during the 2-day period of air pollution monitoring. 
7. Who is organizing the study?  
The research is being done by researchers at the College of Medicine, Malawi Liverpool Wellcome 
Trust, Liverpool School of Tropical Medicine, and Queen Mary University of London. 
8. Who will know what we find out?  
We will record the information we collect about you using a small computer. This information will be 
transferred to a computer database but without using your name or address so that you could not 
be identified from this information. This database will be analyzed by researchers at the College of 
Medicine, Malawi Liverpool Wellcome Trust and Liverpool School of Tropical Medicine. We will share 
the results of this study with you and your community, at local charity or research meetings and will 
present the findings at an international conference and in journals. We will not share any 
information that would allow you to be identified 
9. What happens if I change my mind?  
If you agree to join the study you can change your mind and withdraw your consent at any time. If 
you have any questions about this study, please contact our Senior Field Co-ordinator, Andrew 
Naunje on [+265 999981414]. 
For any questions regarding participant rights in the scope of this study, please contact the chairman 
of the local ethics committee (COMREC). This committee has reviewed and approved all of these 
studies. The contact details are: COMREC Secretariat, College of Medicine, P/bag 360, Blantyre 3. Tel 
no: [01871911 ext 334].  
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Name of parent/guardian: 
 
Name of child: 
 
Participant ID number: 
Address: 
 
1 Have you read or listened to the participant information sheet (v5, 01/02/17)?  
 
YES NO 
2 Have you had the opportunity to ask questions?  
 
YES NO 
3 Have your questions been answered, and do you feel that you have had enough 
information about this study?  
 
YES NO 
4 Do you understand that you are free to withdraw from the study at any time 
without giving a reason and without any penalties?  
 
YES NO 
5 Do you understand that data collected during the study may be looked at by 
individuals from Liverpool School of Tropical Medicine and regulatory 
authorities? All information will be anonymised. 
YES NO 
 
If you have answered ‘yes’ to questions 1-5 please sign the form, or place a thumbprint below, which 
means that you voluntarily agree to enter the study. 







Witness to consent if participant unable to sign their name 









Please tick to confirm that the child has been asked and is happy to take part in the study □ 
Investigator obtaining consent 
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To be administered by CLHS staff using Kobotoolbox form 
Section 1 General data 
Section 2 BOLD cough 
Section 3 BOLD phlegm 
Section 4 BOLD breathlessness 
Section 5 ISAAC core asthma 6/7 years 
Section 6 ISAAC core rhinitis 6/7 years 
Section 7 ISAAC core eczema 6/7 years 
Section 8 Respiratory questions 
 
Section 1 
1.1 How old is your child? 
 1 digit number 
 
1.2 What is your child’s date of birth? 
 --/--/---- (Date/Month/Year) 
 
1.3 Are they male or female? 
 Male (code=1) / Female (code=2) 
 
1.4 Does your child attend school? 
 Yes (code=1) / No (code=0) 
 
1.5 On average, how many hours do they spend away from home each day? 
 1 digit number 
 
1.6 Does your child help with the cooking? 
Yes (code=1) / No (code=0) / Don’t know (code=9) 
 
1.7 If yes, how times each day?  
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2.1 Does your child usually cough when they don’t have a cold?  
Yes (code=1) / No (code=0) / Don’t know (code=9) 
 
2.2 Are there months in which they cough on most days? 
Yes (code=1) / No (code=0) / Don’t know (code=9) 
 
2.3 Do they cough on most days for as much as three months each year? 
Yes (code=1) / No (code=0) / Don’t know (code=9) 
 
2.4 For how many years have they had this cough? 
 1 digit number 
 
Section 3 
3.1 Does your child usually bring up phlegm from their chest when they don’t have a cold? 
Yes (code=1) / No (code=0) / Don’t know (code=9) 
 
3.2 Are there months in which they have this phlegm on most days? 
Yes (code=1) / No (code=0) / Don’t know (code=9) 
 
3.3 Do they bring up phlegm on most days for as much as three months each year? 
Yes (code=1) / No (code=0) / Don’t know (code=9) 
 
3.4 For how many years have they had this phlegm? 
 1 digit number 
 
Section 4 
4.1 Is your child unable to walk due to a condition other than shortness of breath? 
Yes (code=1) / No (code=0) / Don’t know (code=9) 
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4.2 Is your child troubled by shortness of breath when hurrying on the level or walking up a slight 
hill?  
Yes (code=1) / No (code=0) / Don’t know (code=9) 
 
4.3 Does your child have to walk slower than children of their age on level ground because of 
shortness of breath? 
Yes (code=1) / No (code=0) / Don’t know (code=9) 
 
4.4 Does your child ever have to stop for breath when walking at their own pace on level ground? 
Yes (code=1) / No (code=0) / Don’t know (code=9) 
 
4.5 Is your child too short of breath to leave the house or short of breath on dressing or undressing? 
Yes (code=1) / No (code=0) / Don’t know (code=9) 
 
4.6 Have breathing problems interfered with your child’s usual daily activities or caused them to 
miss school? 
Yes (code=1) / No (code=0) / Don’t know (code=9) 
 
If yes, how many times has this happened in the past 12 months? 
 
Section 5 
5.1 Have your child ever had wheezing or whistling in the chest at any time in the past? 
Yes (code=1) / No (code=0) / Don’t know (code=9) 
If no, please skip to question 5.6 
 
5.2 Has your child had wheezing or whistling in the chest in the past 12 months? 
Yes (code=1) / No (code=0) / Don’t know (code=9) 
If no, please skip to question 5.6 
 
5.3 How many attacks of wheezing has your child had in the past 12 months? 
 None (code=0)/ 1 to 3 (code=1)/ 4 to 12 (code=2) / More than 12 (code=3) 
Ch3_Study questionnaire_English 10
Child Lung Health Study 
Participant questionnaire  





5.4 In the past 12 months how often, on average, has your child’s sleep been disturbed due to 
wheezing? 
Never (code=0)/ Less than one night per week (code=1)/ One or more nights per week (code=2) 
 
5.5 In the past 12 months has wheezing ever been severe enough to limit your child’s speech to only 
one or two words at a time between breaths? 
 Yes (code=1) / No (code=0) / Don’t know (code=9) 
 
 
5.6 Has your child ever had asthma? 
Yes (code=1) / No (code=0) / Don’t know (code=9) 
 
5.7 In the past 12 months has your child’s chest sounded wheezy during or after exercise? 
Yes (code=1) / No (code=0) / Don’t know (code=9) 
 
5.8 In the past 12 months, has your child had a dry cough at night, apart from a cough associated 
with a cold or chest infection? 
Yes (code=1) / No (code=0) / Don’t know (code=9) 
 
Section 6 
6.1 Has your child ever had a problem with sneezing, or a runny or blocked nose when they DID NOT 
have a cold or the flu? 
Yes (code=1) / No (code=0) / Don’t know (code=9) 
If no, please skip to question 6.6 
 
6.2 In the past 12 months, has your child had a problem with sneezing, or a runny or blocked nose 
when they DID NOT have a cold or the flu? 
Yes (code=1) / No (code=0) / Don’t know (code=9) 
If no, please skip to question 6.6 
 
6.3 In the past 12 months, has this nose problem been accompanied by itchy-watery eyes? 
Ch3_Study questionnaire_English 11
Child Lung Health Study 
Participant questionnaire  




Yes (code=1) / No (code=0) / Don’t know (code=9) 
 
6.4 In which of the past 12 months did this nose problem occur? (Tick any which apply) 
January / February / March / April / May / June / July / August / September / October / November / 
December (code = 1/2/3/4/5/6/7/8/9/10/11/12) 
 
6.5 In the past 12 months, how much did this nose problem interfere with your child’s daily 
activities? 
Not at all (code=0) / A little (code=1) / A moderate amount (code=2) / A lot (code=3) 
 
6.6 Has your child ever had hayfever? 
Yes (code=1) / No (code=0) / Don’t know (code=9) 
 
Section 7 
7.1 Has your child ever had an itchy rash which was coming and going for at least six months? 
Yes (code=1) / No (code=0) / Don’t know (code=9) 
If no, please skip to question 7.7 
 
7.2 Has your child had this itchy rash at any time in the past 12 months? 
Yes (code=1) / No (code=0) / Don’t know (code=9) 
If no, please skip to question 7.7 
 
7.3 Has this itchy rash at any time affected any of the following places: the folds of the elbows, 
behind the knees, in front of the ankles, under the buttocks, or around the neck, ears or eyes? 
Yes (code=1) / No (code=0) / Don’t know (code=9) 
 
7.4 At what age did this itchy rash first occur? 
Under 2 years (code=1) / 2 to 4 years (code=2) / Age 5 years or more (code=3) 
 
7.5 Has this rash cleared completely at any time during the past 12 months? 
Yes (code=1) / No (code=0) / Don’t know (code=9) 
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7.6 In the past 12 months, how often, on average, has your child been kept awake at night by this 
itchy rash? 
Never (code=0)/ Less than one night per week (code=1)/ One or more nights per week (code=2) 
 
7.7 Has your child ever had eczema? 
Yes (code=1) / No (code=0) / Don’t know (code=9) 
 
Section 8 
8.1 Has your child ever been admitted to hospital with severe cough or difficulty breathing? 
Yes (code=1) / No (code=0) / Don’t know (code=9) 
If no, skip to question 8.5 
 
8.2 How many times has this happened? 
One or two digit number 
 
8.3 How old were they when this happened the first time?  
One digit (age in years, if less than 1 year enter 0) 
 
8.4 How old were they when this happened the last time? 
One digit (age in years, if less than 1 year enter 0) 
 
8.5 Has your child been treated with antibiotics for a chest problem in the last year? 
Yes (code=1) / No (code=0) / Don’t know (code=9) 
 
8.6 If yes, how many times? 
One or two digit number 
 
8.7 Has your child ever been treated for TB? 
Yes (code=1) / No (code=0) / Don’t know (code=9) 
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8.8 Has anyone living in the house been treated for TB, since this child (the participant) was born?  
Yes (code=1) / No (code=0) / Don’t know (code=9) 
 
8.9 Has your child ever had an HIV test? 
Yes (code=1) / No (code=0) / Don’t know (code=9) 
 
8.10 If yes, what was the result? 
HIV negative (code=0)/ HIV positive (code=1)/ Don’t know (code=9) 
 
8.11 Is your child taking any regular medicines? 
ART / Cotrimoxazole / other (please list) 
 
Questions relating to cooking methods, parental smoking, poverty markers will be obtained from 
adult household member as part of Adult Lung Health Study. 
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Thursday, 12 July 2018 
 
Dear Dr Rylance, 
Research Protocol (18-018) ‘A randomised controlled trial of enhanced asthma care package vs 
standard outpatient care on asthma control in Malawian children’ 
Thank you for your correspondence of 2 July 2018 providing the necessary in-country approvals for 
this project. I can confirm that the protocol now has formal ethical approval from the LSTM Research 
Ethics Committee. 
 
The approval is for a fixed period of three years and will therefore expire on 11 July 2018. The 
Committee may suspend or withdraw ethical approval at any time if appropriate.  
Approval is conditional upon: 
• Continued adherence to all in-country ethical requirements. 
 
• Notification of all amendments to the protocol for approval before implementation.  
 
• Notification of when the project actually starts. 
 
• Provision of an annual update to the Committee. 
Failure to do so could result in suspension of the study without further notice. 
 
• Reporting of new information relevant to patient safety to the Committee 
 
• Provision of Data Monitoring Committee reports (if applicable) to the Committee  
 
Failure to comply with these requirements is a breach of the LSTM Research Code of Conduct and 
will result in withdrawal of approval and may lead to disciplinary action. The Committee would also 
like to receive copies of the final report once the study is completed. Please quote your Ethics 
Reference number with all correspondence. 
Yours sincerely 
 
Dr Angela Obasi 
Chair 
LSTM Research Ethics Committee 
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09 July 2018
To Whom It May Concern:
RE: A randomised controlled trial of an enhanced asthma care package vs standard outpatient care 
on asthma control in Malawian children.
As project manager for the Pan African Clinical Trial Registry (www.pactr.org) database, it is my 
pleasure to inform you that your application to our registry has been accepted. Your unique 
identification number for the registry is PACTR201807211617031.
Please be advised that you are responsible for updating your trial, or for informing us of changes to 
your trial.
Additionally, please provide us with copies of your ethical clearance letters as we must have these on 
file (via email or post or by uploading online) at your earliest convenience if you have not already done 
so.





+27 021 938 0835
The South African Medical Research Council
Cochrane South Africa  |  PO Box 19070, Tygerberg, 7505 
Tel: +27 (0)21 938 0438  |  Email: cochrane@mrc.co.za  |  Web: www.southafrica.cochrane.org 
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Childhood asthma study 
1. What is research? 
Research is a way we try to find out the answers to questions. 
 
2. Why is the project being done? 
The research is being done to learn more about asthma in Malawian children. We want to see how 
well the treatments that you take for your asthma are working. 
 
3. What is asthma? 
Having asthma means that the little tubes that take air into your lungs sometimes don’t work very 
well. That can make if difficult for you to breathe, and you might you cough or wheeze.  
 
4. Why me? 
You have been chosen because you are being treated for asthma at the children’s clinic in Queen 
Elizabeth Central Hospital 
 
5. Do I have to take part? 
No, it is your decision whether to join the study and you can always change your mind. If you do not 
join the study, you can still come to the clinic and see the doctors for your asthma. 
 
6. What will happen? 
If you agree to take part we will choose whether you start in group A or group B.  
Group A: We will ask you and your guardian some questions about your asthma. We will see you 
again for some more questions after 3-months. Then if you choose, you can move to group B. 
Group B: You will come for an extra visit to the clinic. During this visit we will do some tests to check 
your lungs and ask you questions about your asthma. 
We will measure how tall you are and how much you weigh. 
We will ask you to blow into a machine to test the 
air that comes out of your lungs. 
We will ask you to blow into another machine 
called a spirometer. Then we will give you 4 





We may ask you to repeat the blowing tests several times, to get a good result. 
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We will ask you to run around for 6 minutes and then ask you to blow 
into the spirometer again.  
 
We will put a clip on your finger to measure the level of oxygen in 
your body. 
 
None of the tests will hurt at all. If you want to stop the tests or have a rest, you can just tell us. 
Then we will ask you to breath in some steamy salty water and cough up, into a small pot. 
Now you can have a rest and we will give you something to eat and drink. 




We will see you again after 6 weeks, if we think your asthma treatment needs improving. 
We will see everyone after 3-months to ask some more questions about your asthma. 
You may be invited by the study team to take part in a small group meeting. We would like to know 
how you found the education session and understand how we can improve it. The discussion will be 
recorded so that we can listen to it again later. The information will be kept private and it is your 
decision to take part. 
7. What if something goes wrong? 
Your doctor thinks that is is safe for you to do these tests. We will be looking after you carefully 
during the study visit. If you feel unwell at all, we will stop the tests and give you your asthma 
medicine (inhaler). 
 
8. Will taking part help me? 
During the study we will spend time teaching you about asthma and trying to improve your 
treatment. 
 
9. What happens when the research study stops? 
The research will be talked about and written down, but no-one will know that you took part. All 
your information will be kept private. 
 
10. What if I don’t want to do the research anymore? 
Just tell your parents and the study team that you do not want to take part any more. You don’t 
have to give a reason. It is your choice. 
 
11. Did anyone else check the study is OK to do? 
Before any research can start, it is checked by a group of experts, to make sure that the research is 
fair. 
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12. How can I find out more about this study? 
If you have any questions, please ask Dr. Sarah Rylance or any of the the study team. 
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1. Introduction. 
We would like to learn more about asthma in Malawian children, to try and improve the treatment 
your child receives. In asthma, the small airways in the lungs become swollen and narrow causing 
cough, wheeze and difficulty in breathing. Children with asthma may share similar features 
(phenotypes) and they may respond to treatment differently. Knowing more about these shared 
features may help us to understand the causes of asthma and to give the best treatment.  
2. Why has my child been chosen? 
We are collecting information from all children attending the asthma clinic at Queen Elizabeth 
Central Hospital (QECH), to see how much of a problem their asthma is.  
Children will be chosen at random to attend for an extra visit, during which we will make a detailed 
assessment of their asthma, provide some asthma education and make changes to their treatment if 
needed. 
3. Does my child have to take part in the study? 
It is your choice whether or not your child takes part. If you or your child would prefer not to, your 
child will continue to be reviewed in the asthma clinic and receive all treatment, as before. You or 
your child can choose to leave the study at any time, without providing a reason. 
4. What will be involved if you agree for your child to take part in this study? 
Half of the children will be chosen at random for a detailed asthma assessment, asthma education 
and adjustment of their asthma treatment if needed (group B). Half the children will continue to 
receive care in the general clinic (group A).  
If your child is in group A, we will ask you some questions before you leave clinic today, and contact 
you again in 3-months to attend for a study visit. If the study supervisors are happy that the 
assessment and treatment in group B have been well tolerated /safe, we will offer you the 
opportunity to attend for the detailed assessment and education session, after the trial finishes.  
If your child is in group B, we will make an appointment for your child to come for an extra 
appointment at the hospital.  
During the assessment…. 
We will ask you some questions about your child’s health and record the results on a small 
computer. These will include questions about your child’s asthma, problems relating to their health, 
and the treatment they receive. 
We will measure your child’s weight using scales, height using a ruler and upper arm circumference. 
We will perform several tests to look at how inflamed your child’s airways are – this helps to see if 
your child’s current treatment is working. 
a. FeNO  
  
We will ask your child to breathe slowly into a cardboard tube attached to a small machine. This will 
take about 10 seconds. We may repeat the test up to 3 times, with a 5-minute rest in between 
attempts. 
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b. Spirometry 
We will ask your child to blow into a machine which measures how their lungs are working. The 
study staff will then give them 4 puffs of a Salbutamol inhaler to try and improve the way their lungs 
work. We will then ask your child to blow into the machine again. It can take a little while to get a 
good result and we will ask your child to repeat the blowing test at least 3 times, up to a maximum 
of 8 attempts. 
c. Sputum induction 
We will ask your child to breath a steam (made from salt water) in and out for 5 minutes, then we 
will ask them to cough up into a small pot. We will repeat this up to 4 times, until your child has 
coughed up enough sputum.   
d. Exercise challenge 
We will ask your child to run outside, as fast as they can, for 6 minutes. At the end, we will check 
their heart rate and oxygen levels with a small plastic clip attached to their finger. Then they will rest 
and we will check their lung function (spirometry) after 5, 10 and 15 minutes.  
e. Chest X-ray 
If the doctor thinks it will be helpful, your child will be sent for a chest x-ray in the X-ray Department 
at QECH. 
f. Carboxyhaemoglobin measurement 
We will place a small plastic clip on your child’s finger for a few moments to take a measurement of 
the levels of carbon monoxide in their body. This measurement does not involve taking a blood 
sample and does not hurt.  
Following the assessment, we will spend some time talking to you and your child about asthma and 
their treatment. The doctor will adjust the treatment to try and improve your child’s asthma. We will 
arrange to review your child again, after 3 months and repeat some of the tests. If your child’s 
asthma needs closer monitoring, we will arrange to see them after 6 weeks. 
After completion of 3-months in group B 
 
a. Focus group discussions and interviews  
You and your child may be invited by the study team to participate in a small group discussion or 
one-to-one interview. We are interested to know how you have found the education session and to 
understand how we can improve the experience. The sessions will be recorded so that we can listen 
again later to the conversation. The information will be kept confidentially and it is you and your 
child’s decision whether you would like to take part in the discussions. 
 
After the 3-month study period, we will continue to follow-up all children in the general clinic, and 
will repeat any assessments needed as part of clinical care.  
5. Will there be any risks involved in the study?  
Some of the tests are designed to test how sensitive your child’s airways are. There is therefore a 
small chance that performing the test may bring on asthma symptoms. These tests are part of 
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normal asthma care in Europe and the USA and are not considered dangerous in any way. We will 
check your child’s lung function before and during the tests, so that we can quickly detect any 
problem. If your child does become wheezy, the test will be stopped immediately and we will give 
treatment to stop the symptoms. A senior nurse or doctor will always be present when the tests are 
being performed. 
6. Will there be any benefits involved in being in the study? 
During the study visit, your child will have a thorough assessment by a senior children’s doctor. At 
the moment these tests are only available to study patients, as they are not part of routine asthma 
care in Malawi. All results will be explained to you and your child during asthma clinic follow-up 
visits, as soon as they are available. It is possible that participation in the study will lead to an 
improvement in your child’s asthma treatment. Overall, we hope that the study will lead to better 
asthma care for children in Malawi.  
The assessment will take several hours and may be tiring for your child. You will receive 
compensation for your time, travel and inconvenience for attending study visits (outside of normal 
clinic appointments), in keeping with current COMREC guidance (~10USD) 
7. Who is organizing the study?  
The study is led by Dr. Sarah Rylance, the Senior doctor in charge of the asthma clinic at QECH. Dr. 
Rylance is working with Malawi Liverpool Wellcome Trust and Liverpool School of Tropical Medicine. 
Other researchers supervising the study are from; Liverpool School of Tropical Medicine, Queen 
Mary University of London, and Lancaster University in the UK. 
8. Who will know what we find out?  
We will record the information we collect about your child using a computer. This information will 
be transferred to a computer database with the child’s name removed, so that they cannot be 
identified from this information. The information will be stored securely for 5-years. Dr. Rylance will 
have responsibility for the asthma clinic file, which will contain your child’s medical record – this will 
be stored in a secure location within QECH. 
The results of the study will be shared at research meetings (in Malawi and overseas) and will be 
published in medical journals, so that other doctors and patients can benefit from our findings.  
9. What happens if I change my mind?  
If you agree to join the study you can change your mind and withdraw your consent at any time. If 
you have any questions about this study, please contact our Senior Research Nurse, Beatrice 
Chinoko on [+265 0998319218]. 
The local ethics committee (COMREC) has reviewed and approved this study – any problems that 
cannot be addressed by the study team, should be directed to:  
COMREC Secretariat, College of Medicine, P/bag 360, Blantyre 3. Tel no: [01871911 ext. 334].  
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Participant ID number: 
Please circle yes / no 
1 Have you read or listened to the participant information sheet for children 
(v1.1, 02/04/2019)?  
 
YES NO 




3 Do you understand that you may be invited to take part in a group discussion 
about the education session? 
YES NO 








6 Do you understand that you can stop being in the study at any time, without 
giving a reason?  
 
YES NO 





If any answers are “No” or you don’t want to take part, do no write your name! 







Witness to consent if child unable to write their name 









Investigator obtaining consent 
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Participant ID number: 
Please circle yes / no 
1 Have you read or listened to the participant information sheet (v2.4, 
02/04/2019)?  
YES NO 
2 Have you had the opportunity to ask questions?  
 
YES NO 
3 Have your questions been answered, and do you feel that you have had enough 
information about this study?  
 
YES NO 
4 Do you understand that you are free to withdraw from the study at any time 
without giving a reason and without any penalties?  
 
YES NO 
5 Do you understand that you may be invited by the study team to be involved in 
a small group discussion or one-to-one interview after going through the 
intervention? 
YES  NO 
6 Do you understand that data collected during the study may be looked at by 
individuals from Liverpool School of Tropical Medicine and regulatory 
authorities? All information will be anonymised. 
YES NO 
 
If you have answered ‘yes’ to questions 1-5 please sign the form, or place a thumbprint below, which 
means that you voluntarily agree to enter the study. 
I voluntarily agree to enter this study.      YES / NO 











Witness to consent if participant unable to sign their name 









Please tick to confirm that the child has been asked and is happy to take part in the study □ 
Investigator obtaining consent 










Childhood Asthma Control Test, English, v2.2, 02/04/18 
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Have your child complete these questions. 














2. How much of a problem is your asthma when you run, exercise or play sports? 
 
 
It's a big problem, I can't do what I want to do. 
 
 
It's a problem and I don't like it. 
 
 
It's a little problem but it's okay. 
 
 
It's not a problem. 
 
3. Do you cough because of your asthma? 
 
 
Yes, all of the time. 
 
 
Yes, most of the time. 
 
 
Yes, some of the time. 
 
 
No, none of the time. 
 
4. Do you wake up during the night because of your asthma? 
 
 
Yes, all of the time. 
 
 
Yes, most of the time. 
 
 
Yes, some of the time. 
 
 
No, none of the time. 
 
 
Please complete the following questions on your own 
5. During the last 4 weeks, how many days did your child have any daytime asthma 
symptoms? 
  
Not at all 
 
1-3 days  
 









6. During the last 4 weeks, how many days did your child wheeze during the day 
because of asthma? 
  
Not at all 
 











7. During the last 4 weeks, how many days did your child wake up during the night 
because of asthma? 
  
Not at all 
 
1-3 days  
 
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I am going to ask you some questions about your child’s breathing problem / asthma. Children with 
asthma usually suffer with cough, wheeze and difficulty breathing, which comes and goes – these 
are called “symptoms”. We would like to know how much of a problem their symptoms have been 
recently and what treatments they are taking.  
Ndikufunsani mafunso okhuza mavuto amapumidwe amwana wanu / mphumu. Ana odwala 
mphumu nthawi zambiri amakhosomola, kuliza makwiyo, ndi kubanika, zomwe zimabwera ndi 
kupita – izi zimatchedwa “zizindikilo”. Tikufuna tidziwe zambiri zamavuto ndi zizindikilo zake m’mene 
zilili pano ndi thandizo la mankhwala limene akulandira.   
To be administered by study staff using KoboToolbox  
Assessment of exacerbations 
Kuunikira m'mene nthenda yafikira poyipa 
1a Has your child ever been admitted to hospital because of 
their asthma? For example; for cough, wheeze, or difficulty 
breathing 
Yes / No 
If no, go to Q2a 
 Kodi mwana wanu anayambapo wagonekedwa kuchipatala 
chifukwa cha nthenda ya mphumu? Mwachitsanzo; 
kukhosomola, kuliza makwiyo, kapena kubanika. 
Eya / Ayi 
Ngati ayi, pitani ku funso 2a 
1b If yes, how many times? Once / twice / ≥3 times 
 Ngati ndi Eya, kangati? Kamodzi / kawiri / kupyora 
katatu 
1c Has your child been admitted to hospital because of their 
asthma, in the past 3-months? 
Yes / No 
If no, go to Q1e 
 Kodi mwana wanu anayamba wagonekedwa kuchipatala 
chifukwa cha nthenda ya mphumu pamiyezi itatu yapitayi? 
Eya / Ayi 
Ngati ayi, pitani ku funso 1e 
1d If yes, how many times, in the past 3-months? 
 
Number 
 Ngati ndi Eya anagonekedwa kangati pa miyezi itatu 
yapitayi? 
Number 
1e If yes (to 1c), when was the last time this happened? 
 
Month 
 Ngati ndi Eya (kufunso 1c), ndiliti komaliza izi zinachitika? Miyezi 










1g Verified with health passport (past 3-months)? Yes / No / Not available 
2a Have you ever taken your child to a health centre because 
of their asthma, in the past 3-months? 
 
Yes / No 
If no, go to Q3a 
 Munayambapo mwamutengera mwana wanu kuchipatala 
chaching’ono chifukwa cha nthenda ya mphumu pa miyezi 
itatu yapitayi? 
Eya / Ayi,  
Ngati ayi, pitani ku funso 3a 
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 Ngati ndi Eya, kangati? Number 
2c If yes, when was the last time this happened? 
 
Month 
 Ngati ndi Eya, ndiliti komaliza izi zinachitika? Miyezi 
2d Verified with health passport? Yes / No / Not available 
3a In the past 3-months, has your child missed any days of 
school, because of their asthma?  
Yes / No 
 Pa miyezi itatu yapitayi, kodi mwana wanu anajombapo 
kusukulu chifukwa cha nthenda ya mphumu? 
Eya / Ayi 
3b If yes, how many? Number 
 Ngati ndi Eya, kangati? Number 
Assessment of treatment 
Kuunukira za thandizo la mankhwala 
4 Does your child have any inhalers? Yes / No 
If no, go to Q6 
 Kodi mwana wanu ali ndi mankhwala opumira/ofayira 
(inhalers) 





Please ask to see and write name and dose (show 
pictures) 
Choices: Salbutamol 100, Beclomethasone 50/100/200, 
other (please list) 
 
 
 We would like to know how they use it - 
 Tikufuna tidziwe m’mene amagwiritsira ntchito - 
a How many puffs each time? 
 
Number 
 Panthawi imene akugwiritsa ntchito amafayira kangati? Number 
b How many times in a day? 
 
Number 
 Patsiku amapanga kangati? Number 
c Regularly or when needed 
 
Regularly / when needed 
 Nthawi zonse kapena akafunikira? Nthawi zonse / akafunikira 
d With / without spacer With spacer / without 
 Ndi chipangizo cha botolo kapena ayi? Ndichipangizo cha botolo/ 
ayi 
 If they have a Salbutamol inhaler:  
5 What happens when they use it? They get better / 
They get worse / 
There is no change 
 Chimachitika ndi chani mukagwiritsa ntchito? Amapeza bwino 
Zimaonjezereka / 
Sizisintha 
 If they have a Beclomethasone inhaler, which they use regularly: 
6 How many times/week do you think they forget a dose? Once / 2-4 times/ 5 or more 
times 
 Ndi nthawi yochuluka bwanji kapena sabata imene inu 
mukuganizira kuti amatha kuyiwala kutenga mankhwala? 
Kamodzi/ kawiri kapena 
kanayi / kasanu kapena 
kupitilira apo  
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7 Are they taking any other treatment for their asthma, at 
the moment? (tablets, syrup) 
Please list 
 Akumwa mankhwala a mphumu pakali pano? (mapilisi, 
amadzi) 
Chonde fotokozani 
Assessment of asthma control (GINA) 
Kuunikira njira zochepetsera nthenda ya mphumu 
 In the last 4 weeks, has your child had; 
 M’masabata anayi apitawo, mwana wanu wakhalapo ndi; 
8a Daytime asthma symptoms (cough, wheeze, difficulty 
breathing) more than twice/week 
Yes / No 
 Zizindikilo za mphumu monga (kukhosomola, kuliza 
makwiyo, kubanika) nthawi ya masana koposera kawiri pa 
sabata 
Eya / Ayi 
8b Any night waking due to asthma symptoms Yes / No 
 Kodi amadzuka usiku chifukwa cha zizindikilo za mphumu Eya / Ayi 
8c Inhaler needed for symptoms more than twice/week? Yes / No 
 Kodi amafuna mankhwala opumira/ofayira amphumu 
kawiri pa sabata chifukwa cha zizindikilo? 
Eya / Ayi 
8d Any activity limitation due to asthma (missed school, 
stopped sports, difficult walking/running due to symptoms) 
Yes / No 
 Pali zomwe amalephera kupanga chifukwa cha mphumu 
(kujomba ku sukulu, kuleka masewero, kuvutika 
kuyenda/kuthamanga chifukwa cha zizindikilo) 
Eya / Ayi 
ISAAC 
9a Has your child had wheezing or whistling in the chest in the 
past 12 months? 
Yes / No  
If no, go to 8c 
 Kodi mwana wanu amamveka makwiyo m’chifuwa 
m’miyezi khumi ndi iwiri yapitayi? 
Eya / Ayi  
Ngati ayi, pitani ku funso 9c 
9b How many attacks of wheezing has your child had in the 
past 12 months? 
None / 1-3 / 4-12 / More 
than 12 
 Wadwalapo makwiyo kangati m’miyezi khumi ndi iwiri 
yapitayi? 
Palibe / 1-3 / 4-12 / 
Kopitilira 12 
9c In the past 12 months how often, on average, has your 
child’s sleep been disturbed due to wheezing? 
Never/ <1 night per week / 
≥1 nights per week 
 Miyezi 12 yapitayi zachitika pafupi pafupi bwanji kuti 
mwana wanu kuvutika kugona chifukwa cha makwiyo? 
Sizinachitike / kosapitilira 
usiku umodzi pa sabata / 
usiku umodzi kapena 
kuposera apo pa sabata 
9d In the past 12 months has wheezing ever been severe 
enough to limit your child’s speech to only one or two 
words at a time between breaths? 
Yes / No 
 Miyezi 12 yomwe yapitayi kulira makwiyo kwapangisa 
mwana wanu kuvutika kutulutsa liwu kapena mau ali 
mkatikati mopuma? 
Eya / Ayi 
9e Has your child ever had a problem with sneezing, or a 
runny or blocked nose when they DID NOT have a cold or 
the flu? 
Yes / No  
 
 Kodi mwana wanu anakhalapo ndi vuto la ku fwenthela, 
kutuluka mamina kapena kutsekeka m’mphuno mwake 
ngakhale munthawiyo samadwala chimfine? 
Eya / Ayi  
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9f Has this nose problem been accompanied by itchy-watery 
eyes? 
Yes / No  
 
 Vuto la m’mphuno limeneli limaphatikizana ndi kutuluka 
kwa misozi yoyabwa m’maso? 
Eya / Ayi  
 
9g Has your child ever had an itchy rash which was coming 
and going for at least six months? 
Yes / No  
 
 Kodi mwana wanu anatulukapo nsungu zoyabwa zomwe 
zimabwera ndi kupita kosachepera miyezi isanu ndi 
umodzi? 
Eya / Ayi  
 
9h Has this itchy rash at any time affected any of the following 
places: the folds of the elbows, behind the knees, in front 
of the ankles, under the buttocks, or around the neck, ears 
or eyes? 
Yes / No  
 
 Nsungu zoyabwa zinayamba zamutuluka mwana wanu 
m’malo monga awa: popinda nkono, kumbuyo kwa bondo, 
pamwamba pa kakolo, m’musi mwa matako, m’khosi, 
m’makutu kapena m’maso? 
Eya / Ayi  
 
Potential contributing factors 
Zithu zimene zimapangitsa kuonjezera nthendayi 
10 How many brothers and sisters do they have? Number 
 Kodi ali ndi azilongo kapena azichemwali angati? Number 
11 How many people live in the family home? Number 
 Kodi m’banja mwanu mulipo anthu angati? Number 
12a Does anyone else in the family have asthma? Yes / No / Don’t know 
 Alipo wina aliyense ali ndi nthenda ya mphumu m’banja 
mwanu? 
Eya / Ayi / Sindikuziwa 
12b If yes, who in the family has asthma? Mother/ father/ sibling/ 
other 
 Ngati ndi Eya, ndi ndani m’banja mwanu ali ndi nthenda ya 
mphumu? 
Amayi / abambo / chemwali 
kapena mlongo / ena 
13 Does your child have any allergies, eg. to food, medicine? Yes / No / Don’t know 
 Kodi mwana wanu ali ndi ziwengo, chitsanzo: kuzakudya 
kapena kumankhwala? 
Eya / Ayi / Sindikuziwa 
14 Does anyone smoke at home? No-one / mother / father / 
other 
 Alipo amene amasuta fodya pakhomo panu? Palibe/ amayi / abambo/ 
ena 
15 Are there any animals living inside the house? None /Dog / Cat / Chickens / 
Goat / Other 
 Pali ziweto zina zimene zimakhala m’nyumba mwanu?  Palibe /Galu /Mphaka 
/Nkhuku /Mbuzi / Zina 
16 Does the family keep any animals outside the house? None /Dog / Cat / Chickens / 
Guinea fowl /Goat /Sheep/ 
Pig / Cow / Rabbits / Horse / 
Donkey / other 
 Kodi banja lanu limaweta ziweto izi kunja kwa nyumba? Palibe / Galu / Mphaka / 
Nkhuku / Nkhanga / Mbuzi / 
Nkhosa / Nkhumba / 
Ng’ombe / Mbira / Hatchi / 
Bulu / zina 
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17 What method do the family use to cook at home? Charcoal / Wood / 
Electricitiy / Gas / Coal / 
Crop residue / other 
 Kodi banja lanu limagwiritsa ntchito moto wanji pophika 
pakhomo panu? 
Makala / Nkhuni / Magetsi / 
Gasi / Malasha / Zosalira za 
mbeu mmunda / zina 
18 What method do the family use for lighting at home? Electricity / Gas / Kerosene / 
Candles / Torch / Other 
 Kodi mumagwiritsa ntchito chani pofuna kuwaritsa 
mnyumba mwanu? 
Magetsi / Gasi / Parafini / 
Makandulo / Matochi / zina 
19 Did your child get admitted to hospital with a chest 
infection before the age of 1 years? 
Yes / No / Don’t know 
 Kodi mwana wanu anayambapo wagonekedwa m’chipatala 
chifukwa cha vuto la pachifuwa asanakwanitse chaka 
chimodzi? 
Eya / Ayi / Sindikuziwa 
20 Were they born on time/early? On time / Early 
 Kodi amabadwa munthawi yake kapena nthawi 
isanakwane 
Munthawi yake / nthawi 
yosakwanira 
21 How much did they weigh when they were born? Weight / Don’t know 
 Kodi amalemera bwanji atangobadwa kumene? Kulemera / Sindikudziwa 
22 At what age did your child first have any asthma 
symptoms? 
Years 
 Kodi mwana wanu anayamba koyamba liti kuonetsa 
zizindikilo za mphumu ali ndi zaka zingati? 
Zaka  
Triggers / activity levels 
Zoyambitsa / mulingo wa tchito zochitika 
23 Have you noticed anything that makes their asthma 
symptoms worse? 
Dust / wind / smoke / 
vehicle fumes / changes in 
the weather / exercise / 
animals? 
 Kodi munazindikira chimene chimapangitsa kuti zizindikilo 
za mphumu zikwere? 
Fumbi / mphepo / utsi / utsi 
wa galimoto / kusintha kwa 
nyengo / popanga 
masewera / zinyama 
24a Does your child go to school? Yes / No  
If no, go to Q24 
 Mwana wanu amapita ku sukulu? Eya / Ayi 
Ngati ayi, pitani ku funso 25 
24b If yes, which class? Standard 1-7, form 1-4 
 Ngati ndi Eya, ali mu kalasi yanji? Standard 1-7, form 1-4 
25a What interests does the child have, at school and at home? 
 
Running / playing games / 
football / singing / dancing / 
other 
 Kodi mwana wanu amakonda chani, ku sukulu komanso 
pakhomo? 
Kuthamanga / kusewera 
magemu / mpira / kuyimba / 
kuvina / zina 
25b How does their activity compare with their friends or 
siblings? 
More active / less active / 
same 
 Kodi mwana wanu ndi wochangamuka bwanji kusiyanisa 
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Other medical conditions 
Matenda ena 
26 Does your child cough up sputum regularly? Yes / No 
 Kodi mwana wanu amakhosomola makhololo nthawi 
zonse? 
Eya / Ayi  
27 Has your child ever had whooping cough? Yes / No / Don’t know 
 Kodi mwana wanu anayambapo wakhala ndi chifuwa 
chokoka mtima? 
Eya / Ayi / Sindikuziwa 
28 Has your child ever been treated for TB? Yes / No / Don’t know 
  Kodi mwana wanu anayambapo walandira thandizo la 
matenda a chifuwa chachikulu? 
Eya / Ayi / Sindikuziwa 
29a Has your child ever had an HIV test? Yes / No / Don’t know 
If no / don’t know, advise to 
attend under 5s for test 
 Kodi mwana wanu munamuyezesapo magazi kuti muziwe 
ngati ali ndi kachilombo ka HIV? 
Eya / Ayi / Sindikuziwa 
Ngati ayi kapena 
simukudziwa, mupite ku 
chipatala cha ana 
akamuyeze 
29b If yes, what was the result? HIV negative / HIV positive 
 Zosatira zake zinali zotani? Alibe ka chilombo ka HIV / 
Ali ndi kachilombo ka HIV 
 
Also, please complete Childhood Asthma Control Test (paper version) 
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I am going to ask you some questions about your child’s breathing problem / asthma. Children with 
asthma usually suffer with cough, wheeze and difficulty breathing, which comes and goes – these 
are called “symptoms”. We would like to know how much of a problem their symptoms have been 
recently and what treatments they are taking.  
Ndikufunsani mafunso okhuza mavuto amapumidwe amwana wanu / mphumu. Ana odwala 
mphumu nthawi zambiri amakhosomola, kuliza makwiyo, ndi kubanika, zomwe zimabwera ndi 
kupita – izi zimatchedwa “zizindikilo”. Tikufuna tidziwe zambiri zamavuto ndi zizindikilo zake m’mene 
zilili pano ndi thandizo la mankhwala limene akulandira.   
To be administered by study staff using KoboToolbox  
Assessment of exacerbations 
Kuunikira m'mene nthenda yafikira poyipa 
1a Has your child ever been admitted to hospital because of 
their asthma? For example; for cough, wheeze, or difficulty 
breathing 
Yes / No 
If no, go to Q2a 
 Kodi mwana wanu anayambapo wagonekedwa kuchipatala 
chifukwa cha nthenda ya mphumu? Mwachitsanzo; 
kukhosomola, kuliza makwiyo, kapena kubanika. 
Eya / Ayi 
Ngati ayi, pitani ku funso 2a 
1b If yes, how many times? Once / twice / ≥3 times 
 Ngati ndi Eya, kangati? Kamodzi / kawiri / kupyora 
katatu 
1c Has your child been admitted to hospital because of their 
asthma, in the past 3-months? 
Yes / No 
If no, go to Q1e 
 Kodi mwana wanu anayamba wagonekedwa kuchipatala 
chifukwa cha nthenda ya mphumu pamiyezi itatu yapitayi? 
Eya / Ayi 
Ngati ayi, pitani ku funso 1e 
1d If yes, how many times, in the past 3-months? 
 
Number 
 Ngati ndi Eya anagonekedwa kangati pa miyezi itatu 
yapitayi? 
Number 
1e If yes (to 1c), when was the last time this happened? 
 
Month 
 Ngati ndi Eya (kufunso 1c), ndiliti komaliza izi zinachitika? Miyezi 










1g Verified with health passport (past 3-months)? Yes / No / Not available 
2a Have you ever taken your child to a health centre because 
of their asthma, in the past 3-months? 
 
Yes / No 
If no, go to Q3a 
 Munayambapo mwamutengera mwana wanu kuchipatala 
chaching’ono chifukwa cha nthenda ya mphumu pa miyezi 
itatu yapitayi? 
Eya / Ayi,  
Ngati ayi, pitani ku funso 3a 
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 Ngati ndi Eya, kangati? Number 
2c If yes, when was the last time this happened? 
 
Month 
 Ngati ndi Eya, ndiliti komaliza izi zinachitika? Miyezi 
2d Verified with health passport? Yes / No / Not available 
3a In the past 3-months, has your child missed any days of 
school, because of their asthma?  
Yes / No 
 Pa miyezi itatu yapitayi, kodi mwana wanu anajombapo 
kusukulu chifukwa cha nthenda ya mphumu? 
Eya / Ayi 
3b If yes, how many? Number 
 Ngati ndi Eya, kangati? Number 
Assessment of treatment 
Kuunukira za thandizo la mankhwala 
4 Does your child have any inhalers? Yes / No 
If no, go to Q6 
 Kodi mwana wanu ali ndi mankhwala opumira/ofayira 
(inhalers) 





Please ask to see and write name and dose (show 
pictures) 
Choices: Salbutamol 100, Beclomethasone 50/100/200, 
other (please list) 
 
 
 We would like to know how they use it - 
 Tikufuna tidziwe m’mene amagwiritsira ntchito - 
a How many puffs each time? 
 
Number 
 Panthawi imene akugwiritsa ntchito amafayira kangati? Number 
b How many times in a day? 
 
Number 
 Patsiku amapanga kangati? Number 
c Regularly or when needed 
 
Regularly / when needed 
 Nthawi zonse kapena akafunikira? Nthawi zonse / akafunikira 
d With / without spacer With spacer / without 
 Ndi chipangizo cha botolo kapena ayi? Ndichipangizo cha botolo/ 
ayi 
 If they have a Salbutamol inhaler:  
5 What happens when they use it? They get better / 
They get worse / 
There is no change 
 Chimachitika ndi chani mukagwiritsa ntchito? Amapeza bwino 
Zimaonjezereka / 
Sizisintha 
 If they have a Beclomethasone inhaler, which they use regularly: 
6 How many times/week do you think they forget a dose? Once / 2-4 times/ 5 or more 
times 
 Ndi nthawi yochuluka bwanji kapena sabata imene inu 
mukuganizira kuti amatha kuyiwala kutenga mankhwala? 
Kamodzi/ kawiri kapena 
kanayi / kasanu kapena 
kupitilira apo  
Ch5_Review questionnaire 35
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7 Are they taking any other treatment for their asthma, at 
the moment? (tablets, syrup) 
Please list 
 Akumwa mankhwala a mphumu pakali pano? (mapilisi, 
amadzi) 
Chonde fotokozani 
Assessment of asthma control (GINA) 
Kuunikira njira zochepetsera nthenda ya mphumu 
 In the last 4 weeks, has your child had; 
 M’masabata anayi apitawo, mwana wanu wakhalapo ndi; 
8a Daytime asthma symptoms (cough, wheeze, difficulty 
breathing) more than twice/week 
Yes / No 
 Zizindikilo za mphumu monga (kukhosomola, kuliza 
makwiyo, kubanika) nthawi ya masana koposera kawiri pa 
sabata 
Eya / Ayi 
8b Any night waking due to asthma symptoms Yes / No 
 Kodi amadzuka usiku chifukwa cha zizindikilo za mphumu Eya / Ayi 
8c Inhaler needed for symptoms more than twice/week? Yes / No 
 Kodi amafuna mankhwala opumira/ofayira amphumu 
kawiri pa sabata chifukwa cha zizindikilo? 
Eya / Ayi 
8d Any activity limitation due to asthma (missed school, 
stopped sports, difficult walking/running due to symptoms) 
Yes / No 
 Pali zomwe amalephera kupanga chifukwa cha mphumu 
(kujomba ku sukulu, kuleka masewero, kuvutika 
kuyenda/kuthamanga chifukwa cha zizindikilo) 
Eya / Ayi 
 
Also, please complete Childhood Asthma Control Test (paper version) 
Ch5_Review questionnaire 36
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Key messages
What is the key question?
 ► Is the high burden of chronic respiratory 
morbidity and household air pollution exposure 
described in Malawian adults, also seen in 
children, and would a cleaner-burning biomass-
fuelled cookstove intervention have a positive 
effect on lung function in early life?
What is the bottom line?
 ► We found a substantial burden of chronic 
respiratory symptoms, spirometric abnormalities 
and carbon monoxide exposures among young 
children living in rural Malawi, together with 
a signal of beneficial effect of a cookstove 
intervention on carboxyhaemoglobin and 
forced vital capacity.
Why read on?
 ► Chronic respiratory morbidity in adulthood is 
influenced by lung health in early life—greater 
understanding of contributing factors is vital 
to promote healthy lung development during 
childhood.
AbsTrACT
background non-communicable lung disease and 
exposure to air pollution are major problems in sub-
Saharan africa. a high burden of chronic respiratory 
symptoms, spirometric abnormalities and air pollution 
exposures has been found in Malawian adults; whether 
the same would be true in children is unknown.
Methods this cross-sectional study of children 
aged 6–8 years, in rural Malawi, included households 
from communities participating in the cooking and 
Pneumonia Study (caPS), a trial of cleaner-burning 
biomass-fuelled cookstoves. We assessed; chronic 
respiratory symptoms, anthropometry, spirometric 
abnormalities (using global lung initiative equations) 
and personal carbon monoxide (cO) exposure. 
Prevalence estimates were calculated, and multivariable 
analyses were done.
results We recruited 804 children (mean age 7.1 
years, 51.9% female), including 476 (260 intervention; 
216 control) from caPS households. chronic respiratory 
symptoms (mainly cough (8.0%) and wheeze (7.1%)) 
were reported by 16.6% of children. average height-
for-age and weight-for-age z-scores were −1.04 and 
−1.10, respectively. Spirometric abnormalities (7.1% 
low forced vital capacity (FVc); 6.3% obstruction) were 
seen in 13.0% of children. Maximum cO exposure and 
carboxyhaemoglobin levels (cOHb) exceeded WHO 
guidelines in 50.1% and 68.5% of children, respectively. 
children from caPS intervention households had lower 
cOHb (median 3.50% vs 4.85%, p=0.006) and higher 
FVc z-scores (−0.22 vs −0.44, p=0.05) than controls.
Conclusion the substantial burden of chronic 
respiratory symptoms, abnormal spirometry and air 
pollution exposures in children in rural Malawi is 
concerning; effective prevention and control strategies 
are needed. Our finding of potential benefit in caPS 
intervention households calls for further research 
into clean-air interventions to maximise healthy lung 
development in children.
InTroduCTIon
Non-communicable lung diseases are major global 
health priorities across the life course.1 2 Asthma 
is the the most common chronic disease of child-
hood and one of the the most common chronic 
diseases of adulthood, affecting around 358 million 
people while COPD affects 174 million people, 
worldwide.3
Although most of the children and adults with 
these conditions live and die in low-income countries 
and middle-income countries (LMICs), the majority 
of the research into these conditions is done in 
high-income countries. Research is especially scarce 
in the LMICs of sub-Saharan Africa where limited 
studies suggest the prevalence of childhood asthma 
is increasing in urban settings, and that children 
with symptoms of asthma are likely to be severely 
symptomatic.4 5 In adult populations, Burden of 
Obstructive Lung Diseases (BOLD) studies from 
countries in sub-Saharan Africa, including sites in 
urban and rural Malawi, have found a high burden 
of impaired lung function—particularly low forced 
vital capacity (FVC)6–8—which is concerning given 
the association between low FVC and mortality in 
other populations.9
In these same sub-Saharan African popula-
tions, there is widespread reliance (by around 
700 million people) on inefficiently burned solid 
fuels for cooking, heating and lighting.10 Studies 
in rural Malawi report exclusive biomass fuel use 
(wood, crop waste and charcoal) with households 
using traditional ‘open-fire’ cooking methods.11 
The widespread exposure of children to pollut-
ants such carbon monoxide (CO) and particulate 
matter, resulting from incomplete fuel combustion, 
is particularly concerning. Household air pollu-
tion has been suggested as a potential contributing 
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factor in the development of non-communicable lung diseases 
in low-income countries.12 However, the links between house-
hold air pollution exposure, new-onset asthma in children and 
obstructive lung disease in adults, are unclear, with controversy 
over the interpretation of available data.13–17 Environmental 
exposures, including inhaled pollutants, during periods of lung 
growth and development may lead to irreversible long term defi-
cits in adult lung function.18 19
In this context, the Cooking and Pneumonia Study (CAPS) 
was done to determine whether an intervention comprising two 
cleaner burning biomass-fuelled cookstoves and a solar charger 
would reduce the incidence of Integrated Management of Child-
hood Illness-defined pneumonia in children under the age of 5 
years in rural Malawi compared with continuation of traditional 
cooking methods.11 CAPS recruited households from village clus-
ters in Chikhwawa between December 2013 and February 2016. 
The primary intention-to-treat analysis found no difference 
in pneumonia incidence between the two trial arms. Recently 
reported secondary analyses in adults from a subset of CAPS 
households found no difference in chronic respiratory symp-
toms, lung function or personal air pollution exposures between 
participants from the intervention and control groups.20 That 
said, median exposure to fine particulate matter (PM2.5) was 71 
µg/m3, well above WHO annual and 24 hours guidelines.
Is it not known whether the same pattern of respiratory symp-
toms, spirometric abnormalities and air pollution exposures 
would be seen in children as in adults or whether the CAPS inter-
vention would have beneficial effects on any of these outcomes 
in children? In this paper we report the findings of a cross-sec-
tional study, conducted in the same village communities as CAPS, 
which set out to: (1) measure the prevalence and determinants 
(including measured exposure to household air pollution) of 
non-communicable lung disease in a population representative 
sample of children in rural Malawi and (2) conduct an analysis 
comparing lung function between young children in the inter-
vention group and those in the control group in CAPS. Some of 
the data have been previously presented in abstract form.21
MeThods
study design
We conducted a cross-sectional study of the prevalence and 
determinants of non-communicable respiratory disease among 
children living in Chikhwawa District, Malawi.
setting
Chikhwawa is a rural area, located in the Southern Region of 
Malawi on the Shire River, 50 km from the nearest city, Blan-
tyre. The population consists largely of subsistence farmers 
living in village communities and is highly vulnerable to climatic 
shocks, having experienced flooding, crop failures and famine 
in recent years. Infectious diseases (malaria, pneumonia and 
gastroenteritis), HIV/AIDS, malnutrition and limited access to 
basic healthcare contribute to high childhood mortality rates, 
although a considerable reduction in the mortality rate for chil-
dren under 5 years old has been seen in Malawi over the past 
25 years.22
Participants
Following widespread community engagement events, children 
aged between 6 and 8 years, living in households that had taken 
part in CAPS and BOLD-Chikhwawa were identified by local 
community advisors and invited to participate if the child’s 
parent/guardian gave written informed consent (or witnessed 
thumbprint for those unable to read and write). Exclusion 
criteria were current treatment for tuberculosis, current acute 
respiratory infection (defined as cough of <1-week duration, 
associated with fever and/or increased work of breathing) and 
other contraindications to spirometry (chest or abdominal pain, 
haemoptysis). We recruited all children from the study area 
meeting the eligibility criteria.
Procedures
Fieldworkers visited the children in the community to admin-
ister an electronic questionnaire, and assess anthropometry, lung 
function, and personal exposure to household air pollution. An 
electronic questionnaire was administered in Chichewa, the local 
language, detailing respiratory symptoms and potential contrib-
uting factors. Core written questions from the International 
Study of Asthma and Allergy in Children (ISAAC) were included, 
which had been forward and back-translated.23 Height, weight 
and mid-upper arm circumference (MUAC) were measured 
according to standardised protocols. Height and weight were 
interpreted using the WHO 2007 child growth standards.24 
MUAC was used to assess nutritional status.25
Prebronchodilator and postbronchodilator spirometry was 
performed by BOLD centre-certified technicians, according to 
American Thoracic Society/European Respiratory Society (ATS/
ERS) standards using an Easy On-PC Spirometer (ndd Medical 
Technologies; Zurich, Switzerland).26 Regular calibration was 
performed according to the manufacturer’s instructions. The 
highest forced expiratory volume in one second (FEV1) and 
FVC measurements for each participant were selected (from a 
maximum eight attempts), before and after administration of 
400 µg inhaled salbutamol, via Volumatic spacer. Reversibility 
was defined as ≥12% improvement between prebronchodilator 
and postbronchodilator FEV1.
Spirometry over-reading was performed by two indepen-
dent reviewers. Two sets of ATS/ERS standards (aged 4–6 years 
and aged seven and above) are relevant for the children in this 
study.26 27 As the age range of our study children overlaps both 
sets of standards, and to maximise the use of spirometric data 
collected, we defined acceptable (grade C) quality as two traces 
within 150 mL or 10% (online supplementary table S1).
Carboxyhaemoglobin level (COHb) was measured at a single 
time-point using a Rad-57 pulse CO-oximeter (Masimo Corpo-
ration, California, USA). Performance verification was ensured 
at study outset, according to the manufacturer service manual. 
To assess personal CO exposure levels, children wore an EasyLog 
CO USB data logger (Lascar Electronics, Wiltshire, UK), for up 
to 48 hours, starting immediately after the field visit.
Variables
Clinical outcomes were presence or absence of symptoms, as 
assessed by the following questions; Chronic cough: defined by a 
positive response to both ‘Does your child usually have a cough 
when they don’t have a cold?’ and ‘Are there months in which 
they cough on most days?’; Current wheeze: ‘Has your child 
had wheezing or whistling in the chest in the past 12 months?’; 
Severe asthma: current wheeze, and ≥4 attacks of wheeze, or 
≥1 night per week sleep disturbance from wheeze, or wheeze 
affecting speech, in the past 12 months; Shortness of breath: 
a composite outcome, positive if children were reported to be 
breathless during normal daily activities or on minimal exertion; 
Any respiratory symptom: a composite outcome, positive if a 
participant was reported to have any of the previously described 
symptom outcomes.
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Figure 1 Participant recruitment flow diagram. CAPS, Cooking and Pneumonia Study; CO, carbon monoxide; COHb, carboxyhaemoglobin level.
Continuous FEV1 and FVC values were used in the primary 
analysis. Standardised z-scores and lower limits of normal 
(LLN) for FEV1, FVC and FEV1/FVC were derived from the 
GLI 2012 reference equations for African-Americans, which 
provide race-specific and sex-specific reference values, taking 
into account height and age.28
Personal CO exposure monitoring data were not analysed 
if <24 hours were recorded. To allow comparison of varying 
lengths of recording, all data were truncated at 24 hours for the 
final analysis.
Potential effect modifiers included were height (cm), weight 
(kg), age and sex.
study size
We calculated a sample of 600 participants (300 male, 300 
female) would estimate the prevalence of non-communicable 
lung disease in each sex stratum with a precision (95% CI) of 
±3.3 to ±5.0% (assuming a prevalence of 10%–25%). To allow 
for unequal sex distributions, refusals and inability to provide 
spirometry of acceptable quality, we aimed to recruit 1000 
children.
statistical analysis
Descriptive analysis was performed, using Student’s t-test 
and Pearson’s χ2 to compare continuous and categorical data. 
For population proportions, Wald-type SEs were calculated, 
assuming a binomial distribution. Bivariate associations between 
spirometric and clinical outcomes, and variables including CO, 
COHb, hospital admission for respiratory illness during infancy, 
and CAPS allocation were explored. Harmonic regression was 
used to account for any possible effect of seasonality on the 
outcome measures. This was implemented by including sinu-
soidal functions (sine and cosine terms) of time with a period 
of 1 year. Linear multivariable regression was used to estimate 
the association between exposures and continuous lung function 
values (FEV1 and FVC). Multivariable logistic regression models 
were constructed for dichotomous clinical outcomes. All models 
included age, sex, height and weight a priori, and variables 
with a p value <0.2 on bivariate analysis. A backward stepwise 
regression technique was used to develop multivariable models. 
An analysis was conducted to compare FEV1, FVC and FEV1/
FVC, symptom prevalence and exposure variables between the 
intervention and control groups of CAPS. CO was log10 trans-
formed for inclusion in linear models to ensure normality of 
residuals.
Analyses were conducted using R V.3.4.1 statistical software.29
role of the funding source
The funders had no role in the study design, data collection, 
analysis, interpretation or writing of the report. The corre-
sponding author had full access to all the study data and had 
final responsibility for the decision to submit for publication.
Ethical approval was given by the College of Medicine 
Research Ethics Committee in Malawi (reference P.07/16/1994) 
and Liverpool School of Tropical Medicine Research Ethics 
Committee in the UK (reference 16–040).
resulTs
Between February and December 2017, we approached 886 
children of whom 804 were confirmed to be eligible and 
were recruited (79/82 were outside the eligible age range; 
3/82 guardians declined to consent). Questionnaire data were 
collected for all but one participant who withdrew from the 
study shortly after giving consent. Anthropometry, spirometry, 
COHb measurement and personal CO monitoring were done 
on 99.9% (802/803), 99.9% (802/803), 99.4% (798/803) and 
99.3% (797/803) of these participants, respectively. Grade A–C 
prebronchodilator traces were achieved in 65% (522/802) of the 
children. The duration of CO monitoring was 24 and 48 hours 
for 91.9% (738/803) and 79.5% (638/803) children, respec-
tively. There were 476 (260 intervention and 216 control) chil-
dren from households included in CAPS (figure 1).
The mean age (SD) of participants was 7.13 (0.77) years and 
417 (51.9%) participants were female. Most (700 (87.2%)) were 
attending primary school. The mean (SD) height-for-age and 
weight-for-age z-scores were −1.04 (0.90) and −1.10 (0.89), 
respectively. Mean (SD) MUAC was 15.98 (1.26) cm (table 1). 
No children met the criteria for severe or moderate acute 
malnutrition, but 11/789 (1.4%) children were ‘at risk for acute 
malnutrition’.
Chronic respiratory symptoms were reported by 133 (16.6% 
(SE 1.3)) children, most commonly cough (8.0% (SE 1.0)), and 
current wheeze (7.1% (SE 0.9)) (table 1). One-fifth (159/803) 
of children had been admitted to hospital with respiratory 
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Table 1 Demographics and clinical characteristics (n=803)
Female, n (%) 417 (51.9)
Age, mean (SD) years 7.13 (0.77)
School attendance, n (%) 700 (87.2)
Anthropometry
Weight-for-age z-score, mean (SD) −1.10 (0.89)
Height-for-age z-score, mean (SD) −1.04 (0.90)
MUAC, mean (SD) cm* 15.98 (1.26)
Chronic respiratory symptoms n (%)
Wheeze ever 97 (12.1)
Current wheeze (in the past 12 months) 57 (7.1)
Severe asthma (in the past 12 months) 31 (3.9)
Wheeze with exercise 44 (5.5)
Dry cough at night 145 (18.1)
Chronic cough 64 (8.0)
Chronic sputum production 13 (1.6)
Chronic shortness of breath 49 (6.1)
Any chronic respiratory symptom 133 (16.6)
*MUAC measurement available for 789 participants.
MUAC, mid-upper arm circumference.
symptoms in the past; on one (9.7%), two (6.1%) and three or 
more (4.0%) occasions. Admission for a respiratory problem 
during the first year of life was reported for 70 (8.7%) children. 
Antibiotic use for a chest problem in the last year was common, 
reported for 112 (13.9%) children, with 69 (8.6%) receiving 
these on more than one occasion. Half (54.4%) of children 
with current wheeze had symptoms of severe asthma, repre-
senting 3.9% of children overall. Of these, 22 (71.0%) had a 
previous hospital admission, and 10 (32.2%) missed school due 
to breathing problems. Very few (0.4%) children had previously 
been treated for tuberculosis, and 2.0% (6/307) of children who 
had been tested for HIV were HIV-positive.
Children producing grade A–C spirometry were older than 
those with unacceptable traces (mean age 7.23 vs 6.96 years, 
p<0.001); otherwise there were no significant differences in 
growth parameters and respiratory symptoms between the two 
groups (online supplementary table S2). Overall, participants 
had a mean (SD) FEV1 z-score −0.48 (0.93) and mean (SD) 
FVC z-score of −0.30 (0.96). Children from CAPS intervention 
households had higher FVC z-scores than those from control 
households (−0.22 vs −0.44, p=0.05). Prebronchodilator spiro-
metric abnormalities were found in 68/522 (13.0%) of children; 
7.1% with low FVC and 6.3% obstruction (table 2). Postbron-
chodilator spirometry was attempted by 706 children, with 72% 
(505/706) producing grade A–C traces. Both prebronchodilator 
and postbronchodilator traces were available for 432 children, 
26 of whom had a prebronchodilator FEV1/FVC ratio below the 
LLN which was reversible in 8 (30.7%).
Personal CO monitoring showed considerable variation in 
exposure throughout the monitored period (figure 2). Mean 
exposure levels ranged from 0 to 15.1 parts per million (ppm), 
with a median CO exposure of 0.20 ppm (IQR 0.07–0.54). 
Peaks exceeding the 15 min indoor WHO guideline (81 ppm; 
100 mg/m3) were observed in 370/738 (50.1%) of participants 
(figure 3).30 Median %COHb was 4.00 (IQR 1.50–6.50). 68.5% 
of participants had a level greater than 2%, and 6.0% greater 
than 10% (figure 4). We found no association between respi-
ratory symptoms or spirometric indices and personal CO and 
COHb measurements in bivariate analyses and therefore these 
variables were not carried forward into multivariable analysis. 
In logistic multivariable analysis, chronic cough (OR 2.63 (95% 
CI 1.13 to 6.12)), current wheeze (OR 5.48 (95% CI 2.45 to 
12.26)) and symptoms of severe asthma (OR 6.36 (95% CI 2.34 
to 17.28)) were all associated with hospital admission during 
infancy (table 3). We found no association between respiratory 
symptoms and spirometric indices in bivariate or multivariable 
analysis (table 3).
In the analysis comparing intervention and control groups, we 
found statistically significant associations between the interven-
tion arm and both FVC (coefficient estimate 0.04 (95% CI 0.00 
to 0.07)), and COHb level (coefficient estimate −0.89 (95% CI 
−1.53 to 0.26) (table 4A). We found no significant differences 
between CAPS arms for growth parameters (table 4A) or chronic 
respiratory symptom rates (table 4B).
dIsCussIon
This is one of the first studies to report lung function and 
personal household air pollution exposure, measured concur-
rently in young children, and it was conducted in the context 
of the largest trial of a cleaner-burning cookstove intervention 
to date. Among children living in rural Malawi, we found that; 
one in six reported chronic respiratory symptoms; over half with 
current wheeze had severe symptoms; anthropometric and lung 
function parameters were generally decreased compared with 
global reference ranges; the majority of children had COHb 
levels above WHO recommended guidelines; and half of chil-
dren exceeded WHO guidelines for CO exposure (100 mg/m3), 
during 24 hours monitoring.10 Overall, we found no evidence of 
an association between CO exposure and respiratory symptoms 
or lung function. However, children from CAPS intervention 
households had higher FVC z-scores and lower COHb levels 
than controls.
There are limited data regarding chronic respiratory symp-
toms in children from Africa, and particularly rural settings. One 
study from rural Senegal reported similar rates with 9% current 
wheeze and 5% severe asthma among children aged 5–8 years.31 
Studies from urban settings in sub-Saharan Africa, including 
ISAAC sites, reported rates of current wheeze in 5%–16% of 
young children, with symptoms of severe asthma in half of 
these.4 32–34 Globally 11.5% of children aged 6–7 years have 
current wheeze, and 4.9% have symptoms of severe asthma; 
severe symptoms are seen in one-third of children with current 
wheeze in Europe.4 The high rates of severe symptoms seen in 
low-income countries are concerning, and likely reflect multiple 
challenges within healthcare systems, which are better equipped 
to manage acute episodes relating to infectious diseases, rather 
than chronic non-communicable conditions. In keeping with 
this, recent research from Nigeria and South Africa has reported 
high rates of under-diagnosed and untreated asthma in school-
children.35 36
We found decreased lung function parameters in this study, 
comparable to values reported for community controls in a 
recent study exploring long-term outcomes after severe acute 
malnutrition, at the referral hospital in Blantyre, Malawi.37 
These lung function deficits, when compared with international 
reference ranges, may reflect host and environmental factors 
such as undernutrition, frequent respiratory infections, low birth 
weight, exposure to pollutants in utero and early life, which can 
have adverse effects on lung growth and development.38–42 No 
children in this study were acutely malnourished (as defined 
by MUAC measurement), although other anthropometric 
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Table 2 Prebronchodilator lung function parameters for participants with grade A–C spirometry, including the CAPS subgroup








FEV1 z-score, mean (SD) −0.48 (0.93) −0.41 (0.92) −0.60 (0.97) P=0.10
FVC z-score, mean (SD) −0.30 (0.96) −0.22 (0.97) −0.44 (0.98) P=0.05
FEV1/FVC z-score, mean (SD) −0.38 (0.90) −0.40 (0.91) −0.34 (0.93) P=0.57
FVC<LLN, n (%) 37/522 (7.1%) 11/167 (6.6%) 12/133 (9.0%) P=0.57
Obstructive spirometry
FEV1/FVC<LLN, n (%)
33/522 (6.3%) 11/167 (6.6%) 10/133 (7.5%) P=0.93
Abnormal spirometry
(low FVC, obstruction, mixed), n (%)
68/522† (13.0%) 21/167‡ (12.6%) 22/133 (16.5%) P=0.42
*Comparison of means using Student’s t-test; comparison of proportions using Pearson’s χ2 test.
†Mixed pattern in two participants.
‡Mixed pattern in one participant.
CAPS, Cooking and Pneumonia Study; FEV1, forced expiratory volume in one second; FVC, forced vital capacity.
Figure 2 Example of a typical 48 hours CO monitoring trace. CO, 
carbon monoxide.
Figure 3 Maximum CO levels recorded during monitoring period for 
738 participants. Dashed line represents who recommended indoor 
exposure guideline for a 15 min time period. CO, carbon monoxide.
Figure 4 Percentage of COHb level for 798 participants. Dashed line 
represents the WHO COHb guideline. COHb, carboxyhaemoglobin level.
parameters (weight-for-age and height-for-age z-scores) were 
reduced compared with international standards, suggesting a 
level of chronic undernutrition in this community. There are 
limited data regarding normal lung function in healthy African 
paediatric populations, and consequently it is difficult to under-
stand the clinical significance of these apparent spirometric 
deficits.43 Further research is needed to describe optimal lung 
growth in African populations, and determine the morbidity and 
mortality associated with lung function abnormalities.44
Consistent with our previous findings in Chikhwawa, we 
noted exposure to high peaks of CO, reaching up to three times 
the WHO guidelines around cooking times, although mean and 
median levels were low; median CO 1.23 ppm (IQR 0.79–1.93) 
in adults and mean CO 1.27 ppm (SD 2.79) in younger chil-
dren.20 45 Median CO exposure levels were lower (0.20 ppm 
(IQR 0.07–0.54) in our older paediatric population perhaps 
reflecting long periods of time that children spend away from 
the home environment during the school day. Cookstove trial 
analyses exploring adult lung function as a secondary outcome 
have found no evidence of intervention benefit.20 46 47 Paediatric 
lung function outcomes in cookstove trials are inconclusive, but 
signal a possible beneficial effect of the interventions. Secondary 
analysis from the RESPIRE trial found decreased lung growth at 
around 5 years of age (measured by peak expiratory flow), associ-
ated with delayed chimney stove installation, although there was 
no association between lung function at age five and measured 
personal CO exposure during the first 18 months of life.48 The 
GRAPHS birth cohort in rural Ghana recently reported an asso-
ciation between prenatal CO exposure and infant lung function 
at 30 days of life, with an increased effect of exposure on female 
infants.49 Cross-sectional studies from Nigeria have described 
decreased lung volumes (FEV1 and FVC) and increased asthma 
symptoms in children with self-reported exposure to biomass 
cooking fuels.36 50
The association between CAPS intervention group and higher 
FVC is interesting, given the lack of evidence for an association 
between lung function and CO exposure or COHb level. This 
positive finding must be interpreted cautiously as it is the result 
of exploratory secondary analyses, unadjusted for multiplicity 
and therefore may be due to chance. However, when taken with 
the second signal of a potential effect, lower COHb observed in 
the intervention group, the results may be evidence of a genuine 
impact. We may have observed a benefit among our partici-
pants, who were aged 3–6 years during the CAPS trial period, 
in contrast to findings from adult populations, because the early 
childhood years represent a key period for lung development. 
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Table 3 OR (95% CI) for chronic respiratory symptoms estimated by multivariable logistic regression (n=522)
Cough Current wheeze severe asthma
shortness of 
breath
Age (years) 0.72 (0.48 to 1.06) 0.55 (0.31 to 0.96)* – –
Sex – – – –
Height (cm) – 1.07 (0.99 to 1.17) 1.18 (1.04 to 1.35)* 1.06 (0.98 to 
1.14)
Weight (kg) – – 0.72 (0.54 to 0.94)* –
Admission during infancy 2.63 (1.13 to 6.12)* 5.48 (2.45 to 12.26)† 6.36 (2.34 to 17.28)† –
FEV1 (l)‡ – 0.14 (0.01 to 1.72) 0.04 (0.00 to 1.09) 1.24 (0.01 to 
1.17)
*Significant at 0.05 level.
†Significant at 0.001 level.
‡Prebronchodilator FEV1.
 
FEV1, forced expiratory volume in one second.
Table 4A CAPS secondary trial analyses: mean or median values, with linear model coefficient estimates (95% CI) for continuous outcomes
Intervention Control Intervention versus control P value
FEV1, mean (SD) L* 1.02 (0.18) 0.97 (0.19) 0.02 (−0.01 to 0.06) 0.135
FVC, mean (SD) L* 1.16 (0.21) 1.09 (0.21) 0.04 (0.00 to 0.07) 0.033
FEV1/FVC, mean (SD) * 0.88 (0.06) 0.89 (0.06) −0.01 (−0.02 to 0.01) 0.411
%COHb, median (IQR)†‡ 3.50 (1.00 to 6.00) 4.85 (2.00 to 7.00) −0.89 (−1.53 to −0.26) 0.006
Mean CO ppm, median (IQR)§‡¶** 0.18 (0.05 to 0.55) 0.20 (0.08 to 0.52) 0.03 (−0.35 to 0.42) 0.857
Weight-for-age z-score, mean (SD)† −1.20 (0.89) −1.06 (0.85) −0.13 (−0.29 to 0.02) 0.096
Height-for-age z-score, mean (SD)† −1.10 (0.84) −1.06 (0.93) −0.04 (−0.20 to 0.12) 0.624
MUAC, mean (SD) cm†† 15.92 (1.29) 15.94 (1.30) −0.02 (−0.26 to 0.21) 0.846
*Spirometry data for 300 participants; 167 intervention, 133 control. FEV1, FVC and FEV1/FVC adjusted for age, sex, height and weight in regression model.
†COHb, height and weight data for 476 participants; 260 intervention, 216 control.
‡Adjusted for seasonality in linear regression model.
§24 hours CO monitoring for 436 participants; 239 intervention, 197 control.
¶Log10 CO values used in linear regression model.
**Mean exposure was estimated over the monitoring period per individual, the median of these values (and IQR) is presented for the study population.
††MUAC for 466 participants; 260 intervention, 206 control.
CO, carbon monoxide; COHb, carboxyhaemoglobin level; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; MUAC, mid-upper arm circumference.
Table 4b CAPS secondary trial analyses: proportions and OR (95% CI) for symptom outcomes (n=476)
Intervention n=260 Control n=216 Intervention versus control P value
Cough,
n (%)
30 (7.7%) 18 (8.3%) 0.92 (0.47 to 1.78) 0.797
Current wheeze,
n (%)
19 (7.3%) 17 (7.9%) 0.92 (0.47 to 1.82) 0.817
Severe asthma,
n (%)
11 (4.2%) 10 (4.6%) 0.91 (0.38 to 2.19) 0.833
Shortness of breath, n (%) 13 (5.0%) 14 (6.5%) 0.75 (0.34 to 1.63) 0.471
Any respiratory symptom, n (%) 37 (14.2%) 40 (18.5%) 0.72 (0.44 to 1.18) 0.193
There is rapid alveolar expansion and resulting lung growth 
during the first 2 years of life, which stabilises around 8 years of 
age.51 Alveolar number is reflected by FVC in childhood and so 
it is biologically plausible that we might see improved lung func-
tion in children from the intervention arm; the apparent differ-
ence of 70 mL in mean FVC between CAPS groups represents 
approximately 6% of a child’s lung volume. Furthermore, young 
children have increased susceptibility to air pollutants, exhib-
iting increased deposition of particles in the lung, due to phys-
iological and anatomical factors.52 CO exposure measures do 
not appear to be associated with lung function or respiratory 
symptoms—perhaps CO is an inadequate proxy for other pollut-
ants of interest, such as PM2.5 and nitrogen dioxide. Our previous 
air pollution monitoring work in Chikhwawa has demonstrated 
that monitored CO exposure correlates weakly with COHb, 
PM2.5 exposure, and measured black carbon in airway cells from 
induced sputum.20 45 53
This study was conducted in the context of the largest cook-
stove intervention trial to date—a major strength enabling 
us to assess the effect of a cookstove intervention on child-
hood spirometry and air pollution exposure outcomes. Other 
strengths include high participation rates for spirometry and 
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CO exposure monitoring, and good quality spirometry in a 
representative sample of children, despite the highly chal-
lenging research environment of a rural area in a low-income 
country. We achieved our sample size, even though field work 
was disrupted by vampirism hysteria in the community. We 
acknowledge limitations to our study including that personal 
monitoring of CO for 48 hours provides only a snapshot of 
exposure to a single pollutant. There are substantial limitations 
to the methods currently available for monitoring personal 
exposure to other pollutants in this young age group; the Lascar 
CO-monitoring device represents one of the best options avail-
able, at present. Monitoring during a 48 hours exposure period 
may not describe individual variation in daily and seasonal 
routines but reflected a compromise in terms of feasibility and 
acceptability in this large study population. Questionnaire data 
may have been subject to recall bias, with limited information 
on contributing factors such as birth weight, gestation at birth, 
HIV-status and exposure to passive smoking.
In conclusion, the substantial burden of chronic respiratory 
symptoms, abnormal spirometry and air pollution exposures in 
children in rural Malawi is concerning and calls for strategies to 
maximise healthy lung development and to effectively manage 
chronic respiratory conditions. To achieve this, research will 
be needed to develop ways to increase awareness of non-com-
municable lung diseases, such as asthma, at a community level 
to inform healthcare seeking behaviours and ensure access to 
appropriately trained healthcare providers and effective long-
term treatment such as inhaled medication. Our finding of a 
potential beneficial effect of a cleaner burning biomass-fuelled 
cookstove on lung function (FVC) calls for further research 
into clean-air initiatives, tackling multiple sources of air pollu-
tion in a community-wide approach to promote lung health in 
children.
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ABSTRACT
Rationale There are no population- based studies from 
sub- saharan africa describing longitudinal lung function 
in adults.
Objectives To explore the lung function trajectories 
and their determinants, including the effects of air 
pollution exposures and the cleaner- burning biomass- 
fuelled cookstove intervention of the cooking and 
Pneumonia study (caPs), in adults living in rural Malawi.
Methods We assessed respiratory symptoms and 
exposures, spirometry and measured 48- hour personal 
exposure to fine particulate matter (PM2.5) and carbon 
monoxide (cO), on three occasions over 3 years. 
longitudinal data were analysed using mixed- effects 
modelling by maximum likelihood estimation.
Measurements and main results We recruited 1481 
adults, mean (sD) age 43.8 (17.8) years, including 523 
participants from caPs households (271 intervention; 
252 controls), and collected multiple spirometry and air 
pollution measurements for 654 (44%) and 929 (63%), 
respectively. compared with global lung Function 
initiative african- american reference ranges, mean (sD) 
FeV1 (forced expiratory volume in 1 s) and FVc (forced 
vital capacity) z- scores were −0.38 (1.14) and −0.19 
(1.09). FeV1 and FVc were determined by age, sex, 
height, previous TB and body mass index, with FeV1 
declining by 30.9 ml/year (95% ci: 21.6 to 40.1) and 
FVc by 38.3 ml/year (95% ci: 28.5 to 48.1). There was 
decreased exposure to PM2.5 in those with access to a 
cookstove but no effect on lung function.
Conclusions We did not observe accelerated lung 
function decline in this cohort of Malawian adults, 
compared with that reported in healthy, non- smoking 
populations from high- income countries; this suggests 
that the lung function deficits we measured in adulthood 
may have origins in early life.
InTROduCTIOn
Non- communicable respiratory diseases including 
chronic obstructive pulmonary disease (COPD) and 
asthma are a growing global concern, particularly 
in low- income and middle- income countries.1–3 Air 
pollution, including exposure to tobacco smoke, 
outdoor and household air pollutants, and occu-
pational exposure to dust and fumes, is considered 
a major risk factor for non- communicable respi-
ratory disease development and exacerbations.1 4 
However, conflicting findings from recent studies 
have cast uncertainty over the specific role of 
household air pollution in COPD development.5 6 
Approximately 3 billion people worldwide rely on 
highly polluting biomass fuels for cooking, heating 
and lighting.7 It is therefore a global public health 
priority to better understand the impact of house-
hold air pollution on non- communicable respira-
tory disease morbidity and mortality.
The lung function trajectories of adults from sub- 
Saharan Africa (sSA) are largely undescribed; limited 
published data relate to cohorts from South Africa 
with HIV- infection and occupational silica dust 
exposure.8 9 There are no data from population- 
representative cohorts in sSA; it is not known 
whether adults exposed to biomass- related air pollu-
tion would experience accelerated age- related decline 
in lung function and therefore an increased risk of 
developing obstructive airways diseases as occurs in 
those exposed to tobacco smoke.10 11
Key messages
What is the key question?
 ► Are the low lung volumes previously reported 
in adults from Malawi a result of impaired lung 
development in early life or accelerated lung 
function decline in adulthood or both, and does 
biomass smoke exposure influence the rate 
of decline in the same way as tobacco smoke 
exposure?
What is the bottom line?
 ► In an adult population with high biomass 
smoke exposure, we found rates of lung 
function decline comparable with healthy non- 
smokers in high- income countries and lung 
function z- scores consistent with those reported 
in children from the same rural Malawian 
community.
Why read on?
 ► We report the first longitudinal lung function 
data from a population- representative cohort 
in sub- Saharan Africa: the results suggest that 
exposure to biomass fuel smoke may be less 
harmful than exposure to tobacco smoke or 
traffic- related air pollution, as reported in high- 
income settings.
  1Rylance S, et al. Thorax 2020;0:1–7. doi:10.1136/thoraxjnl-2019-213941
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Figure 1 Timeline showing CAPS and BOLD- Chikhwawa activities. BOLD, Burden of Obstructive Lung Disease; CAPS, Cooking and Pneumonia Study.
The cross- sectional BOLD (Burden of Obstructive Lung 
Disease) study, conducted in urban Blantyre, Malawi found 
unexpectedly high rates of decreased forced vital capacity (FVC) 
and high levels of self- reported exposure to biomass smoke.12 
The finding of a high burden of low FVC was concerning 
given the association between this and increased mortality.13 To 
further explore this phenomenon, we did a second study in rural 
Chikhwawa, Malawi (entitled BOLD- Chikhwawa) with the 
same protocol as the Blantyre BOLD study, but with the addition 
of measurement of personal exposure to air pollutants: carbon 
monoxide (CO) and fine particulate matter <2.5 µm (PM2.5).
14 
We found comparably high rates of spirometric abnormalities, 
with decreased FVC seen in 35% of participants, but no asso-
ciation between spirometric outcomes and exposure to CO or 
PM2.5 despite high levels of air pollution. Participants were from 
village communities which also participated in the Cooking 
and Pneumonia Study (CAPS), a cluster randomised trial of a 
cleaner- burning biomass- fuelled cookstove.15 Secondary analysis 
of adults from a subset of CAPS households found no difference 
in respiratory symptoms, lung function or personal air pollution 
exposures between intervention and control groups, but these 
analyses were done using cross- sectional data that were collected 
only a short time after introduction of the intervention—it is not 
known whether the rate of decline in lung function over time 
would be different between the trial arms.14
In this paper, we report the findings of lung function and 
personal air pollutant exposure monitoring during 3 years of 
follow- up for the BOLD- Chikhwawa cohort, to explore the 
determinants of lung function trajectories, including the effect 




Chikhwawa is a rural district, approximately 50 km south of 
Blantyre, on the Shire River valley. During the study period, 
this district experienced severe flooding and crop failures. CAPS 
recruited children aged <4.5 years in Chikhwawa between 
December 2013 and August 2015; intervention households 
received two cleaner- burning biomass- fuelled cookstoves, a solar 
panel to charge the stove- fan battery and user training at the 
time of randomisation. Those in the control arm continued using 
traditional cooking methods, mostly open fires, but received 
cookstoves at the end of the CAPS follow- up in May 2016.
BOLD- Chikhwawa was a separate study, recruiting adults 
from the same village communities as CAPS: not all BOLD- 
Chikhwawa participants were enrolled in CAPS. Figure 1 shows 
the timeline of CAPS and BOLD- Chikhwawa activities.
Participants
Age- stratified and gender- stratified population- representative 
sample of adults from 50 villages in Chikhwawa was taken as 
previously described.14 Written informed consent (or witnessed 
thumbprint) was obtained, with the information provided in the 
local language, Chichewa.
Procedures
Fieldworkers conducted follow- up visits in the community, 
approximately 1 and 2 years after enrolment, according to 
BOLD study standardised operating procedures, to collect 
questionnaires, spirometry and personal air pollution exposure 
data.16 Fieldworkers administered an abbreviated version of the 
BOLD study questionnaire in Chichewa, and measured height 
and weight.
BOLD Centre- certified fieldworkers conducted spirometry 
according to European Respiratory Society(ERS)/American 
Thoracic Society (ATS) standards using an EasyOne Spirom-
eter (ndd Medical Technologies; Zurich, Switzerland), before 
and after administration of 200 μg of Salbutamol via Volumatic 
spacer.17 Spirometry overreading was performed by an indepen-
dent technician, according to the BOLD criteria for acceptability 
and repeatability.
After completing the questionnaire and spirometry assessment, 
participants were given an Indoor Air Pollution (IAP) 5000 Series 
Monitor (Aprovecho Research Centre, Oregon, USA) which they 
were instructed to wear in a small backpack during the day and 
to keep beside their sleeping mat at night, to estimate personal 
exposure to PM2.5 and CO over a 48- hour period. These moni-
tors continuously sample air from the breathing zone, and 
PM2.5 and CO are measured using a light- scattering photometer 
and electrochemical cell CO sensor, respectively. Fieldworkers 
encouraged compliance with personal exposure monitoring 
during frequent community visits. IAP traces with outlying PM2.5 
or CO values (extremely high or low) were visually inspected for 
expected daily variation in exposure: traces without variability, 
suggesting that backpacks had not been worn, were excluded 
from the analysis.
2 Rylance S, et al. Thorax 2020;0:1–7. doi:10.1136/thoraxjnl-2019-213941
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Table 1 Respiratory symptoms and exposures reported by 









  Cough: Do you usually cough when you 







  Sputum: Do you usually bring up phlegm 








  Wheeze: Have you had wheezing/
whistling in your chest in the last 







  MRC dyspnoea II: Are you troubled by 
shortness of breath when hurrying on the 







  Functional limitation: Have breathing 































Clinical outcomes were assessed by the questions detailed in 
table 1. Raw forced expiratory volume in 1 s (FEV1) and FVC 
values were used as continuous variables in the longitudinal anal-
ysis. Lung function parameters were compared with age, sex and 
height- standardised global lung initiative (GLI) reference ranges 
for African- Americans and NHANES III reference ranges for 
Caucasians and African- Americans.18 19 Restriction was defined 
as FVC below the lower limit of normal (LLN), and obstruction 
as FEV1/FVC ratio below the LLN; values below the fifth centile 
in a healthy, non- smoking reference population.
Exposures included estimated personal exposure to PM2.5 
and CO, and questionnaire assessment of smoking status and 
previous tuberculosis. At baseline, first and second follow- up, 
participants were classed as having access to a cookstove if their 
household had been given a cleaner- burning biomass- fuelled 
cookstove by the CAPS study team prior to data collection.
Baseline PM2.5 and CO levels were zeroed at the 0.1th percen-
tile of values obtained during each monitoring period. Observa-
tions were included if >24 hours were recorded, with recording 
truncated into 24- hour periods to reflect daily variation in 
personal exposure patterns, and only full 24- hour periods anal-
ysed. Log mean 24- hour PM2.5 and CO estimates were used for 
mixed- effects modelling.
Potential effect modifiers: body mass index (BMI) and/or 
height and weight, age, years of education and sex, were eval-
uated as fixed covariates in the FEV1 and FVC linear mixed- 
effects models.
Study size
A total of 3000 adults were initially invited to enrol in the base-
line BOLD- Chikhwawa cohort. Participants were followed up if 
they had completed a baseline questionnaire (1481 participants) 
and were included in the longitudinal lung function analysis if 
they had at least two valid spirometry assessments during the 
study period.
Statistical methods
Descriptive analysis was performed, with the Student t test and 
Pearson’s χ2 to compare continuous and categorical data.
Participants with incomplete data (lost- to- follow- up or 
failing to complete spirometry) were compared with those with 
complete data using χ2 and Student t tests. Positive associations 
(p<0.2) on bivariate analysis were explored in multivariable 
logistic regression.
Two separate mixed- effects models were developed for the 
analysis of repeated exposure and lung function outcomes. 
In the log- linear exposure models, repeated estimates (mean 
24 hours CO and PM2.5) from individuals were accounted for 
using an individual- level random effect, with an additional 
random- effect accounting for clustering of 24- hour measure-
ments within 48- hour monitoring periods. Fixed- effect covari-
ates were selected sequentially to determine the optimum model 
fit by likelihood ratio testing under maximum likelihood estima-
tion (MLE), with the calculation of parameter estimates, stan-
dard errors and p values (see the online supplementary tables S2 
and S3). Harmonic terms were included in the exposure models 
to account for any possible effect of seasonality on the outcome 
measures. This was implemented by including sinusoidal func-
tions (sine and cosine terms) of time with a period of 1 year.
Longitudinal lung function (FEV1 and FVC) linear models 
included the fitted CO and PM2.5 values from the exposure 
model as fixed covariates; an average value was calculated where 
participants had multiple periods of exposure monitoring. 
Fixed- effect covariates were sequentially assessed by likelihood 
ratio testing under MLE (see the online supplementary tables S4 
and S5), with interaction terms to explore the change in lung 
function over time. The final regression equations used in the 
exposure and lung function analysis are included in the online 
supplementary text S1.
Analyses were conducted using R V.3.4.1 statistical software.
RESulTS
Between August 2014 and July 2015, 1481 adults were enrolled 
in the study at baseline and followed up on two subsequent occa-
sions.14 Three- quarters (75%, n=1090) were reassessed during 
the first follow- up period (August 2015–November 2016) and 
two- thirds (67%, n=989) during the second follow- up period 
(January 2017–November 2017) with data collected as shown 
in figure 2. Demographic data for participants with or without 
a questionnaire, spirometry or exposure monitoring are shown 
in the online supplementary table S1. Participants completing 
the second follow- up visit were more likely to be women (OR 
(95% CI): 1.88 (1.50 to 2.37), and to have spent fewer years in 
education (OR (95% CI): 0.96 (0.93 to 0.99)).
Spirometry was attempted by 950/1481 (64%), 628/1090 
(58%) and 571/989 (58%), and personal air pollution exposure 
monitoring completed for 1029/1481 (69%), 830/1090 (76%) 
and 811/989 (82%) at baseline, first and second follow- ups, 
respectively (figure 2). Multiple spirometry measurements were 
available for 654/1481 (44%) of participants, whereas 413 
(28%) had only one spirometry measurement and 413 (28%) 
had none. Personal air pollution exposure was estimated on 
more than one occasion for 929/1481 (63%) of participants, 
whereas 401 (27%) had only one episode of monitoring and 151 
(10%) had none.
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Table 2 Estimated risk ratios and 95% CIs for fixed- effects 




Sex 1.27 (1.13 to 1.42) 1.60 (1.51 to 1.72)
Current smoking – 1.22 (1.12 to 1.34)
Seasonality: cosine function – 0.85 (0.81 to 0.89)
Seasonality: sine function – 0.99 (0.96 to 1.03)
Access to cookstove 0.85 (0.75 to 0.97) –
CO, carbon monoxide; PM2.5, fine particulate matter.
Figure 2 Participant flow diagram.
At baseline, the cohort included 424 participants from CAPS 
households: this rose to 523 participants (271 from intervention 
and 252 from control households) as CAPS continued to recruit 
until August 2015.
The baseline demographics of the cohort have been previously 
reported.14 In brief, at baseline the mean (SD) age of partici-
pants was 43.8 (17.8) years, 57% were women and all house-
holds (99.8%) used biomass fuels for cooking. One third had 
never attended school and half had not been educated beyond 
the primary school level.
The frequency of reported respiratory symptoms increased 
greatly over the course of the study (table 1): overall 13.6% 
(95% CI: 11.9 to 15.4) of participants reported respiratory 
symptoms at baseline compared with 36.2% (95% CI: 33.3 to 
39.4) at the final follow- up. Self- reported rates of smoking and 
TB did not change over time; current smoking was reported by 
13.9% and 12.9%, and previous TB infection reported by 3.2% 
and 2.6%, at the baseline and final follow- up, respectively.
Personal exposure monitoring
A total of 1768 personal exposure monitoring episodes lasted 
>48 hours, and a further 902 lasted between 24 and 48 hours. 
Within episodes of >48 hours, there was fair correlation between 
the first and second 24- hour periods, for both PM2.5 (adjusted 
R2=0.68) and CO (adjusted R2=0.59). Correlation between 
exposures to the two air pollutant measures (mean PM2.5 and 
CO), analysed for a total of 4438 24 hours monitoring periods 
was poor (adjusted R2=0.027).
Overall, the 24 hours median personal PM2.5 and CO expo-
sures were 77.0 µg/m3 (IQR, 42.8–153.1) and 1.27 ppm (IQR, 
0.79–2.05), respectively. Personal PM2.5 (median (IQR)) was 
71.7 µg/m3 (42.8–128.0), 84.6 µg/m3 (45.9–175.7) and 75.9 µg/
m3 (40.1–176.4) at baseline, first and second follow- up, respec-
tively. Personal CO exposure (median (IQR)) was 1.26 (0.79–
2.07) ppm, 1.33 (0.81–2.22) ppm and 1.22 (0.75–1.90) ppm, at 
baseline, first and second follow- up, respectively.
In total, 4377 24- hour monitoring periods with complete 
covariate data from 1304 individuals were included in mixed- 
effects exposure models, with CO and PM2.5 as the response 
variables. In the final CO model, we found strong evidence that 
female sex, current smoking status and seasonality were asso-
ciated with the CO level (tables 2 and online supplementary 
table S2). In the final PM2.5 model, female sex was associated 
with increased PM2.5 and access to a cookstove with decreased 
PM2.5 (risk ratio 0.85; 95% CI: 0.75 to 0.97) (tables 2 and online 
supplementary table S3).
Spirometry
Of those attempting spirometry, ERS/ATS standards were 
achieved by 886/950 (93.3%), 594/628 (94.6%) and 537/571 
(94.0%) at baseline, first and second follow- up visits, respec-
tively (figure 2). On bivariate analysis, factors associated with 
failing to complete spirometry were: older age, lower BMI, 
female sex, current smoking, cough or any respiratory symp-
toms. In logistic multivariable analysis, participants who were 
women (OR (95% CI), 0.52 (0.39–0.71)), older (OR (95% CI), 
0.97 (0.96–0.98)) or with a lower BMI (OR (95% CI), 1.09 
(1.04–1.14)) were significantly less likely to complete spirom-
etry. Participants with longitudinal spirometry data had reduced 
lung function at baseline, compared with those who performed 
spirometry on only one occasion: mean (SD) FEV z- score −0.48 
(1.03) vs -0.22 (1.28), mean (SD) FVC z- score −0.33 (1.01) vs 
0.03 (1.19), respectively.
Best post- bronchodilator traces were analysed for 1068 partic-
ipants who completed at least one spirometry session to ERS/ATS 
standards. Overall, mean (SD) FEV1 and FVC were 2.55 (0.64) 
L and 3.16 (0.73) L, respectively, with a mean (SD) FEV1/FVC 
ratio of 0.80 (0.09) (table 3). When compared with GLI African- 
American reference ranges, mean (SD) FEV1, FVC and FEV1/
FVC ratio z- scores were −0.38 (1.14), –0.19 (1.09) and −0.37 
(1.04), respectively, with spirometric obstruction seen in 11.2% 
(95% CI: 9.4% to 13.2%) and low FVC in 8.1% (95% CI: 6.5% 
to 9.9%). Rates of obstruction were similar when NHANES 
Caucasian reference ranges were used (11.5% (95% CI: 9.6% 
to 13.5%)), but considerably more—approximately 50%—of 
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Table 3 Best post- bronchodilator spirometry values* and 
classification by GLI and NHANES reference ranges for 1068 
participants
Spirometry value
Raw Mean (SD) FEV1, L 2.55 (0.64)
Mean (SD) FVC, L 3.16 (0.73)
Mean (SD) FEV1/FVC ratio 0.80 (0.09)
Z- scores† Mean (SD) FEV1 z- score −0.38 (1.14)
Mean (SD) FVC z- score −0.19 (1.09)
Mean (SD) FEV1/FVC ratio z- score −0.37 (1.04)
Classification
% of Population 
(95% CI)
Obstruction FEV1/FVC<LLN GLI African- American 11.2 (9.4 to 13.2)
FEV1/FVC<LLN NHANES African- American 11.5 (9.6 to 13.5)
FEV1/FVC<LLN NHANES Caucasian 9.8 (8.1 to 11.7)
Restriction FVC <LLN GLI African- American 8.1 (6.5 to 9.9)
FVC <LLN NHANES African- American 7.7 (6.2 to 9.5)
FVC <LLN NHANES Caucasian 49.7 (46.7 to 52.8)
†Z- scores calculated using GLI African- American reference ranges.
*For participants with spirometry measured at more than one time point, the best 
FEV1 and FVC values were analysed.
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GLI, global lung 
initiative; LLN, lower limit of normal.
Table 4 Parameter estimates for multiple fixed- effects covariates 
included in final FEV1 and FVC linear mixed- effect models*
FEV1 (ml) FVC (ml)
Estimate 95% CI Estimate 95% CI
Time (years) −30.9 −40.1 to 21.6 −38.3 −48.1 to −28.5
Age (years) −18.7 −20.4 to −16.9 −11.0 −13.0 to −9.1
Sex (female) −500.1 −566.6 to −433.6 −678.0 −751.4 to 
−604.7
Height (cm) 23.6 19.9 to 27.3 32.8 28.7 to 36.9
Previous TB (yes) −404.9 −539.7 to −230.2 −334.2 −526.6 to 
−141.8
BMI 21.9 13.8 to 30.0 21.3 12.4 to 30.2
*Models include FEV1 and FVC data from 950 individuals, including 654 with two or 
more lung function measurements
BMI, body mass index; FEV1, forced expiratory volume in 1 second; FVC, forced vital 
capacity; TB, tuberculosis.
participants were classified as having a low FVC (49.7% (95% 
CI: 46.7% to 52.8%).
Overall, the annual rate of lung function decline was 30.9ml 
(95% CI: 21.6 to 40.1) for FEV1 and 38.3ml (95% CI: 28.5 to 
48.1) for FVC. Age, sex, height, previous TB infection and BMI 
were included in the final mixed- effects models as significant 
fixed- effect covariates for FEV1 and FVC (all p<0.001, online 
supplementary table S4 and S5), although they did not affect 
the rate of lung function decline. Current smoking, access to a 
cookstove, PM2.5 and CO exposure levels did not significantly 
improve either model. Decreased FEV1 and FVC were associ-
ated with increasing age, female sex, previous TB infection and 
decreased height and BMI (table 4).
dISCuSSIOn
This is the first prospective cohort study to report longitudinal 
lung function and personal exposure to air pollution in an sSA 
population. The main findings were that: FEV1 and FVC were 
determined by age, sex, height, previous TB and BMI, whereas 
there was no evidence of accelerated lung function decline 
(30.9 mL FEV1 and 38.3 mL FVC annual decrease) as might have 
been expected in this population compared with the natural age- 
related decline reported in populations from Europe and the 
USA.10 Mean (SD) FEV1 and FVC z- scores (−0.38 (1.14) and 
−0.19 (1.09)) were comparable with those previously reported 
for children from this community adding to evidence that spiro-
metric abnormalities in adults have their origins in early life.20 
Lung function was not associated with exposure to CO, PM2.5 or 
access to a cookstove. Estimated CO and PM2.5 correlated poorly 
and were associated with different covariates. Exposure to PM2.5 
was increased in women and decreased by a factor of 0.85 (95% 
CI: 0.75 to 0.97) in those with access to a cookstove. Exposure 
to CO was increased in women and current smokers and showed 
a seasonal trend.
We did not find evidence of accelerated lung function decline 
despite exposure to high levels of PM2.5. Previous studies 
exploring the impact of PM2.5 on lung function in high- income 
settings have focused on PM2.5 from ambient air pollution, partic-
ularly traffic- related air pollution (TRAP). Faster lung function 
decline was associated with increasing PM2.5 in longitudinal 
cohorts from the USA and Taiwan, the effects of other pollutants 
were not reported.21 22 A large multicentre metanalysis from the 
European ESCAPE cohorts did not find an association between 
air pollution and lung function decline but noted that NO2 was 
negatively associated with lung function.23 It is possible that the 
emissions from incomplete biomass combustion are less harmful 
to the airways than the many constituents (including nitrogen 
oxides) of TRAP.
Previous work from Malawi has reported lung function rela-
tive to NHANES III Caucasian reference values to facilitate 
comparison with other BOLD studies.12 14 In this analysis, we 
have additionally compared our data with African- American 
reference ranges (NHANES and GLI). The prevalence of 
reduced FVC varies greatly depending on which reference equa-
tion is used.24 The prognostic significance of markedly different 
predicted values in different ethnic populations is unclear.25 
Reduced FVC is seen in restrictive lung disease, however a more 
detailed assessment of total lung capacity by plethysmography is 
needed to further characterise the pattern of lung defect seen in 
African populations.
The use of GLI reference ranges permitted direct comparison 
with spirometry data from children living in the same commu-
nity. We recently reported lung function for children aged 6–8 
years, living in Chikhwawa; FEV1, FVC and FEV1/FVC ratio 
z- scores were −0.48 (0.93),–0.30 (0.96) and −0.38 (0.90), 
respectively, compared with GLI African- American reference 
ranges.20 The finding of similar z- scores in both the children and 
adults living in this community suggests that factors which influ-
ence lung growth and development act in early childhood before 
6 years of age, perhaps even starting in- utero.
We found an increase in self- reported respiratory symptoms 
over the 3- year follow- up period but no changes in exposures 
(self- reported TB or smoking status, or measured PM2.5 or CO). 
We speculate this is due to changes in reporting behaviour rather 
than a true change in symptom prevalence. During the CAPS 
period, the local community were exposed to messages about 
the health impact of air pollution and may have become sensi-
tised to the issues of clean air and respiratory health. Participants 
became familiar with the same questions asked on repeated occa-
sions: this may have led to a positive reporting bias. Alterna-
tively, responses at baseline may have underreported symptom 
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prevalence: a community survey in two rural districts in Central 
Malawi reported chronic respiratory symptoms in 22.5% of the 
population.26
Previous cookstove intervention trials have explored lung 
function in adult women only.27 28 The RESPIRE randomised 
controlled trial in Guatemala reported a reduction in 48- hour 
personal CO exposure in the intervention group using a plancha 
woodstove but no effect on women’s lung function at 12–18 
months in an intention- to- treat analysis.28 A subsequent expo-
sure–response analysis did find a significantly decreased rate of 
decline with decreased exposure to CO.29 The use of a Patsari stove 
in rural Mexico was associated with a significantly decreased rate 
of lung function (FEV1) decline in women compared with those 
cooking on open fires (31 vs 62 mL), over 1 year of follow- up, 
but this effect was not observed on intention- to- treat analysis.27 
This decrease in decline is comparable with that reported among 
ex- smokers, in the first year after quitting; their FEV1 trajectory 
showed half the rate of annual decline compared with those who 
continued to smoke ((mean±SD) 31±48 vs 62±55 mL).30 Our 
finding of FEV1 annual decline of 30.9 mL is consistent with the 
ranges seen in non- smokers from various studies.11
Our findings would suggest that low lung volumes seen in 
Malawian adults are not a result of accelerated decline in lung 
function, but more likely a failure to reach maximal lung volumes 
in early adulthood, either due to low lung function at birth or 
suboptimal lung growth during early childhood. Low birth 
weight and prematurity are of particular relevance in Malawi; 
the country has the highest rate of preterm birth worldwide, and 
intrauterine growth restriction, in both term and preterm infants, 
is common in low- income countries due to maternal factors 
including young maternal age, short- interpregnancy intervals 
and congenital infections.31 32 Adverse effects of prenatal expo-
sure to household air pollution on infant lung function have been 
suggested by the recent GRAPHS trial in Ghana.33 The adverse 
effect of early respiratory infections on lung health in adulthood 
has long been recognised; such infections are common in ssA, 
particularly during the first year of life.34 35
Several studies have used CO levels as a proxy for particu-
late matter, which is challenging to measure in the field in 
low- resource settings. However, respirable particulate matter 
≤2.5 µm (PM2.5) can reach the alveolar level in the lungs and 
is of greater interest when considering the adverse respiratory 
effects of air pollution. We found no association between PM2.5, 
CO or access to a cookstove and lung function. In keeping 
with findings from Peru, Nepal and Kenya, we observed poor 
correlation between CO and PM2.5 measurements and different 
explanatory covariates for the two pollutants in our exposure 
models.36 Although observed levels of exposure to both CO 
and PM2.5 exceeded WHO upper safety limits, the duration of 
these high exposures was brief and we speculate that adverse 
pulmonary effects are limited by the low intensity of exposure 
in rural Malawi where most cooking is done outdoors. Similarly, 
we found that current smoking was not associated with FEV1 in 
this population, likely reflecting the low intensity of tobacco use 
among smokers in this community; less than one- fifth of current 
or ex- smokers at baseline reported cigarette consumption of 
>10 pack years.
Strengths of our study include the collection of longitudinal 
lung function and personal air pollution exposure data in a rural 
cohort in one of the world’s poorest countries; high- quality 
spirometry performed by BOLD- certified technicians, with 
external quality control of traces by an independent expert 
reviewer. Limitations include potential recall bias and highly 
variable responses to questionnaires, and bias introduced by 
those not attempting spirometry or lost to follow- up. Partici-
pants performing spirometry were younger and hence, it is likely 
that spirometric abnormalities, such as obstruction, which are 
associated with increasing age are likely to be under- represented. 
Throughout the study the team struggled with cultural beliefs 
that older members of the community were “too weak” or “phys-
ically unable” to attempt spirometry. One- third of participants 
from baseline were lost to follow- up by the end of the study; we 
were unable to ascertain the reasons for this due to limitations 
of the data collected, but comparison of the demographic data 
for those who remained in the study at each phase suggested that 
men and those with better education were more likely to be lost, 
reflecting the more economically active, mobile sector of society. 
We recognise that 3 years is a relatively short time period to 
track longitudinal changes in lung function but believe we would 
more likely observe any effect of the intervention during the 
CAPS study period when the use of the cookstoves was actively 
supported by a repair and maintenance programme. Given that 
the rate in decline in lung function we observed over 3 years 
was consistent with the rate of decline seen in healthy adults in 
Europe and North America, it seems likely that this observation 
is accurate and that a longer period of follow- up would not have 
yielded additional useful rate of decline information.
In conclusion, in our cohort of adults living in rural Malawi, 
we observed (a) reduced FVC compared with Caucasian refer-
ence populations, similar in relative magnitude to what we previ-
ously reported in children living in the same communities, (b) no 
evidence of accelerated decline in FEV1 or FVC and c) no effect 
of access to cleaner- burning cookstoves on lung function decline. 
We suggest that future efforts to improve the lung health of those 
living in the poorest parts of the world should focus on antenatal 
and early childhood interventions to maximise lung growth and 
development. Further research is required to define the prog-
nostic significance of reaching adulthood with suboptimal lung 
volumes, regardless of the comparative reference range in terms 
of morbidity, mortality and associated socioeconomic costs.
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